id,tipo,text_start,text_end,text
10561201,MajorClaim,1,162,"A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer."
10561201,Premise,992,1058,"At 6 weeks, both groups showed improvement in several HQL domains,"
10561201,Premise,1063,1187,"only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group."
10561201,Premise,1188,1447,"After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),"
10561201,Premise,1452,1568,"the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05)."
10561201,Premise,1569,1768,"The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003)."
10561201,Claim,1769,1945,"Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone."
10561203,Claim,1,318,"In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m))."
10561203,Premise,1354,1442,"responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3."
10561203,Premise,1443,1592,"Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days)."
10561203,Premise,1593,1827,"While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m)."
10561203,Premise,1828,1978,"The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m)."
10561203,Premise,1979,2055,"Although the CR/PR and SD(6m) groups had similar times to treatment failure,"
10561203,Claim,2056,2167,"patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment."
10653877,Claim,1,156,"Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC)."
10653877,Premise,957,1203,"Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048)."
10653877,Premise,1204,1296,"Comparing survival for the two dose levels of paclitaxel revealed no significant difference."
10653877,Premise,1297,1464,"The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152)."
10653877,Premise,1465,1611,"For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246)."
10653877,Premise,1612,1864,"With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms."
10653877,Premise,1865,1928,"Quality of life (QOL) declined significantly over the 6 months."
10653877,Claim,1938,2001,"QOL scores were not significantly different among the regimens."
10653877,Claim,2037,2191,"paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial."
10675381,MajorClaim,218,449,"In nonrandomized studies involving patients with different tumor types including non-small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and deterioration of quality of life (QOL) and performance status."
10675381,Premise,1028,1208,"Mean weight changes per 4-week period were -1.0 kg (95% confidence interval [CI] = -1.5 to -0.5) in the control group and 0.2 kg (95% CI = -0.2 to +0.6) in the ATP group (P =.002)."
10675381,Premise,1209,1394,"Serum albumin concentration declined by -1.2 g/L (95% CI= -2.0 to -0.4) per 4 weeks in the control group but remained stable (0.0 g/L; 95% CI = -0.3 to +0.3) in the ATP group (P =.006)."
10675381,Premise,1395,1579,"Elbow flexor muscle strength declined by -5.5% (95% CI = -9.6% to -1. 4%) per 4 weeks in the control group but remained stable (0.0%; 95% CI= -1.4% to +1.4%) in the ATP group (P =.01)."
10675381,Premise,1580,1646,"A similar pattern was observed for knee extensor muscles (P =.02)."
10675381,Premise,1647,1843,"The effects of ATP on body weight, muscle strength, and albumin concentration were especially marked in cachectic patients (P =.0002, P =.0001, and P =. 0001, respectively, for ATP versus no ATP)."
10675381,Premise,1844,2152,"QOL score changes per 4-week period in the ATP group showed overall less deterioration than in the control group-physical scores (-0.2% versus -2.4%; P =. 0002); functional scores (+0.4% versus -5.5%; P =.02); psychologic scores (-0.7% versus -2.4%; P =.11); overall QOL score (+0.1% versus -3.5%; P =.0001)."
10675381,Claim,2193,2288,"ATP has beneficial effects on weight, muscle strength, and QOL in patients with advanced NSCLC."
10735887,Premise,552,677,"Overall objective response (OR) rates were higher in patients treated with EXE than in those treated with MA (15.0% v 12.4%);"
10735887,Premise,678,757,"a similar trend was noted in patients with visceral metastases (13.5% v 10.5%)."
10735887,Premise,758,1101,"Median survival time was significantly longer with EXE (median not reached) than with MA (123.4 weeks; P =.039), as were the median duration of overall success (OR or stable disease > or = 24 weeks; 60.1 v 49.1 weeks; P =.025), time to tumor progression (20.3 v 16.6 weeks; P =.037), and time to treatment failure (16.3 v 15.7 weeks; P =.042)."
10735887,Premise,1102,1195,"Compared with MA, there were similar or greater improvements in pain, TRSS, and QOL with EXE."
10735887,Claim,1196,1227,"Both drugs were well tolerated."
10735887,Premise,1228,1305,"Grade 3 or 4 weight changes were more common with MA (17.1% v 7.6%; P =.001)."
10735887,Claim,1306,1555,"EXE prolongs survival time, time to tumor progression, and time to treatment failure compared with MA and offers a well-tolerated treatment option for postmenopausal women with progressive advanced breast cancer who experienced failure of tamoxifen."
10856098,Premise,1116,1219,"The response rates, QOL, and median RD, TTP, and TTF were not significantly different between the arms."
10856098,Premise,1220,1293,"Median OS was 13.8 months for arm 1 versus 14.4 months for arm 2 (P =.4)."
10856098,Premise,1294,1434,"Grade 3 or 4 granulocytopenia was equivalent in both arms but more grade 3/4 neurotoxicity, mild venous toxicity, and FN were seen on arm 1."
10856098,Claim,1435,1501,"The survival with DOX and VNB is not superior to DOX alone in MBC."
10880548,MajorClaim,1,223,"Menopausal symptoms (e.g., hot flashes, vaginal dryness, and stress urinary incontinence) are very common in breast cancer survivors and cannot be managed with standard estrogen replacement therapy (ERT) in these patients."
10880548,Premise,1493,1661,"Patients receiving the intervention demonstrated statistically significant improvement (P =.0004) in menopausal symptoms but no significant change in vitality (P =.77)."
10880548,Premise,1662,1789,"Sexual functioning was statistically significantly improved (P =.04) in the treatment group compared with the usual-care group."
10880548,Claim,1790,2009,"A clinical assessment and intervention program for menopausal symptom management in breast cancer survivors is feasible and acceptable to patients, leading to reduction in symptoms and improvement in sexual functioning."
10880548,Claim,2010,2079,"Measurable improvement in a general QOL measure was not demonstrated."
10880550,Claim,1,135,"In phase II trials, paclitaxel has been shown to have antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC)."
10880550,Premise,1028,1226,"Survival was statistically significantly better in the paclitaxel plus supportive care arm than in the supportive care alone arm (two-sided P =.037) (median survival = 6.8 months versus 4.8 months)."
10880550,Premise,1227,1380,"Cox multivariate analysis showed paclitaxel plus supportive care to be statistically significantly associated with improved survival (two-sided P =.048)."
10880550,Premise,1381,1421,"QOL was similar for both treatment arms,"
10880550,Premise,1422,1610,"except for the functional activity score of the Rotterdam Symptom Checklist, where QOL data statistically significantly favored the paclitaxel plus supportive care arm (two-sided P =.043)."
10880550,Claim,1611,1829,"The addition of paclitaxel to best supportive care significantly improved survival and time to disease progression compared with best supportive care in patients with advanced NSCLC and may improve some aspects of QOL."
10930797,Premise,985,1133,"The final multivariate model predicted poor survival with multiple sites of visceral disease (P=0.003), DFI </=2 years (P=0.026) and pain (P=0.003)."
10930797,Premise,843,984,"For survival, multiple sites of visceral disease, pain, global QL and fatigue were significant prognostic factors in the univariate analysis."
10930797,Premise,1134,1248,"For response, age, dyspnoea, fatigue and global QL were significant predictive factors in the univariate analysis."
10930797,Premise,1249,1408,"The final multivariate model for response selected DFI (P=0.009), multiple sites of visceral disease (P=0.037) and dyspnoea (P=<0.001) using forward selection,"
10930797,Premise,1409,1548,"but model instability was indicated by the inclusion of fatigue and emotional function in the final model when backward selection was used."
10930797,Claim,1588,1721,"patient-assessed QL variables appear to be prognostic for survival and response to chemotherapy in women with advanced breast cancer."
10930797,Claim,1722,1892,"However, identification of prognostic factors from responses to questionnaires may be unstable, and their reliability and clinical utility should be tested prospectively."
10944126,Premise,759,979,"Patients allocated to oxaliplatin plus LV5FU2 had significantly longer progression-free survival (median, 9.0 v 6.2 months; P =.0003) and better response rate (50.7% v 22.3%; P =.0001) when compared with the control arm."
10944126,Premise,980,1081,"The improvement in overall survival did not reach significance (median, 16.2 v 14.7 months; P =. 12)."
10944126,Premise,1082,1381,"LV5FU2 plus oxaliplatin gave higher frequencies of National Cancer Institute common toxicity criteria grade 3/4 neutropenia (41. 7% v 5.3% of patients), grade 3/4 diarrhea (11.9% v 5.3%), and grade 3 neurosensory toxicity (18.2% v 0%), but this did not result in impairment of quality of life (QoL)."
10944126,Premise,1382,1528,"Survival without disease progression or deterioration in global health status was longer in patients allocated to oxaliplatin treatment (P =.004)."
10944126,Claim,1529,1738,"The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL."
10944130,Premise,742,893,"Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14)."
10944130,Premise,894,1106,"Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03)."
10944130,Premise,1107,1277,"Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05)."
10944130,Premise,1278,1402,"Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26)."
10944130,Premise,1403,1488,"QOL decreased during the first 8 weeks of treatment, and a partial recovery followed."
10944130,Premise,1489,1547,"Lower scores were associated with the combination therapy."
10944130,Claim,1548,1691,"Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC."
10944130,Claim,1692,1788,"13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors."
10944130,Claim,1789,1876,"Treatment, particularly the combination therapy, was associated with a decrease in QOL."
11034245,MajorClaim,153,238,"Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy,"
11034245,MajorClaim,243,313,"oral 5-FU derivatives have been shown a comparable antitumor activity."
11034245,Claim,1,152,"Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate."
11034245,Premise,1354,1453,"Mean numbers of chemotherapy cycles were 6.5+/-3.7 (IV arm) vs. 7.2+/-4.3 (oral arm), respectively."
11034245,Premise,1454,1566,"The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5 %) in the oral arm, respectively (P = .937)."
11034245,Premise,1567,1681,"Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II; 1.1%) in the oral arm, respectively."
11034245,Premise,1682,1800,"Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively."
11034245,Premise,1801,1859,"The most common site of systemic recurrence was the liver."
11034245,Premise,1860,1998,"Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm."
11034245,Premise,1999,2040,"Diarrhea was more common in the oral arm."
11034245,Premise,2041,2176,"Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy."
11034245,Premise,2177,2293,"Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P<.05)."
11034245,Claim,2294,2457,"Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy."
11034245,Claim,2458,2543,"The oral regimen also can be safely given with appropriate toxicity and tolerability."
11106123,Premise,1620,1768,"After a median follow-up time of 62 (range 18-108) weeks, the median time to progression was 38, 25, and 27 weeks for arm A, B, and C, respectively."
11106123,Premise,1769,1872,"With 94 patients still alive, the one-year probability of survival was 61%, 54%, and 59%, respectively."
11106123,Premise,1873,1995,"WHO grade 3 or 4 neutropenia and diarrhoea affected 46% and 16%, respectively, of patients treated with CPT-11 + LFA 5-FU."
11106123,Premise,1996,2087,"Median relative dose intensity over eight cycles (DI8) was 78% for CPT-11 and 82% for 5-FU."
11106123,Premise,2088,2226,"Severe toxicities of TOM + LFA-5-FU were neutropenia (16%) and diarrhoea (16%), but median relative DI8 was 93% for TOM, and 82% for 5-FU."
11106123,Premise,2227,2377,"CPT-11 + LFA-5-FU compares favorably in term of activity and toxicity with other combination regimens including CPT-11 and continuous infusional 5-FU."
11106123,Claim,2378,2495,"The hypothesis of a RR 15% higher than the MTX + LFA-5-FU treatment can not be ruled out after this interim analysis."
11106123,Claim,2496,2683,"The TOM + LFA 5-FU regimen showed a RR and a toxicity profile very close to the MTX + LFA 5-FU combination, and does not deserve further evaluation in advanced colorectal cancer patients."
11142481,Premise,905,1197,"Nine CR and twenty-seven PR were obtained on one hundred eleven evaluable patients treated in experimental arm (RR = 32%, 95% confidence interval (95% CI): 24%-42%), while two CR and eleven PR were observed among one hundred three evaluable patients in control arm (RR = 13%, 95% CI: 7%-21%)."
11142481,Premise,1198,1302,"WHO grade 3-4 toxicity occurred in 13% of cycles of experimental arm and in 8% of cycles in control arm."
11142481,Premise,1303,1405,"The PFS was significantly longer in experimental arm (6.2 vs. 4.3 months, odds ratio 0.66, P = 0.003),"
11142481,Premise,1412,1523,"the overall survival was similar in both arms (14.8 months in experimental arm vs. 14.1 months in control arm);"
11142481,Claim,1524,1560,"quality of life was similar as well."
11142481,Premise,1561,1681,"Eighty percent of patients receiving second-line chemotherapy in control arm were treated with continuous infusion 5-FU."
11142481,Claim,1695,1829,"schedule-specific biochemical modulation of FU is more active than MTX --> 5-FU as first-line treatment of advanced colorectal cancer."
11142481,Claim,1830,2017,"However, the overall survival was similar suggesting that alternating bolus and infusional 5-FU upfront may be as effective as giving them in sequence as first- and second-line treatment."
11181777,MajorClaim,1,121,"The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC)."
11181777,Premise,1209,1465,"Patients in the PCDE arm had a statistically significant higher frequency of combined complete plus partial responses compared with those in the EP arm (21% plus 55% versus 13% plus 48%, respectively; P =.02 for difference in combined objective responses)."
11181777,Premise,1466,1653,"Patients in the PCDE arm survived longer than those in the EP arm (1-year survival rate: 40% and 29%, respectively; median survival: 10.5 and 9.3 months, respectively; log-rank P =.0067)."
11181777,Premise,1654,1812,"In the Cox model, the relative risk of death for patients in the PCDE arm compared with those in the EP arm was 0.70 (95% confidence interval = 0.51 to 0.95);"
11181777,Premise,1813,1881,"the disease also progressed more slowly in patients in the PCDE arm."
11181777,Premise,1882,2004,"Hematologic toxicity was higher in the PCDE arm (22% with documented infections compared with 8% in the EP arm; P =.0038),"
11181777,Premise,2009,2099,"the toxicity-related death rate was 9% in the PCDE arm versus 5.5% in the EP arm (P =.22)."
11181777,Claim,2100,2182,"The global health status showed similar improvement in both arms during treatment."
11181777,Claim,2183,2392,"Compared with the EP regimen, the PCDE regimen yielded higher response rates and better survival rates in patients with extensive SCLC without affecting the quality of life of the patients during chemotherapy."
11250991,Premise,1118,1193,"The projected 2-year PFS is 90.4% on three cycles and 89.4% on four cycles."
11250991,Premise,1194,1297,"The difference in PFS between three and four cycles is -1.0% (80% confidence limit [CL], -3.8%, +1.8%)."
11250991,Claim,1298,1421,"Equivalence for three versus four cycles is claimed because both the upper and lower bounds of the 80% CL are less than 5%."
11250991,Premise,1422,1558,"In the 5- versus 3-day comparison, the projected 2-year PFS is 88.8% and 89.7%, respectively (difference, -0.9%, (80% CL, -4.1%, +2.2%)."
11250991,Claim,1566,1613,"equivalence is claimed in this comparison also."
11250991,Premise,1614,1696,"Frequencies of hematologic and nonhematologic toxicities were essentially similar."
11250991,Premise,1697,1770,"Quality of life was maintained better in patients receiving three cycles;"
11250991,Premise,1771,1834,"no differences were detected between 3 and 5 days of treatment."
11250991,Claim,1852,1960,"three cycles of BEP, with etoposide at 500 mg/m(2), is sufficient therapy in good-prognosis germ cell cancer"
11250991,Claim,1970,2085,"the administration of the chemotherapy in 3 days has no detrimental effect on the effectiveness of the BEP regimen."
11304763,Premise,780,862,"Complete and partial response rates to induction PE were 3% and 32%, respectively."
11304763,Premise,863,956,"A 7% response rate was observed with topotecan (complete response, 2%; partial response, 5%)."
11304763,Premise,957,1027,"The median survival time for all 402 eligible patients was 9.6 months."
11304763,Premise,1028,1198,"Progression-free survival (PFS) from date of randomization on step 2 was significantly better with topotecan compared with observation (3.6 months v 2.3 months; P <.001)."
11304763,Premise,1208,1371,"overall survival from date of randomization on step 2 was not significantly different between the observation and topotecan arms (8.9 months v 9.3 months; P =.43)."
11304763,Premise,1372,1524,"Grade 4 neutropenia and thrombocytopenia occurred in 50% and 3%, respectively, of PE patients in step 1 and 60% and 13% of topotecan patients in step 2."
11304763,Premise,1525,1612,"Grade 4/5 infection was observed in 4.6% of PE patients and 1.8% of topotecan patients."
11304763,Premise,1613,1682,"Grade 3/4 anemia developed in 22% of patients who received topotecan."
11304763,Premise,1683,1820,"No difference in quality of life between topotecan and observation was observed at any assessment time or for any of the subscale scores."
11304763,Claim,1821,1989,"Four cycles of PE induction therapy followed by four cycles of topotecan improved PFS but failed to improve overall survival or quality of life in extensive-stage SCLC."
11304763,Claim,1990,2124,"Four cycles of standard PE remains an appropriate first-line treatment for extensive-stage SCLC patients with good performance status."
12122096,MajorClaim,1,118,"The role of adjuvant chemotherapy in postmenopausal patients with lymph node-negative breast cancer is controversial."
12122096,Premise,1161,1385,"The added benefit of CMF followed by tamoxifen over tamoxifen alone was statistically significantly dependent on ER status (tests for interaction: P =.01 for disease-free survival [DFS] and P =.07 for overall survival [OS])."
12122096,Premise,1386,1826,"For patients with ER-negative tumors, the addition of CMF statistically significantly improved DFS (5-year DFS = 84% for CMF-->tamoxifen versus 69% for tamoxifen alone; difference = 15%; 95% confidence interval [CI] = 6% to 24%; risk ratio [RR] = 0.52; 95% CI = 0.34 to 0.79; P =.003) and OS (5-year OS = 89% for CMF-->tamoxifen versus 81% for tamoxifen alone; difference = 8%; 95% CI = 0% to 16%; RR = 0.51; 95% CI = 0.30 to 0.87; P =.01)."
12122096,Premise,1827,2233,"By contrast, for patients with ER-positive tumors, addition of CMF provided no benefit in terms of DFS (5-year DFS = 84% for CMF-->tamoxifen versus 85% for tamoxifen alone; difference = -1; 95% CI = -6% to 4%; RR = 0.99; 95% CI = 0.75 to 1.30; P =.92) or OS (5-year OS = 95% for CMF-->tamoxifen versus 93% for tamoxifen alone; difference = 2%; 95% CI = -1% to 5%; RR = 0.95; 95% CI = 0.64 to 1.40; P =.80)."
12122096,Claim,2234,2412,"Postmenopausal patients with lymph node-negative breast cancer benefited substantially from adjuvant chemotherapy if their cancer was ER-negative (i.e., endocrine-nonresponsive)."
12122096,Claim,2413,2574,"In contrast, if their cancer was ER-positive (i.e., endocrine-responsive), they obtained no benefit from the combination treatment compared with tamoxifen alone."
12131085,Claim,131,268,"A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems."
12131085,Claim,269,368,"Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative"
12131085,Premise,1187,1306,"At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage."
12131085,Premise,1316,1413,"there were no differences in the bowel function, continence score, and quality of life at 1 year."
12131085,Premise,1414,1500,"There were no differences in the anorectal manometry and endoanal ultrasound findings."
12131085,Claim,1501,1597,"Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function."
12131085,Claim,1610,1674,"the J-pouch remains the benchmark for routine clinical practice,"
12131085,Claim,1679,1767,"due care (including defunctioning stoma) should be exercised in situations requiring CP."
12131085,Premise,1148,1186,"CP resulted in more anastomotic leaks."
12181240,Claim,1,83,"Chemotherapy is moderately efficient as a treatment for pancreatic adenocarcinoma,"
12181240,Claim,84,172,"but patient survival and quality of life has improved with this modality in some trials."
12181240,Premise,1271,1482,"Toxicity (WHO grade 3-4) was lower with FU than with FUP (20% versus 48%, P <0.001), as was neutropenia (6% versus 23%), vomiting (4% versus 17%) and toxicity-related deaths (one versus four early in the trial)."
12181240,Premise,1483,1605,"The response rate was low in both arms, but superior in the FUP arm: 12% versus 0% (intention-to-treat analysis, P <0.01)."
12181240,Premise,1606,1761,"The survival rates at 6 months were 28% and 38% for the FU and FUP arms, respectively, and 1-year survival rates were 9% and 17% (log-rank test, P = 0.10)."
12181240,Premise,1762,1860,"One-year progression-free survival was 0% with FU versus 10% with FUP (log-rank test, P = 0.0001)."
12181240,Claim,1861,2030,"In advanced pancreatic carcinomas with a poor prognosis, FUP was superior to FU in terms of response and progression-free survival, but not in terms of overall survival."
12181240,Claim,2142,2219,"A more effective, better tolerated version of this FUP combination is needed."
12195763,Claim,1,99,"Amitriptyline is the most common analgesic adjuvant used in cancer patients with neuropathic pain,"
12195763,Claim,112,160,"no specific studies have demonstrated a benefit."
12195763,Premise,1210,1474,"No significant benefits in analgesia were found in the global pain intensity of the previous week of treatment, the least pain intensity or the pain evaluated just after a week of treatment, at the moment of the visit, when amitriptyline was compared with placebo."
12195763,Premise,1475,1545,"A significant difference was evidenced for the worst pain (P < 0.035)."
12195763,Premise,1546,1615,"No differences in opioid doses during the period of study were found."
12195763,Premise,1616,1765,"Drowsiness, confusion and dry mouth were significantly more intense with amitriptyline than with placebo (P < 0.036, 0.003, and 0.034, respectively)."
12195763,Premise,1766,1884,"There were no substantial differences between the two treatments in Spitzer's quality of life score and for each item."
12195763,Premise,1885,1965,"No differences in patients' preference for the two treatment periods were found."
12195763,Claim,1966,2053,"The analgesic effects of amitriptyline were slight and associated with adverse effects."
12195763,Claim,2101,2168,"the extensive use of the drug for cancer pain should be questioned."
12202326,Premise,1968,2147,"No evidence of a difference was observed between the two treatment groups in terms of activity level, anxiety, depression, and psychological distress, as recorded by the patients."
12202326,Premise,2148,2213,"Adverse events were more common in the immediate treatment group."
12202326,Premise,2214,2295,"Neither group had a survival advantage (hazard ratio 0.95, 0.73 to 1.24; P=0.71)."
12202326,Premise,2296,2342,"Median survival was 8.3 months and 7.9 months,"
12202326,Premise,2347,2458,"the survival rates were 31% and 29% at 12 months, for the immediate and delayed treatment groups, respectively."
12202326,Claim,2459,2759,"In minimally symptomatic patients with locally advanced non-small cell lung cancer, no persuasive evidence was found to indicate that giving immediate palliative thoracic radiotherapy improves symptom control, quality of life, or survival when compared with delaying until symptoms require treatment."
12202326,Premise,1733,1967,"The primary outcome measure was achieved in 28% of the immediate treatment group and 26% of patients from the delayed treatment group (27/97 and 27/103, respectively; absolute difference 1.6%, 95% confidence interval -10.7% to 13.9%)."
12243809,Premise,1279,1384,"The incidence of Grade 4 toxicity was 56% in patients receiving mitomycin-C and 29% in those who did not."
12243809,Premise,1385,1491,"Only 1 patient in each group had acute nonhematologic toxicity greater than Grade 3 (nausea and vomiting)."
12243809,Premise,1492,1538,"No acute Grade 4 radiation toxicity developed."
12243809,Premise,1539,1608,"The incidences of long-term toxicity were equivalent across the arms."
12243809,Premise,1609,1798,"Three treatment-related deaths occurred: 2 patients in the surgical arms (one late pulmonary toxicity and one pulmonary embolus), and 1 patient in the radiation arm (radiation pneumonitis)."
12243809,Premise,1799,1859,"Induction chemotherapy was completed in 78% of the patients."
12243809,Premise,1860,1938,"Complete resection was performed in 73% of 26 patients undergoing thoracotomy."
12243809,Premise,1939,2003,"Consolidation chemotherapy was completed in 75% of the patients."
12243809,Premise,2004,2079,"No statistically significant difference was found among the treatment arms."
12243809,Premise,2080,2160,"The overall progression-free survival rate was 53% at 1 year and 17% at 3 years."
12243809,Premise,2161,2212,"The median progression-free survival was 14 months."
12243809,Premise,2213,2348,"No difference in the 1-year survival rate (70% vs. 66%) or median survival time (19.4 vs. 17.4 months) between the surgery and RT arms."
12243809,Premise,2349,2438,"The median survival in the patients receiving induction chemotherapy only was 8.9 months."
12243809,Premise,2439,2488,"Mitomycin-C had no impact on survival (p = 0.75)."
12243809,Premise,2489,2601,"No statistically significant difference was noted in the time to local failure between the surgical and RT arms."
12243809,Claim,2602,2666,"The patient accrual to this trial made its results inconclusive,"
12243809,Claim,2720,2845,"histologic confirmation of N2 disease in the surgical and nonsurgical arms eliminated the usual biases from clinical staging."
12243809,Claim,2863,2946,"local control and survival were essentially equal between the surgical and RT arms."
12243809,Claim,2947,3062,"The 3- and 5-year survival rates of nonsurgical therapy were comparable to published surgical trials of N2 disease."
12351592,Premise,1,92,"Mucositis occurs in almost all patients treated with radiotherapy for head and neck cancer."
12351592,Premise,862,927,"Toxicity profiles were similar between the two arms of the study."
12351592,Premise,928,1068,"The median time to development of severe mucositis from the start of radiotherapy was 3.61 weeks on BCoG and 3.96 weeks on placebo (P =.61)."
12351592,Premise,1069,1268,"There were no statistically significant differences between the arms in the extent of severe mucositis as measured by physician, in oral toxicities as recorded by patients, or in radiotherapy delays."
12351592,Claim,1466,1602,"in this group of patients treated with conventional radiotherapy, the lozenge did not impact significantly on the severity of mucositis."
12351592,Claim,1603,1815,"Whether such a lozenge would be beneficial in treatment situations where rate of severe mucositis is higher (ie, in patients treated with unconventional fractionation or with concomitant chemotherapy) is unknown."
12359855,Claim,1,85,"Bone metastases are a common cause of morbidity in patients with prostate carcinoma."
12359855,Premise,964,1318,"A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222)."
12359855,Premise,1319,1594,"Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo)."
12359855,Premise,1595,1803,"Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001)."
12359855,Premise,1804,1924,"Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,"
12359855,Premise,1929,2042,"there were no differences in disease progression, performance status, or quality-of-life scores among the groups."
12359855,Claim,2043,2116,"Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,"
12359855,Claim,2121,2184,"the 8-mg dose was associated with renal function deterioration."
12359855,Claim,2185,2290,"Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases."
12395333,Claim,159,269,"Tamoxifen (TMX) is believed to inhibit HCC positive for estrogen receptor (ER), but most HCCs are ER negative."
12395333,Claim,270,362,"Results of previous phase 3 trials in inoperable HCC have been conflicting and inconclusive."
12395333,Claim,363,440,"At higher doses, however, TMX inhibits HCC through ER-independent mechanisms."
12395333,Premise,1112,1317,"Three-month survival rates for the P, TMX60, and TMX120 groups were 44%, 41%, and 35%, respectively, with a statistically significant trend difference in survival across the 3 treatment regimens (P =.011)."
12395333,Premise,1318,1468,"There was a significantly higher risk of death in the TMX120 group compared with the P group (hazard ratio, 1.39; 95% confidence interval, 1.07-1.81)."
12395333,Premise,1469,1525,"Adverse drug reactions were reported in 3% (9 patients),"
12395333,Premise,1530,1564,"8 patients were lost to follow-up."
12395333,Claim,1580,1703,"TMX does not prolong survival in patients with inoperable HCC and has an increasingly negative impact with increasing dose."
12395333,Claim,1704,1758,"No appreciable advantage to QoL with TMX was observed."
12431965,Claim,1,111,"Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC)."
12431965,Premise,859,1028,"Best response to induction therapy was complete remission for 176 patients (33%), partial remission for 341 (64%), and 15 patients (3%) had undergone surgical resection."
12431965,Premise,1155,1262,"Median survivals for marimastat and placebo patients were 9.3 months and 9.7 months, respectively (P =.90)."
12431965,Premise,1029,1154,"The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P =.81)."
12431965,Premise,1263,1353,"Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat)."
12431965,Premise,1354,1524,"Dose modifications for musculoskeletal toxicity were required in 90 patients (33%) on the marimastat arm, and 87 (32%) permanently stopped marimastat because of toxicity."
12431965,Premise,1525,1607,"Patients on marimastat had significantly poorer quality of life at 3 and 6 months."
12431965,Claim,1608,1748,"Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life."
12431971,Claim,1,204,"Morbidity associated with wound complications may translate into disability and quality-of-life disadvantages for patients treated with radiotherapy (RT) for soft tissue sarcoma (STS) of the extremities."
12431971,Premise,779,982,"Patients treated with postoperative RT had better function with higher MSTS (25.8 v 21.3, P <.01), TESS (69.8 v 60.6, P =.01), and SF-36 bodily pain (67.7 v 58.5, P =.03) scores at 6 weeks after surgery."
12431971,Premise,1031,1194,"Scores on the physical function, role-physical, and general health subscales of the SF-36 were significantly lower than Canadian normative data at all time points."
12431971,Premise,1442,1589,"When wound complication was included in the model, patients with complications had lower MSTS and TESS scores in the first 2 years after treatment."
12431971,Claim,1590,1689,"The timing of RT has minimal impact on the function of STS patients in the first year after surgery"
12431971,Claim,1691,1783,"Tumor characteristics and wound complications have a detrimental effect on patient function."
12453852,Premise,691,752,"The overall response rate was 34.6% for NP and 35.7% for NIP."
12453852,Premise,753,868,"Median and 1-year survival rates were 10.0 months and 38.4% for NP, and 8.2 months and 33.7% for NIP, respectively."
12453852,Premise,923,1219,"The major World Health Organization grade 3-4 toxicities for NP and NIP, respectively, were: neutropenia (20.3% compared with 9% of cycles), anaemia (4.1% compared with 5% of cycles), nausea and vomiting (22.2% compared with 19.4% of patients) and alopecia (5.6% compared with 29.8% of patients)."
12453852,Premise,1220,1286,"Four toxic deaths occurred in the NP arm and eight in the NIP arm."
12453852,Premise,1287,1422,"The different schedules of vinorelbine in the two arms led to a greater survival in the NP arm without impairing the tolerance profile,"
12453852,Premise,1423,1470,"although this is not statistically significant."
12453852,Claim,1471,1564,"This confirms that the two-drug combination NP is a reference treatment for metastatic NSCLC."
12453852,Claim,1565,1649,"The role of three-drug combinations remains questionable in this subset of patients."
12467070,Premise,1077,1254,"Among the patients receiving treatment 3 times weekly, 16 of 49 patients (32.7%) achieved a clinical response at the end of the third treatment cycle (no CRs, 1 PR, and 15 SDs)."
12467070,Premise,1255,1376,"Concomitant or prior use of protease inhibitors did not appear to affect the patient's response to treatment (P = 0.183)."
12467070,Premise,1377,1526,"Liposomal tretinoin is a new therapeutic agent that has been reported to have some clinical activity in patients with AIDS-associated Kaposi sarcoma."
12467070,Claim,1527,1690,"A three-times-per-week dosing schedule was noted to be more effective compared with a once-a-week schedule without any significant difference in toxicity reported."
12488409,Premise,894,1028,"There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72)."
12488409,Premise,1029,1199,"With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine."
12488409,Premise,1200,1310,"No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95)."
12488409,Premise,1311,1432,"Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP."
12488409,Premise,1433,1494,"Peripheral neuropathy and alopecia were more common with CVP."
12488409,Premise,1495,1574,"Patients receiving fludarabine had higher scores for social function (P =.008);"
12488409,Premise,1575,1617,"no other differences in QoL were detected."
12488409,Claim,1618,1756,"In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS."
12525531,Claim,1,142,"Anemia, highly common among cancer patients, is often an underlying cause of cancer-related fatigue and other quality-of-life (QOL) deficits."
12525531,Premise,1297,1495,"Comparison of the population norm and clinical trial data showed that treatment with epoetin alfa resulted in clinically meaningful as well as statistically significant improvements in QOL (P <.01)."
12525531,Claim,1648,1804,"In the clinical trial, treatment with epoetin alfa overcame much of the QOL deficit seen in anemic cancer patients compared with the norm population sample."
12560436,Premise,778,871,"No changes were found in arm circumference or arm volume as a result of the exercise program."
12560436,Premise,872,1044,"Three of the quality-of-life domains showed trends toward increases in the exercise group: physical functioning (P =.050), general health (P =.048), and vitality (P =.023)."
12560436,Premise,1045,1125,"Mental health increased, although not significantly, for all subjects (P =.019)."
12560436,Premise,1126,1229,"Arm volume measured by water displacement was correlated with calculated arm volume (r =.973, P <.001),"
12560436,Premise,1230,1315,"although the exercise and control group means were significantly different (P <.001)."
12560436,Claim,1525,1614,"Additional studies should be done in this area to determine the optimum training program."
12560436,Claim,1316,1524,"Participation in an upper-body exercise program caused no changes in arm circumference or arm volume in women with lymphedema after breast cancer, and they may have experienced an increase in quality of life."
12569144,Claim,1,100,"Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases."
12569144,Premise,1013,1228,"Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21)."
12569144,Premise,1229,1533,"The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001)."
12569144,Premise,1534,1641,"The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,"
12569144,Premise,1642,1774,"but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06)."
12569144,Premise,1775,1986,"For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05)."
12569144,Claim,1987,2178,"Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands."
12569144,Claim,2179,2327,"Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases."
12610178,Claim,1,147,"Randomized trials in fluorouracil (FU)-refractory colorectal cancer demonstrate significant survival advantages for patients receiving irinotecan."
12610178,Premise,679,961,"With median follow-up of 15.8 months, there was no significant difference in 1-year survival (46% v 41%, respectively; P =.42), median survival (9.9 v 9.9 months, respectively; P =.43), or median time to progression (4.0 v 3.0 months, respectively; P =.54) between the two regimens."
12610178,Premise,962,1081,"Grade 3/4 diarrhea occurred in 36% of patients treated weekly and in 19% of those treated once every 3 weeks (P =.002)."
12610178,Premise,1082,1200,"Grade 3/4 neutropenia occurred in 29% of patients treated weekly and 34% of those treated once every 3 weeks (P =.35)."
12610178,Premise,1201,1358,"Treatment-related mortality occurred in five patients (5.3%) receiving irinotecan weekly and three patients (1.6%) given therapy once every 3 weeks (P =.12)."
12610178,Premise,1359,1439,"Global quality of life was not statistically different between treatment groups."
12610178,Claim,1440,1608,"Irinotecan schedules of weekly and of once every 3 weeks demonstrated similar efficacy and quality of life in patients with FU-refractory, metastatic colorectal cancer."
12610178,Claim,1609,1714,"The regimen of once every 3 weeks was associated with a significantly lower incidence of severe diarrhea."
12610183,Premise,985,1116,"The dose-intensified arm was slightly more emetogenic and generated more grade 3 to 4 anemia but less febrile neutropenia episodes."
12610183,Premise,1187,1347,"The median PFS was 34 and 33.7 months for CEF and EC, respectively (P =.68), and the 5-year survival rate was 53% and 51% for CEF and EC, respectively (P =.94)."
12610183,Claim,1348,1510,"Dose-intensified EC does not provide a measurable therapeutic benefit over CEF as neoadjuvant chemotherapy for unselected locally advanced breast cancer patients."
12610188,Premise,909,1086,"Median survival was 16.9 months (95% confidence interval [CI], 10.5 to 21.2 months) in the TEE arm and 23.4 months (95% CI, 12.9 to 30.6 months) for patients treated with KA/VE."
12610188,Premise,1087,1206,"Many patients (24%) failed to complete at least 6 weeks of therapy, including five (8%) treatment-related early deaths."
12610188,Claim,1207,1272,"Each of these regimens produced clinically significant responses,"
12610188,Claim,1277,1430,"the observed median survival (18.9 months for all 71 patients) compares favorably with previously published results, especially in the community setting."
12610188,Claim,1431,1524,"Nonetheless, it is apparent that these first-generation regimens must be applied judiciously,"
12610188,Claim,1529,1743,"thus we view efforts at better patient selection and the development of more tolerable therapies as higher priorities than carrying either of these regimens to phase III evaluation in the cooperative group setting."
12618501,Claim,1,129,"Vinorelbine prolongs survival and improves quality of life in elderly patients with advanced non-small-cell lung cancer (NSCLC)."
12618501,Claim,130,229,"Some studies have also suggested that gemcitabine is well tolerated and effective in such patients."
12618501,Premise,1152,1235,"Compared with each single drug, the combination treatment did not improve survival."
12618501,Premise,1236,1477,"The hazard ratio of death for patients receiving the combination treatment was 1.17 (95% confidence interval [CI] = 0.95 to 1.44) that of patients receiving vinorelbine and 1.06 (95% CI = 0.86 to 1.29) that of patients receiving gemcitabine."
12618501,Premise,1478,1547,"Although quality of life was similar across the three treatment arms,"
12618501,Premise,1548,1621,"the combination treatment was more toxic than the two drugs given singly."
12618501,Claim,1622,1794,"The combination of vinorelbine plus gemcitabine is not more effective than single-agent vinorelbine or gemcitabine in the treatment of elderly patients with advanced NSCLC."
12637459,Premise,427,649,"Time to progression (TTP; primary end point) and time to treatment failure (TTF) were significantly longer with AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 v 23.7 weeks; log-rank P =.048)."
12637459,Premise,650,858,"The overall response rate (ORR) was significantly greater for patients taking AT (59%, with 10% complete response [CR], 49% partial response [PR]) than for those taking AC (47%, with 7% CR, 39% PR) (P =.009)."
12637459,Premise,859,1053,"The ORR was also higher with AT in patients with visceral involvement (58% v 41%; liver, 62% v 42%; lung, 58% v 35%), three or more organs involved (59% v 40%), or prior adjuvant CT (53% v 41%)."
12637459,Premise,1054,1104,"Overall survival (OS) was comparable in both arms."
12637459,Premise,1105,1155,"Grade 3/4 neutropenia was frequent in both groups,"
12637459,Premise,1156,1294,"although febrile neutropenia and infections were more frequent for patients taking AT (respectively, 33% v 10%, P <.001; 8% v 2%, P =.01)."
12637459,Premise,1295,1409,"Severe nonhematologic toxicity was infrequent in both groups, including grade 3/4 cardiac events (AT, 3%; AC, 4%)."
12637459,Claim,1410,1486,"AT significantly improves TTP and ORR compared with AC in patients with MBC,"
12637459,Claim,1487,1520,"but there is no difference in OS."
12637459,Claim,1521,1575,"AT represents a valid option for the treatment of MBC."
12953086,MajorClaim,1,152,"Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue."
12953086,Premise,1028,1278,"The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%)."
12953086,Premise,1279,1486,"Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;"
12953086,Premise,1487,1668,"the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively)."
12953086,Premise,1669,1747,"The TC regimen was associated with a higher frequency of hematologic toxicity,"
12953086,Premise,1748,1835,"but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen."
12953086,Premise,1836,2050,"Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68)."
12953086,Claim,2051,2321,"The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer."
12963704,Premise,623,894,"With a median follow-up of more than 3 years, survival did not differ among the treatment groups (median FU + LV, 11.1 months [95% CI, 10.2 to 15.0 months]; FU24h, 13.0 months [95% CI, 10.4 to 15.4 months]; FU24h + LV, 13.7 months [95% CI, 12.0 to 16.4 months]; P =.724)."
12963704,Premise,895,1110,"Progression-free survival (PFS) was significantly longer for FU24h + LV (median FU + LV, 4.0 months [95% CI, 3.4 to 4.9]; FU24h, 4.1 months [95% CI, 3.4 to 5.0]; FU24h + LV 5.6 months [95% CI, 4.4 to 6.7]; P =.029)."
12963704,Premise,1111,1272,"The response rates in the subgroup of patients with measurable disease were 12%, 10%, and 17% for FU + LV, FU24h, and FU24h + LV, respectively (not significant)."
12963704,Premise,1273,1399,"Occurrence of grade 3 and 4 diarrhea was higher in the FU24h + LV arm (22%) compared with the FU24h (6%) or FU + LV (9%) arms;"
12963704,Premise,1400,1537,"however, stomatitis (11% in FU + LV v 3% in FU24h v 5% in FU24h + LV arms) and hematologic toxicity were higher in the bolus FU + LV arm."
12963704,Claim,1538,1598,"Global quality of life did not differ within the three arms."
12963704,Claim,1599,1672,"Neither FU24h + LV nor FU24h prolong survival, relative to bolus FU + LV."
12963704,Claim,1673,1740,"Leucovorin increases PFS if added to FU24h, but increases toxicity."
14550448,Premise,457,608,"Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device."
14550448,Premise,609,752,"Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03)."
14550448,Premise,753,847,"At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006)."
14550448,Premise,848,1000,"Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm."
14550448,Premise,1001,1128,"Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year."
14550448,Premise,1129,1208,"After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02)."
14550448,Claim,1209,1380,"By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy."
14550448,Claim,1381,1560,"Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased."
14594437,Premise,1,226,"In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL."
14594437,Premise,296,414,"a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126])."
14594437,Premise,1352,1605,"The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY."
14594437,Premise,1606,1735,"The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival."
14594437,Claim,1736,1944,"The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy."
14594437,Claim,1945,1978,"Additional studies are warranted."
14698542,Claim,1,142,"In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1-2 months on median survival versus best supportive care."
14698542,Claim,143,190,"Chemotherapy seems to improve symptoms control,"
14698542,Premise,1263,1524,"Despite difficulties in carrying out and analysing QoL items in such patients, the global QoL evaluated by the Spitzer's questionnaire suggested an advantage for MVC regimen (P=0.05) and a significant difference was observed in global health subdomain (P=0.04)."
14698542,Premise,1525,1573,"The disease-related symptoms improved with time,"
14698542,Premise,1578,1630,"the benefits lasted for the entire treatment period."
14698542,Premise,1631,1894,"When evaluated with the EORTC questionnaire there was significantly less nausea and vomiting (P=0.0001), appetite loss (P=0.01), insomnia (P=0.03), constipation (P=0.01) and peripheral neuropathy (P=0.01) in favour of MVC, and a trend for less hair loss (P=0.05)."
14698542,Premise,1895,1953,"The advantage lasted for all the duration of chemotherapy."
14698542,Premise,1954,2052,"No differences were observed in global quality of life subdomain (P=0.40) between the two regimen."
14698542,Premise,2158,2350,"we reported a response rate of 43.1 and 38.6%, respectively, in MVP and MVC arm (P=0.59) and a median survival of 10.2 and 7.2 months, respectively, for cisplatin and carboplatin arm (P=0.39)."
14698542,Premise,2351,2573,"The carboplatin containing regimen (MVC) has a significant better toxicity profile than the cisplatin containing (MVP) regimen as proven both by the EORTC questionnaires and by the WHO toxicity data reported by physicians."
14698542,Claim,2574,2707,"No significant differences in terms of response rate, time to progression and overall survival were observed between the two regimen."
14698542,Claim,2708,2850,"The two chemotherapy regimen showed a similar effectiveness in symptom palliation when evaluated with C30 addendum of EORTC QOL questionnaire."
14698542,Premise,2851,3041,"With the Spitzer's questionnaires a trend towards an improved quality of life index was observed during treatment with the carboplatin combination in comparison to the cisplatin combination."
14698542,Premise,3042,3179,"This difference, however, was not observed when the global quality of life was evaluated with the EORTC patients compiled questionnaires."
14698542,Claim,3180,3412,"A carboplatin containing regimen with better toxicity profile and a similar potentiality for symptoms control offers an option in comparison to similar cisplatin containing combinations in the palliative treatment of advanced NSCLC."
14722035,Premise,1169,1236,"There was no significant difference in RR, RD, or PFS between arms."
14722035,Premise,1237,1343,"DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021)."
14722035,Premise,1344,1417,"DPPE plus DOX was associated with more gastrointestinal and CNS toxicity."
14722035,Premise,1418,1462,"No consistent influence on QOL was detected."
14722035,Claim,1463,1566,"This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX."
14722035,Claim,1567,1608,"Additional studies of DPPE are warranted."
14990635,Premise,1336,1399,"HRQOL and symptom relief were equivalent in the treatment arms."
14990635,Premise,1400,1532,"No significant difference in survival among arms A, B, and C was found, with median survival 8.2, 7.0, and 6.8 months, respectively."
14990635,Claim,1533,1718,"Our data indicate that protracted palliative TRT renders no improvement in symptom relief, HRQOL, or survival when compared with short-term hypofractionated treatment in advanced NSCLC."
14996859,Premise,1,144,"During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy."
14996859,Premise,1185,1331,"Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05)."
14996859,Premise,1332,1461,"At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received."
14996859,Premise,1462,1750,"At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being."
14996859,Premise,1751,1883,"Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001)."
14996859,Claim,1884,2113,"At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy."
14996859,Claim,2114,2307,"Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer."
15120769,Premise,1022,1122,"No between-treatment differences were observed for changes in quality of life or performance status,"
15120769,Premise,1127,1259,"patients started on strong opioids had significantly better pain relief than patients treated according to WHO guidelines (P=0.041)."
15120769,Premise,1260,1502,"Additionally, patients started on strong opioids required significantly fewer changes in therapy, had greater reduction in pain when a change was initiated, and reported greater satisfaction with treatment than the comparator group (P=0.041)."
15120769,Claim,1503,1607,"Strong opioids were safe and well-tolerated, with no development of tolerance or serious adverse events."
15120769,Claim,1608,1723,"These data suggest the utility of strong opioids for first-line treatment of pain in patients with terminal cancer."
15297582,Premise,1119,1232,"On average, there were significantly higher volumes of tris-acryl microspheres used (9.0 mL vs 3.0 mL; P =.0001),"
15297582,Premise,1241,1311,"microcatheter occlusion was more common with PVA (28% vs 4%, P =.001)."
15297582,Premise,1312,1438,"There were no differences in pain severity, other postprocedural symptoms, or medication use between the two treatment groups."
15297582,Premise,1439,1594,"There were also no differences in the frequency of incompletely infarcted leiomyomas, degree of improvement in symptom score, patient satisfaction, or QOL."
15297582,Claim,1595,1723,"No substantive differences were detected between outcomes of embolization with PVA particles or tris-acryl gelatin microspheres."
15338385,Claim,74,196,"Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients."
15338385,Premise,927,1113,"Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37)."
15338385,Premise,1114,1303,"Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);"
15338385,Premise,1304,1403,"however, there was no significant difference between changes in the scores of both groups (p=0.67)."
15338385,Claim,1404,1549,"We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours."
15338385,Claim,1550,1664,"However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting."
15378098,Premise,867,1007,"With a mixed modeling approach, total FACIT F scores for the entire sample declined at a significant rate (p = 0.003) beginning with cycle 3"
15378098,Premise,1008,1067,"but at a slower rate for the experimental group (p = 0.02)."
15378098,Premise,1068,1233,"Fatigue scores indicated less increase and physical well-being subscale scores showed less decline for the experimental group (p = 0.008 and p = 0.02, respectively)."
15378098,Premise,1234,1451,"Women with advanced breast cancer randomized to the seated exercise intervention had a slower decline in total and physical well-being and less increase in fatigue scores starting with the third cycle of chemotherapy."
15378098,Claim,1452,1592,"Seated exercise may be a feasible exercise program for women with advanced cancer for controlling fatigue and improving physical well-being."
15452187,Premise,579,751,"Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001)."
15452187,Premise,752,902,"During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001)."
15452187,Premise,903,1020,"The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively."
15452187,Premise,1124,1176,"The incidence of toxicity in the groups was similar."
15452187,Premise,1177,1302,"Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant)."
15452187,Premise,1303,1512,"The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006)."
15452187,Claim,1513,1605,"Epoetin alfa significantly improved HgB and reduced transfusions in this patient population."
15452187,Claim,1606,1710,"These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia."
15452188,Claim,1,191,"Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions."
15452188,Premise,621,919,"At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001)."
15452188,Premise,920,1175,"Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons)."
15452188,Premise,1176,1281,"Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%)."
15452188,Premise,1282,1371,"More than 90% of patients did not require a dose increase and 28.7% had a dose reduction."
15452188,Claim,1372,1538,"Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients."
15452188,Claim,1539,1636,"The high effectiveness observed could be attributed in part to early treatment with epoetin alfa."
15454357,Premise,803,1098,"Intention-to-treat analysis based on participants with follow-up data indicated a significant difference in total exercise in favor of the recommendation-only group over the usual care group (mean difference, 3.4 MET hr per week; 95% confidence interval [CI], 0.7-6.1 MET hr per week; p = .011)."
15454357,Premise,1099,1293,"There was no significant difference between the recommendation-plus-referral group and the usual care group (mean difference, 1.5 MET hr per week; 95% CI, -1.0 to 4.0 MET hr per week; p = .244)."
15454357,Premise,1294,1582,"Ancillary ""on-treatment"" analyzes showed that participants who recalled an exercise recommendation reported significantly more total exercise than participants who did not recall an exercise recommendation (mean difference, 4.1 MET hr per week: 95% CI, 1.9-6.4 MET hr per week; p < .001)."
15454357,Claim,1583,1776,"Our findings suggest that an oncologist recommendation may increase exercise behavior in newly diagnosed breast cancer survivors, particularly if it is recalled 1 week after the recommendation."
15472910,Premise,1147,1514,"The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales."
15472910,Premise,1515,1669,"In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04)."
15472910,Premise,1670,1834,"The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales."
15472910,Premise,1835,1892,"There were no group differences with respect to survival."
15472910,Claim,1893,1975,"Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy."
15472910,Claim,1985,2104,"Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care."
15472910,Claim,2105,2259,"Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available."
15472910,MajorClaim,2260,2406,"The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures."
15514373,Premise,723,936,"The overall response rates, which were confirmed by an independent expert panel, were 13% (95% CI, 3.4% to 23.3%), 27% (95% CI, 14.1% to 40.4%), and 40% (95% CI, 25.7% to 54.3%) for arms A, B, and C, respectively."
15514373,Premise,937,1357,"Median progression-free survival and overall survival times were 3.2 months (95% CI, 1.8 to 4.6 months) and 6.8 months (95% CI, 2.6 to 11.1 months) with LV5FU2, respectively; 4.9 months (95% CI, 3.5 to 6.3 months) and 9.5 months (95% CI, 6.9 to 12.2 months) with LV5FU2-cisplatin, respectively; and 6.9 months (95% CI, 5.5 to 8.3 months) and 11.3 months (95% CI, 9.3 to 13.3 months) with LV5FU2-irinotecan, respectively."
15514373,Claim,1358,1489,"Of the three regimens tested, the combination of LV5FU2-irinotecan is the most promising and will be assessed in a phase III trial."
15542159,Premise,1148,1277,"At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume."
15542159,Premise,1278,1434,"Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group."
15542159,Premise,1435,1819,"The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively."
15542159,Premise,1820,2172,"There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months."
15542159,Claim,2173,2517,"The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa."
15547181,Premise,936,1605,"After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates."
15547181,Premise,1606,1946,"However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001)."
15547181,Premise,1947,2195,"Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,"
15547181,Premise,2196,2272,"although myelosuppression did not influence dose delivery or patient safety."
15547181,Premise,2273,2321,"Global quality of life was similar in both arms,"
15547181,Premise,2322,2391,"but substantive differences in many symptom scores favored docetaxel."
15547181,Claim,2392,2513,"Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,"
15547181,Claim,2514,2591,"although longer follow-up is required for a definitive statement on survival."
15547181,MajorClaim,2592,2727,"Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer."
15625369,Premise,918,1041,"There was a significant survival advantage for GCa compared with MIC (hazard ratio, 0.76; 95% CI, 0.61 to 0. 93; P = .008)."
15625369,Premise,1042,1242,"Median survival was 10 months with GCa and 7.6 months with MIC (difference, 2.4 months; 95% CI, 1.0 to 4.0), and 1-year survival was 40% with GCa and 30% with MIC (difference, 10%; 95% CI, 3% to 18%)."
15625369,Premise,1243,1316,"Overall response rates were similar (42% for GCa v 41% for MIC; P = .84)."
15625369,Premise,1317,1367,"More thrombocytopenia occurred with GCa (P = .03),"
15625369,Premise,1368,1442,"but this was not associated with increased hospital admission or fatality."
15625369,Premise,1443,1591,"GCa caused less nausea, vomiting, constipation, and alopecia and was associated with fewer admissions for administration and better quality of life."
15625369,Claim,1592,1732,"In patients with advanced NSCLC, GCa chemotherapy was shown to be a better-tolerated treatment that conferred a survival advantage over MIC."
15659490,MajorClaim,1,93,"The role of high-dose chemotherapy (HDCT) in metastatic breast cancer remains controversial."
15659490,Claim,94,185,"Trials with late intensification HDCT have failed to show an advantage in overall survival."
15659490,Premise,813,922,"Intent-to-treat CR rates for patients randomized to HDCT and AT were 12.5% and 11.1%, respectively (P = .84)."
15659490,Premise,923,1042,"Objective response rates were 66.7% for patients in the high-dose group and 64.4% for patients in the AT arm (P = .82)."
15659490,Premise,1043,1352,"In an intent-to-treat analysis, there were no significant differences between the two treatments in median time to progression (HDCT, 11.1 months; AT, 10.6 months; P = .67), duration of response (HDCT, 13.9 months; AT, 14.3 months; P = .98), and overall survival (HDCT, 26.9 months; AT, 23.4 months; P = .60)."
15659490,Premise,1353,1535,"HDCT was associated with significantly more myelosuppression, infection, diarrhea, stomatitis, and nausea and vomiting, whereas patients treated with AT developed more neurotoxicity."
15659490,Claim,1536,1640,"This trial failed to show a benefit for up-front tandem HDCT compared with standard combination therapy."
15659490,Claim,1641,1693,"HDCT was associated with more acute adverse effects."
15668285,Premise,740,896,"The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%)."
15668285,Premise,897,943,"Other grade 3/4 toxic effects were rare (<5%)."
15668285,Premise,944,1057,"Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B."
15668285,Premise,1058,1209,"Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months."
15668285,Premise,1210,1447,"Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients."
15668285,Claim,1651,1803,"The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,"
15668285,Claim,1804,1877,"but the study was not designed to detect differences in these parameters."
15668285,Claim,1891,1962,"tumor response was shown to have a beneficial effect on QoL indicators."
15684319,Premise,730,865,"At radiotherapy completion, energy intake increased in G1/G2 (P < or = .04), G1 more than G2 (P = .001), and decreased in G3 (P < .01)."
15684319,Premise,866,982,"Protein intake increased in G1/G2 (P < or = .007), G1 less than G2 (not significant), and decreased in G3 (P < .01)."
15684319,Premise,983,1060,"At 3 months, G1 maintained nutritional intake and G2/G3 returned to baseline."
15684319,Premise,1061,1175,"After radiotherapy and at 3 months, rates of anorexia, nausea, vomiting, and diarrhea were higher in G3 (P < .05)."
15684319,Premise,1176,1451,"At radiotherapy completion, in G1 all QoL function scores improved proportionally to adequate intake or nutritional status (P < .05); whereas in G2 only three of six function scores improved proportionally to protein intake (P = .04), and in G3 all scores worsened (P < .05)."
15684319,Premise,1452,1665,"At 3 months, G1 patients maintained/improved function, symptoms, and single-item scores (P < .02); in G2, only few function and symptom scales improved (P < .05); in G3, QoL remained as poor as after radiotherapy."
15684319,Premise,1666,1796,"In G1/G2, respectively, improvement/deterioration of QoL correlated with better or poorer intake or nutritional status (P < .003)."
15684319,Claim,1797,1868,"During radiotherapy, both interventions positively influenced outcomes;"
15684319,Claim,1869,2029,"dietary counseling was of similar or higher benefit, whereas even 3 months after RT, it was the only method to sustain a significant impact on patient outcomes."
15705087,Premise,1367,1567,"The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months."
15705087,Premise,1568,1622,"Patients with dysuria had a statistically higher IPSS."
15705087,Premise,1623,1683,"The dysuria resolved faster in patients implanted with 103Pd"
15705087,Premise,1780,1889,"In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores,"
15705087,Premise,1890,2026,"while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria."
15705087,Claim,2027,2087,"Dysuria is common after brachytherapy but is typically mild."
15705087,Claim,2088,2163,"Prophylactic alpha-blockers gave significantly lower maximum dysuria scores"
15705087,Claim,2164,2221,"but did not affect the time to the resolution of dysuria."
15705087,Claim,2222,2309,"The maximum IPSS after the implant was the best predictor of the resolution of dysuria."
15705087,Premise,1684,1779,"but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy."
15713598,Premise,809,921,"There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months."
15713598,Premise,922,1093,"There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement."
15713598,Premise,1094,1253,"Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment."
15713598,Premise,1254,1318,"Response rate, survival, and duration were similar in both arms."
15713598,Claim,1319,1488,"There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule."
15714933,Premise,1016,1212,"TSS improved in 49 patients (77%) on regimen 1, and in 57 (92%) patients on regimen 2, a difference of 15% (95% confidence interval [CI] 3-28) in the proportion improving between the two regimens."
15714933,Premise,1213,1421,"A complete resolution of all symptoms was achieved in three (5%) on regimen 1, and in 14 (23%) patients on regimen 2 (P < 0.001), a difference in the proportion between the two regimens of 21% (95% CI 10-33)."
15714933,Premise,1422,1557,"A significantly higher proportion of patients experienced palliation and complete resolution of chest pain and dyspnoea with regimen 2."
15714933,Premise,1558,1599,"No differences were observed in toxicity."
15714933,Premise,1600,1690,"The median survival was 22.7 weeks for regimen 1 and 28.3 weeks for regimen 2 (P = 0.197)."
15714933,Claim,1691,1795,"Although this trial met the pre-determined criteria for equivalence between the two palliative regimens,"
15714933,Claim,1796,1937,"significantly more patients achieved complete resolution of symptoms and palliation of chest pain and dyspnoea with the fractionated regimen."
15738537,Claim,1,210,"Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC)."
15738537,Premise,918,1056,"Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16)."
15738537,Premise,1057,1156,"Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);"
15738537,Premise,1157,1189,"hazard ratio was 0.50; P = .0002"
15738537,Premise,1191,1274,"Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);"
15738537,Premise,1275,1362,"duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);"
15738537,Premise,1363,1395,"hazard ratio was 0.42; P = .088."
15738537,Premise,1396,1470,"Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)"
15738537,Premise,1471,1556,"but was controlled with oral medication and did not cause study drug discontinuation."
15738537,Claim,1557,1833,"Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival."
15748464,Claim,1,123,"Impaired cognition, fatigue, and diminished quality of life (QOL) are commonly associated with breast cancer chemotherapy."
15748464,Premise,945,1041,"Mean change in EXIT25 scores from baseline to cycle 4 in the epoetin alfa group was 1.3 +/- 3.3;"
15748464,Premise,1042,1153,"the mean change was 0.3 +/- 2.4 in the placebo group (a negative change indicates improved executive function)."
15748464,Premise,1154,1270,"There was no difference between groups in mean change in EXIT25 score from baseline to 6-month follow-up assessment."
15748464,Premise,1271,1395,"Mean hemoglobin levels were higher in the epoetin alfa group compared with the placebo group after 4 cycles of chemotherapy."
15748464,Premise,1396,1592,"Epoetin alfa recipients had less of a decrease in FACT-An subscale scores from baseline to cycle 4 and improvement in FACT-An subscale scores at 6-month follow-up assessment compared with placebo."
15748464,Claim,1593,1633,"Epoetin alfa therapy was well tolerated."
15748464,Claim,1634,1785,"These data suggest that epoetin alfa may have attenuated the cognitive impairment and fatigue that occurred during adjuvant breast cancer chemotherapy."
15750359,Premise,694,951,"There was no evidence of a difference seen between groups for either activity (adjusted difference =-0.4, 95% confidence interval CI -1.0 to 0.2, p = 0.17) or profile scores (adjusted difference = -0.4, 95% CI -0.9 to 0.1, p = 0.13) using this trial design,"
15750359,Claim,952,1102,"although post hoc power calculations suggests that 65-175 would be needed per group to detect differences of this magnitude with sufficient precision."
15750359,Premise,1103,1217,"Clinically relevant improvements in symptoms and mood disturbance were seen for both groups over the study period."
15750359,Claim,1218,1282,"Improvements were seen for symptom scores over the study period."
15750359,Claim,1283,1510,"However, presuming these improvements were caused by the individualized homeopathic approach, the study failed to show clearly that the specific effect of the remedy added further to the nonspecific effects of the consultation."
15750359,Claim,1511,1733,"Future trial design must ensure adequate power to account for the nonspecific impact of such complex individualized interventions while pragmatic designs may more readily answer questions of clinical and cost effectiveness"
15750360,Premise,734,837,"There was no significant difference found in the primary outcome measure, the hot flash severity score,"
15750360,Premise,838,950,"although there was a positive trend in the single remedy group during the first 3 months of the study (p = 0.1)."
15750360,Premise,951,1088,"A statistically significant improvement in general health score in both homeopathy groups (p < 0.05) on the SF-36 after 1 year was found."
15750360,Premise,1089,1238,"Evidence of a homeopathic ""drug proving"" in the subjects receiving the homeopathic combination medicine who were not taking tamoxifen also was found."
15750360,Claim,1239,1286,"Small sample size precludes definitive answers,"
15750360,Claim,1287,1481,"but results from this preliminary trial suggest that homeopathy may be of value in the treatment of menopausal symptoms and improving quality of life, especially in those women not on tamoxifen."
15750360,Claim,1482,1597,"Larger studies should be carried out that also include healthy women who want to avoid hormone replacement therapy."
15753541,MajorClaim,143,282,"Thalidomide, which is an inhibitor of TNF-alpha synthesis, may represent a novel and rational approach to the treatment of cancer cachexia."
15753541,Premise,869,1217,"At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm(3) in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference -2.59 kg (95% confidence interval (CI) -4.3 to -0.8); p = 0.005) and 4.46 cm(3) (absolute difference -5.6 cm(3) (95% CI -8.9 to -2.2); p = 0.002) in the placebo group."
15753541,Premise,1218,1514,"At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm(3) in AMA compared with a loss of 3.62 kg (absolute difference -3.57 kg (95% CI -6.8 to -0.3); p = 0.034) and 8.4 cm(3) (absolute difference -7.9 cm(3) (95% CI -14.0 to -1.8); p = 0.014) in the placebo group."
15753541,Premise,1515,1612,"Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001)."
15753541,Claim,1613,1767,"Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer."
15800308,Premise,1068,1236,"AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03)."
15800308,Premise,1237,1320,"The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9)."
15800308,Premise,1321,1417,"Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025)."
15800308,Premise,1418,1631,"QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003)."
15800308,Premise,1632,1729,"The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87)."
15800308,Claim,1730,1853,"AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy."
15800308,Claim,1854,1986,"However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies."
15839957,Premise,76,269,"For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy."
15839957,Claim,270,386,"However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation."
15839957,Premise,1373,1621,"With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032])."
15839957,Premise,1622,1772,"The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016)."
15839957,Premise,1773,1841,"The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349)."
15839957,Premise,1842,2003,"Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life."
15839957,Claim,2004,2130,"Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer."
15880316,Premise,936,1072,"Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05)."
15880316,Premise,1073,1182,"Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups."
15880316,Premise,1183,1268,"Body weight and whole body fat declined similarly over time in all groups (P < .005),"
15880316,Premise,1277,1355,"lean body mass was unchanged during follow-up compared to preoperative values."
15880316,Premise,1356,1475,"Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups."
15880316,Premise,1476,1544,"There was no difference in recovery of food intake among the groups."
15880316,Claim,1545,1636,"Parenteral feeding was associated with the highest rate of nutrition-related complications,"
15880316,Claim,1645,1702,"enteral feeding reduced quality of life most extensively."
15880316,Claim,1703,1847,"After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian."
15888157,Claim,1,152,"Facial hirsutism is one of the characteristic features of polycystic ovary syndrome (PCOS), and this can lead to high levels of depression and anxiety."
15888157,Premise,838,1036,"Self-reported severity of facial hair in the intervention group (n = 51) fell from 7.3 to 3.6 over the 6-month study period; for the control group (n = 37) the corresponding scores were 7.1 and 6.1."
15888157,Premise,1037,1136,"The change was significantly greater in the intervention group [ancova F((1,83)) = 24.5, P < 0.05]."
15888157,Premise,1137,1315,"Self-reported time spent on hair removal declined from 112 to 21 min per week in the intervention group and from 92 to 56 min in the control group [F((1,80)) = 10.2, P </= 0.05]."
15888157,Premise,1316,1462,"Mean depression scores fell from 6.7 to 3.6 in the intervention group, compared with 6.1 to 5.4 in the control group [F((1,83)) = 14.7, P < 0.05]."
15888157,Premise,1463,1588,"A similar change was seen for mean anxiety scores: intervention 11.1 to 8.2, control 9.6 to 9.3 [F((1,84)) = 17.8, P < 0.05]."
15888157,Premise,1589,1750,"Psychological quality of life also improved more in the intervention group, from 49.6 to 61.2 vs. 50.1 to 51.5 in the control group [F((1,84)) = 10.9, P < 0.05]."
15888157,Claim,1751,1910,"Laser treatment appeared to reduce the severity of facial hair and time spent on hair removal as well as alleviating depression and anxiety in women with PCOS."
15888157,Claim,1911,2056,"These findings suggest that ways of making this method of hair removal more widely available to women with facial hirsutism should be considered."
15892043,Claim,1,172,"For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone."
15892043,Premise,1000,1126,"Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months)."
15892043,Premise,1127,1226,"The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group."
15892043,Premise,1227,1409,"The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel."
15892043,Premise,1410,1519,"The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars)."
15892043,Premise,1520,1629,"Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination."
15892043,Premise,1630,1824,"Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars."
15892043,Claim,1825,2068,"Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies."
15920748,Premise,892,963,"Energy intake after RT increased in both groups 1 and 2 (p < or = .05)."
15920748,Premise,964,1033,"Protein intake also increased in both groups 1 and 2 (p < or = .006)."
15920748,Premise,1034,1110,"Both energy and protein intake decreased significantly in group 3 (p < .01)."
15920748,Premise,1111,1212,"At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels."
15920748,Premise,1213,1264,"After RT, >90% of patients experienced RT toxicity;"
15920748,Premise,1265,1402,"this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07)."
15920748,Premise,1403,1629,"At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001)."
15920748,Premise,1630,1802,"After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05);"
15920748,Premise,1803,1942,"at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL."
15920748,Claim,1943,2057,"During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit;"
15920748,Claim,2058,2143,"in the medium term, only counseling exerted a significant impact on patient outcomes."
16020979,Premise,573,763,"The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively)."
16020979,Premise,764,837,"The rate of grade 2 or above nausea was numerically higher in the GP arm,"
16020979,Premise,838,922,"but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20)."
16020979,Premise,923,1010,"The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96)."
16020979,Premise,1011,1128,"However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001)."
16020979,Premise,1129,1255,"Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively)."
16020979,Premise,1256,1403,"There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP."
16020979,Premise,1404,1516,"The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different."
16020979,Premise,1517,1712,"Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055)."
16020979,Claim,1713,1758,"This toxicity profile of GE is similar to GP,"
16020979,Claim,1759,1830,"but the apparent inferior efficacy may discourage further investigation"
16125515,Premise,1052,1321,"After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up."
16125515,Premise,1322,1479,"Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation."
16125515,Claim,1659,1877,"A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses."
16125515,Claim,1891,2024,"if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component."
16125515,Premise,1480,1658,"If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program."
16135469,Claim,1,146,"Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients."
16135469,Premise,1093,1323,"In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline."
16135469,Premise,1324,1408,"No significant main effect of the interventions emerged on cancer-specific distress,"
16135469,Premise,1409,1537,"but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry."
16135469,Premise,1538,1622,"Between-group differences in the primary outcomes were not significant at 12 months,"
16135469,Premise,1623,1686,"and no significant effects emerged on the secondary end points."
16135469,Claim,1687,1874,"A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry."
16135471,Premise,1077,1394,"Compared with the intervention group, mean difference scores between the baseline (T1) and immediate after the test (T2) assessments increased significantly more for the control group for worst and average fatigue, Functional Assessment of Cancer Therapy-Fatigue, and Piper fatigue severity and interference measures."
16135471,Premise,1395,1474,"These differences were not observed between baseline and T3 and T4 assessments."
16135471,Premise,1475,1658,"No significant differences were identified for any pre- or post-test change scores for confidence with managing fatigue, cancer self-efficacy, anxiety, depression, or quality of life."
16135471,Claim,1659,1781,"Preparatory education and support has the potential to assist women to cope with cancer-related fatigue in the short term."
16135471,Claim,1782,1948,"However, further research is needed to identify ways to improve the potency and sustainability of psychoeducational interventions for managing cancer-related fatigue."
16157934,Premise,659,822,"No differences were seen between groups in mean change scores from baseline for the SF-36 physical and mental component summary scores at 6, 12, 24, and 36 months."
16157934,Premise,823,1145,"Small (< 0.2 standard deviations) but statistically significant differences in mean change scores from baseline were seen for the SF-36 domains of physical functioning (12 months), bodily pain (6 months) and vitality (6 and 12 months), and the MENQOL vasomotor (6, 12, and 24 months) and sexual domains (12 and 24 months)."
16157934,Premise,1146,1406,"On the response analysis, a significant difference was seen between groups for the bodily pain domain (percentage of patients reporting a worsening of QOL, 47% placebo v 51% letrozole; P = .009) and the vasomotor domain (22% placebo v 29% letrozole; P = .001)."
16157934,Claim,1407,1463,"Letrozole did not have an adverse impact on overall QOL."
16157934,Claim,1464,1621,"Small effects were seen in some domains consistent with a minority of patients experiencing changes in QOL compatible with a reduction in estrogen synthesis."
16163445,Claim,503,623,"There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment."
16163445,Premise,624,888,"Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01)."
16163445,Premise,889,982,"The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results."
16163445,Premise,983,1197,"18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001)."
16163445,Premise,1309,1398,"there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05)."
16163445,Premise,1399,1531,"For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01)."
16163445,Claim,1532,1718,"In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer."
16166415,Claim,604,703,"Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate."
16166415,Claim,704,842,"Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect."
16166415,Premise,843,978,"Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events."
16166415,Premise,979,1123,"Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients."
16166415,Premise,1124,1217,"Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea."
16179098,MajorClaim,85,172,"Standard chemotherapy regimens are generally considered too toxic for elderly patients."
16179098,Premise,967,1087,"Among these 32 patients, 8 had a partial response (intent-to-treat response rate, 20%), and 10 (25%) had stable disease."
16179098,Premise,1088,1146,"The median survival was 7.8 months (range, 4-11.6 months)."
16179098,Premise,1147,1210,"The 1- and 2-year survival rates were 25% and 7%, respectively;"
16179098,Premise,1211,1278,"median time to progression was 4.3 months (range, 0.2-13.8 months)."
16179098,Premise,1279,1382,"Grade 3/4 neutropenia was seen in 27 patients (68%), and grade 3/4 anemia was seen in 5 patients (13%)."
16179098,Premise,1383,1440,"One patient died of febrile neutropenia during treatment."
16179098,Premise,1441,1523,"The main nonhematologic adverse effect was fatigue (grade 3/4 in 18% of patients)."
16179098,Claim,1524,1613,"Carboplatin/vinorelbine is well tolerated by elderly patients with extensive-stage NSCLC."
16179098,Claim,1614,1691,"Efficacy is low but similar to that of other treatments used in this setting."
16203762,Claim,1575,1734,"Adverse events during temozolomide treatment included thrombocytopenia, nausea, vomiting, anorexia, constipation, alopecia, headache, fatigue, and convulsions."
16203762,Premise,1472,1574,"Median survival was 14.6 months (temozolomide + radiotherapy) versus 12.1 months (radiotherapy alone)."
16203762,Premise,1386,1471,"The hazard ratio was 0.63 (95% confidence interval, 0.52-0.75; log-rank, P < 0.0001)."
16203762,Claim,1266,1385,"Patients receiving concomitant and maintenance temozolomide + radiotherapy had significantly improved overall survival."
16260701,Claim,1,137,"The combination of interferon alfa (IFNalpha) and isotretinoin has shown a direct antiproliferative effect on human melanoma cell lines,"
16260701,Claim,138,262,"but it remained unclear whether this combination is more effective than IFNalpha alone in patients with metastatic melanoma."
16260701,Premise,1001,1355,"A scheduled interim analysis revealed no significant differences in survival rates, with the isotretinoin group and the placebo group showing 5-year disease-free survival rates of 55% (95% CI, 46% to 65%) and 67% (95% CI, 59% to 75%), respectively, and overall 5-year survival rates of 76% (95% CI, 67% to 84%) and 81% (95% CI, 74% to 88%), respectively."
16260701,Claim,1392,1606,"The addition of isotretinoin to an adjuvant treatment of low-dose IFNalpha in patients with stage IIA and IIB melanoma had no significant effect on disease-free or overall survival and is therefore not recommended."
16280763,Premise,1080,1168,"Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3."
16280763,Premise,1169,1267,"Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively)."
16280763,Premise,1268,1378,"Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01)."
16280763,Premise,1379,1525,"In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05)."
16280763,Premise,1526,1573,"Treatments were well tolerated in the 3 groups."
16280763,Premise,1574,1630,"No differences in QOL between groups 2 and 3 were found."
16280763,Premise,1631,1701,"At a median followup of 26 months we observed 12 biochemical relapses."
16280763,Claim,1702,1805,"Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated."
16280763,Claim,1806,1885,"Tamoxifen has been shown to be more effective and safe than RT in this setting."
16280763,Claim,1886,1968,"QOL and sexual function are not negatively influenced by these 2 treatment options"
16294343,Premise,1259,1470,"Participants completing the intervention demonstrated improvement in male overall distress (P < 0.01), male global sexual function (P < 0.0001), and female global sexual function (P < 0.05) at 3-month follow-up,"
16294343,Premise,1471,1533,"but regression toward baseline was noted at 6-month follow-up."
16294343,Premise,1534,1662,"However, utilization of ED treatments increased from 31% at the time of study entry to 49% at the 6-month follow-up (P = 0.003)."
16294343,Claim,1663,1833,"The results of this brief pilot counseling intervention demonstrated significant gains in sexual function and satisfaction and increased utilization of treatments for ED."
16294343,Claim,1834,1986,"However, modifications are needed in future randomized trials to reduce the rate of premature termination and to improve long-term maintenance of gains."
16319148,Premise,878,1010,"Among the clinical outcome measures, QOL score improvement was greater for UAE with TAGMs compared with PVA (49.0 vs 27.9; P = .02),"
16319148,Premise,1011,1047,"but no other differences were noted."
16319148,Premise,1048,1496,"Of the 25 patients in whom 3-month MR imaging follow-up was completed, those treated with TAGM were significantly more likely to have complete infarction of all leiomyomas (six patients vs one patient; P = .02), were more likely to have at least 90% tumor infarction (eight patients vs four patients; P = .03), and had a lower mean percent of residual perfused fibroid tumor tissue (9.6% vs 44.3%; P = .004) compared with patients treated with PVA."
16319148,Claim,1593,1730,"The use of spherical PVA particles in the manner described herein results in an unacceptably high rate of failed tumor infarction in UAE."
16321761,Premise,1357,1651,"At first follow-up, groups differed only in social functioning, favouring the radiotherapy-only group (mean score 79.0 [SD 3.2] for patients assigned radiotherapy vs 67.4 [2.7] for those assigned radiotherapy and temozolomide; difference between groups 11.6 points [95% CI 3.5-19.7], p=0.0052)."
16321761,Premise,1652,1730,"Over subsequent assessments, HRQOL was much the same between treatment groups."
16321761,Claim,1731,1900,"Addition of temozolomide during and after radiotherapy for patients with newly diagnosed glioblastoma significantly improved survival without a negative effect on HRQOL."
16344321,Claim,1,111,"Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information"
16344321,Premise,936,1147,"In both the patients' subjective assessment of their QL and the physicians' perception of the patients' QL, the largest adverse QL effects of Ax were observed from baseline to the first postoperative assessment,"
16344321,Premise,1148,1206,"but the differences tended to disappear in 6 to 12 months."
16344321,Premise,1207,1463,"At a median follow-up of 6.6 years, results for Sx + Ax and Sx yielded similar DFS (6-year DFS, 67% v 66%; hazard ratio [HR] Sx + Ax/Sx, 1.06; 95% CI, 0.79 to 1.42; P = .69) and OS (6-year OS, 75% v 73%; HR Sx + Ax/Sx, 1.05; 95% CI, 0.76 to 1.46; P = .77)."
16344321,Claim,1464,1658,"Avoiding axillary clearance for women > or = 60 years old who have clinically node-negative disease and receive Tam for endocrine-responsive disease yields similar efficacy with better early QL."
16376417,Claim,1,68,"Chemotherapy can profoundly affect patients' quality of life (QOL),"
16376417,Premise,607,734,"Overall (FACT-G) scores did not differ significantly between arms at the fourth assessment (C = 70.3 (19.6); CP = 72.8 (17.4))."
16376417,Premise,735,821,"Scores were stable over time and considerably lower than the general population norms."
16376417,Premise,822,917,"The BPI-SF revealed a decline in pain scores in both arms from the first to fourth assessments."
16376417,Premise,918,1010,"The CP arm produced a significantly higher response rate and progression-free survival (PFS)"
16376417,Premise,1011,1041,"but not overall survival (OS)."
16376417,Premise,1042,1103,"Greater myelosuppression was reported in the combination arm."
16376417,Premise,1104,1199,"The rate of QOL drop-out for any reason was higher for C (53%) compared to CP (38%) (P < 0.05)."
16376417,Claim,1290,1383,"There was no significant difference in overall QOL scores between treatment arms or serially."
16376417,Claim,1384,1604,"Combined with QOL results, the significant increase in response and PFS in the CP arm and the higher drop-out rate in the C arm suggest a better outcome for the combination regimen despite its increased myelosuppression."
16384850,Claim,130,323,"This procedure has been performed with the patient in the hypothyroid state to promote endogenous TSH stimulation and is often associated with hypothyroid symptoms and impaired quality of life."
16384850,Premise,1375,1720,"Quality of life was well preserved in the euthyroid group, compared with the hypothyroid group, as demonstrated by their lower pretreatment scores on the Billewicz scale for hypothyroid signs and symptoms, 27 +/- 7 vs. 18 +/- 4 (P < 0.0001) and their significantly higher Short Form-36 Health Assessment Scale scores in five of eight categories."
16384850,Premise,1721,1865,"Euthyroid patients had a statistically significant one third lower radiation dose to the blood, compared with patients in the hypothyroid group."
16384850,Claim,1866,2045,"This study demonstrates comparable remnant ablation rates in patients prepared for 131I remnant ablation with 3.7 GBq by either administering rhTSH or withholding thyroid hormone."
16384850,Claim,2046,2156,"rhTSH-prepared patients maintained a higher quality of life and received less radiation exposure to the blood."
16416368,Premise,1291,1424,"An average weight gain in group B contrasted with an average weight loss in group A after four (P < 0.01) and eight weeks (P < 0.05)."
16416368,Premise,1425,1520,"Fat-free mass showed an intergroup difference in favor of group B after eight weeks (P < 0.05)."
16416368,Premise,1521,1699,"Body cell mass was maintained throughout the study in group B, but declined significantly up to weeks 4 and 8 in group A (intergroup difference: P < 0.05 and 0.01, respectively)."
16416368,Premise,1700,1805,"A decrease in the total lymphocyte count by 559 cells/mul occurred with the fat-enriched diet (P < 0.05)."
16416368,Premise,1806,1896,"Several aspects of the quality of life were rated to be better in group B than in group A,"
16416368,Premise,1897,1959,"although not all differences reached statistical significance."
16416368,Claim,1960,2077,"In patients with cancer, a high-fat diet may possibly support the maintenance of both body weight and body cell mass."
16416368,Claim,2078,2132,"However, monitoring the lymphocyte count is advisable."
16446322,MajorClaim,1,138,"For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important."
16446322,Premise,971,1095,"The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048)."
16446322,Premise,1096,1180,"The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);"
16446322,Premise,1181,1251,"at no point was any significant difference apparent on this end point."
16446322,Premise,1252,1314,"Both treatments led to an improvement, over time, in dyspnoea."
16446322,Claim,1315,1422,"This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm."
16446322,Premise,1423,1585,"However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms."
16446322,MajorClaim,1586,1681,"This study provides important information about the HRQOL of chemotherapy-treated MPM patients."
16572647,Premise,941,1071,"The mean amount of residual tumor tissue was 28.9% for standard surgery (SS) and 13.8% for surgery involving neuronavigation (SN)."
16572647,Premise,1072,1181,"The corresponding mean amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%, respectively."
16572647,Premise,1182,1221,"These differences were not significant."
16572647,Premise,1222,1325,"Gross-total removal (GTR) was achieved in five patients who underwent SS and in three who underwent SN."
16572647,Premise,1326,1451,"Median survival was significantly shorter in the SN group (5.6 months compared with 9 months, unadjusted hazard ratio = 1.6);"
16572647,Premise,1452,1563,"however, this difference may be attributable to the coincidental early death of three patients in the SN group."
16572647,Premise,1564,1657,"No discernible important effect on the patients' 3-month postoperative course was identified."
16572647,Claim,1658,1940,"There is no rationale for the routine use of neuronavigation to improve the extent of tumor resection and prognosis in patients harboring a solitary enhancing intracerebral lesion when neuronavigation is not already deemed advantageous because of the size or location of the lesion."
16598426,MajorClaim,1,139,"Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma"
16598426,Premise,783,823,"Overall the treatment was well tolerated"
16598426,Premise,825,897,"Mild or moderate nausea was the most common side effect of estramustine."
16598426,Premise,967,1147,"For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group."
16598426,Premise,1148,1261,"In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively."
16598426,Premise,1262,1406,"Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively."
16598426,Premise,1407,1491,"In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively."
16598426,Premise,1492,1637,"Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups."
16598426,Premise,1638,1767,"No differences between the two treatment groups were evident with respect to quality of life according to the EORTC QLQ-protocol."
16598426,Claim,1768,1922,"In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy,"
16598426,Claim,1923,2035,"however, a trend for a positive response for the estramustine group was found in patients with grade III glioma."
16670385,MajorClaim,1,204,"Sentinel lymph node biopsy in women with operable breast cancer is routinely used in some countries for staging the axilla despite limited data from randomized trials on morbidity and mortality outcomes."
16670385,Premise,998,1324,"The relative risks of any lymphedema and sensory loss for the sentinel lymph node biopsy group compared with the standard axillary treatment group at 12 months were 0.37 (95% confidence interval [CI] = 0.23 to 0.60; absolute rates: 5% versus 13%) and 0.37 (95% CI = 0.27 to 0.50; absolute rates: 11% versus 31%), respectively."
16670385,Premise,1325,1578,"Drain usage, length of hospital stay, and time to resumption of normal day-to-day activities after surgery were statistically significantly lower in the sentinel lymph node biopsy group (all P < .001), and axillary operative time was reduced (P = .055)."
16670385,Premise,1579,1758,"Overall patient-recorded quality of life and arm functioning scores were statistically significantly better in the sentinel lymph node biopsy group throughout (all P < or = .003)."
16670385,Premise,1759,1869,"These benefits were seen with no increase in anxiety levels in the sentinel lymph node biopsy group (P > .05)."
16670385,Claim,1870,2115,"Sentinel lymph node biopsy is associated with reduced arm morbidity and better quality of life than standard axillary treatment and should be the treatment of choice for patients who have early-stage breast cancer with clinically negative nodes."
16787687,Claim,1,98,"Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options;"
16787687,Premise,710,980,"Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item ""QoL today"": P=0.064 for DC and P=0.016 for DCb versus VC; EQ-5D global item ""health state today"": P=0.016 for DC and P<0.001 for DCb versus VC)."
16787687,Premise,981,1061,"DC-treated patients experienced improved pain relief compared with VC (P=0.033),"
16787687,Premise,1070,1110,"pain relief with DCb and VC was similar."
16787687,Premise,1111,1398,"Patients treated with either docetaxel regimen had more favorable changes in performance status (P=0.065 for DC and P<0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P<0.001 for both DC versus VC and DCb versus VC)."
16787687,Claim,1399,1521,"The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC."
16787687,Claim,1522,1673,"DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS ""QoL today"", which was not significant."
16802254,Premise,1130,1345,"In response to training, QOL, VO2peak (mean 3.9 ml/kg/min; 95 % CI, 0.93, 6.90) performance in leg press (17.9 kg; 95 % CI, 12.8, 22.4) and sit-stand test (- 0.67 s; 95 % CI, - 0.52, - 1.2) improved (p < or = 0.05)."
16802254,Premise,1346,1402,"We observed no significant changes in the control group."
16802254,Claim,1403,1567,"Combined cardiorespiratory and resistance training, even of very brief duration, improves the QOL and the overall physical fitness of women breast cancer survivors."
16816536,Premise,861,922,"Two toxicity-related deaths were observed in the Tomudex arm."
16816536,Premise,923,1125,"The treatments gave rise to different rates of grade 3-4 neutropenia (3, 4, 11 and 14% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively, p = 0.028), leucopenia and vomiting."
16816536,Premise,1126,1294,"At least one episode of grade 3-4 toxicity was observed in 27, 25, 38 and 47% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.016)."
16816536,Premise,1295,1441,"An objective response was observed in 28, 21, 22 and 10% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.04)."
16816536,Premise,1442,1637,"Progression-free survival (PFS) of the patients in the Tomudex arm was statistically lower compared to that of patients treated with LV5FU2 or ldLV5FU2 (combined group; p = 0.013, log rank test)."
16816536,Claim,1638,1718,"In conclusion, Tomudex is more toxic and yields shorter PFS than infusional 5FU."
16816536,Claim,1719,1982,"Despite the early closure of the study and the lack of power of the comparison, it seems that ldLV5FU2 could be considered as an active, easier and less expensive option for the treatment of metastatic colorectal cancer compared to classic LV5FU2 or weekly HD-FU."
16823511,Claim,1,161,"DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer."
16823511,Premise,162,332,"However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL)."
16823511,Premise,861,1011,"No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04)."
16823511,Premise,1012,1185,"Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm."
16823511,Premise,1186,1286,"Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores."
16823511,Claim,1350,1503,"in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL."
16823511,Claim,1504,1709,"Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL."
16823511,Claim,1287,1344,"Different analyses yielded slightly different conclusions"
16835585,Claim,1,269,"Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment."
16835585,Premise,1006,1105,"Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;"
16835585,Premise,1106,1174,"the between-group difference was statistically significant (P<0.01)."
16835585,Premise,1175,1273,"The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;"
16835585,Premise,1274,1342,"the between-group difference was statistically significant (P<0.05)."
16835585,Premise,1343,1439,"Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),"
16835585,Premise,1444,1575,"low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period."
16835585,Claim,1576,1808,"Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition."
16849753,Premise,1202,1335,"Intent-to-treat analysis showed no significant differences between the three arms for appetite, QOL, or cannabinoid-related toxicity."
16849753,Premise,1336,1440,"Increased appetite was reported by 73%, 58%, and 69% of patients receiving CE, THC, or PL, respectively."
16849753,Premise,1569,1649,"CE at the oral dose administered was well tolerated by these patients with CACS."
16849753,Claim,1650,1786,"No differences in patients' appetite or QOL were found either between CE, THC, and PL or between CE and THC at the dosages investigated."
16877734,Claim,1,99,"Docetaxel has shown activity in elderly patients with advanced non-small-cell lung cancer (NSCLC)."
16877734,Premise,729,908,"There was no statistical difference in median overall survival with docetaxel versus vinorelbine (14.3 months v 9.9 months; hazard ratio, 0.780; 95% CI, 0.561 to 1.085; P = .138)."
16877734,Premise,909,1016,"There was a significant difference in median progression-free survival (5.5 months v 3.1 months; P < .001)."
16877734,Premise,1017,1124,"Response rates were also significantly improved with docetaxel versus vinorelbine (22.7% v 9.9%; P = .019)."
16877734,Premise,1125,1297,"The most common grade 3 to 4 toxicities were neutropenia (82.9% for docetaxel; 69.2% for vinorelbine; P = .031) and leukopenia (58.0% for docetaxel; 51.7% for vinorelbine)."
16877734,Premise,1298,1354,"Other toxicities were mild and generally well tolerated."
16877734,Premise,1355,1465,"Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20)."
16877734,Premise,1466,1575,"Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine."
16877734,Claim,1576,1651,"Overall survival was not statistically significantly improved at this time."
16877734,Claim,1652,1771,"Docetaxel monotherapy may be considered as an option in the standard treatment of elderly patients with advanced NSCLC."
16882940,Premise,1259,1422,"Median progression-free survival was 18.2 months in the TC-Top arm versus 18.5 months in the TC arm (stratum-adjusted HR = 0.97 [95% CI = 0.85 to 1.10]; P = .688)."
16882940,Premise,1423,1579,"Median overall survival was 43.1 months for the TC-Top arm versus 44.5 months for the TC arm (stratum-adjusted HR = 1.01 [95% CI = 0.86 to 1.18]; P = .885)."
16882940,Premise,1580,1680,"At 3 years, overall survival in both arms was 57% (58.5% in the TC arm and 55.7% in the TC-Top arm)."
16882940,Premise,1681,1988,"Compared with patients in the TC arm, patients in the TC-Top arm had more grade 3-4 hematologic toxic effects (requiring more supportive care) and more grade 3-4 infections (5.1% versus 2.7%; P = .034) but did not have a statistically significant increase in febrile neutropenia (3.3% versus 3.1%; P = .80)."
16882940,Premise,1989,2223,"Among patients who had measurable disease (TC, n = 147; TC-Top, n = 145), overall (i.e., complete or partial) response was 69.0% (95% CI = 61.4% to 76.5%) in the TC-Top arm and 76.2% (95% CI = 69.3% to 83.1%) in the TC arm (P = .166)."
16882940,Claim,2224,2371,"The sequential addition of topotecan to carboplatin-paclitaxel did not result in superior overall response or progression-free or overall survival."
16882940,Claim,2372,2464,"Therefore, this regimen is not recommended as standard of care treatment for ovarian cancer."
16921034,Premise,670,757,"Survival was significantly longer (hazard ratio, 0.70; P < .0001) in the erlotinib arm."
16921034,Premise,758,833,"Compliance with QOL was 87% at baseline and more than 70% during treatment."
16921034,Premise,834,1060,"Patients receiving erlotinib had significantly longer median time to deterioration for all three symptoms (4.9 v 3.7 months for cough [P = .04]; 4.7 v 2.9 months for dyspnea [P = .04], and 2.8 v 1.9 months for pain [P = .03])."
16921034,Premise,1061,1199,"QOL response analyses showed that 44%, 34%, and 42% of patients receiving erlotinib had improvement in these three symptoms, respectively."
16921034,Premise,1200,1353,"This was accompanied by a significant improvement in the physical function (31% erlotinib v 19% placebo, P = .01), and global QOL (35% v 26%, P < .0001)."
16921034,Premise,1354,1513,"Patients with complete or partial response were more likely to have improvement in the QOL response than patients with stable or progressive disease (P < .01)."
16921034,Claim,1514,1664,"Erlotinib not only improves survival in previously treated patients with NSCLC, but also improves tumor-related symptoms and important aspects of QOL."
16921047,Premise,744,911,"Combination treatment in the GemCis arm was associated with a prolonged median progression-free survival (5.3 months v 3.1 months; hazard ratio [HR] = 0.75; P = .053)."
16921047,Premise,912,1042,"Also, median overall survival was superior for patients treated in the GemCis arm as compared with the Gem arm (7.5 v 6.0 months),"
16921047,Premise,1043,1132,"an advantage which did not, however, reach statistical significance (HR = 0.80; P = .15)."
16921047,Premise,1133,1208,"Tumor response rates were comparable between treatment arms (10.2% v 8.2%)."
16921047,Premise,1209,1306,"The rate of stable disease was, however, greater in the combination arm (60.2% v 40.2%; P < .001)"
16921047,Premise,1308,1384,"Grade 3 to 4 hematologic toxicity did not exceed 15% in both treatment arms."
16921047,Claim,1385,1493,"These results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin."
16921047,Claim,1494,1626,"Median overall survival and progression-free survival were more favorable in the combination arm as compared with gemcitabine alone,"
16921047,Premise,1627,1691,"although the difference did not attain statistical significance."
16934909,Claim,1,158,"Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC)."
16934909,MajorClaim,159,244,"Targeted therapies may improve chemotherapy effectiveness without worsening toxicity."
16934909,Claim,409,475,"Le(y) is an attractive target since it is expressed by most NSCLC."
16934909,Premise,476,617,"SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments."
16934909,Premise,1262,1417,"Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively"
16934909,Premise,1419,1450,"Toxicity was mild in both arms."
16934909,Premise,1451,1478,"QOL analyses favored Arm A."
16934909,Claim,1479,1582,"SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients"
16942833,Premise,907,962,"There was a significant decrease in pad use in group A."
16942833,Premise,963,1017,"After 16 wk, 39 patients versus 27 were dry (p=0.007)."
16942833,Premise,1018,1171,"At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008)."
16942833,Premise,1172,1246,"Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)"
16942833,Claim,1248,1359,"The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk."
16942833,Claim,1360,1523,"The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence."
16944295,MajorClaim,1,149,"The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer."
16944295,Premise,681,887,"As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years."
16944295,Premise,888,984,"There were no statistically significant differences between treatment groups in ES total scores."
16944295,Claim,1022,1103,"there were differences between treatment groups in patient-reported side effects:"
16944295,Premise,1104,1328,"diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen."
16944295,Premise,1329,1465,"Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen."
16944295,Claim,1466,1730,"In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups."
16953985,Premise,866,950,"There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation."
16953985,Premise,951,1040,"Climacteric symptoms remained significantly below baseline values after dosage reduction;"
16953985,Premise,1041,1095,"some symptoms recurred after discontinuation of ccHRT."
16953985,Premise,1096,1228,"HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest."
16953985,Premise,1229,1330,"Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9."
16953985,Premise,1331,1396,"They deteriorated during follow-up in women not continuing ccHRT."
16953985,Claim,1397,1534,"Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns."
16953985,Premise,1535,1680,"Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up."
16953985,Claim,1681,1762,"This supports the need for an individualized approach to therapy recommendations."
16965866,Premise,994,1150,"Gastrointestinal and GU toxicity persisted 5 years after RT and did not differ between the two dose schedules other than in regard to urgency of defecation."
16965866,Premise,1151,1294,"However, 1-month GI toxicity was not only worse in patients with the hypofractionated RT schedule but also adversely affected daily activities."
16965866,Premise,1295,1390,"Nadir prostate-specific antigen values occurred at a median of 18.0 (3.0-54.0) months after RT."
16965866,Premise,1391,1561,"A total of 76 biochemical relapses, with or without clinical relapses, have occurred since; of these, 37 were in the hypofractionated and 39 in the conventional schedule."
16965866,Premise,1562,1728,"The 5-year biochemical +/- clinical relapse-free and overall survival was 55.9% and 85.3% respectively for all patients, and did not differ between the two schedules."
16965866,Claim,1855,1940,"The hypofractionated schedule is equivalent in efficacy to the conventional schedule."
16965866,Claim,1729,1854,"Radiation therapy for prostate carcinoma causes persistent GI toxicity that is largely independent of the two dose schedules."
16966687,Claim,1,70,"Most patients with advanced ovarian cancer develop recurrent disease."
16966687,Claim,71,232,"For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;"
16966687,Premise,233,348,"however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation"
16966687,Premise,1140,1214,"The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031)."
16966687,Premise,1215,1360,"Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016)."
16966687,Premise,1361,1431,"The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349)."
16966687,Premise,1432,1570,"While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon."
16966687,Premise,1571,1662,"No statistically significant differences in quality of life scores between arms were noted."
16966687,Claim,1663,1833,"Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer."
16966687,Premise,955,1139,"With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin."
16981945,MajorClaim,172,262,"There is no consensus on an accepted intervention that significantly reduces its severity."
16981945,Claim,1216,1377,"We could not identify any significant difference in the incidence of severe mucositis based on whether patients were allocated to receive misoprostol or placebo."
16981945,Premise,1378,1481,"There was no significant difference in the mean area under the mucositis curve (13.2 vs 16.6; P = 0.1)."
16981945,Premise,1482,1610,"Patients allocated to misoprostol did report slightly increased soreness (7.6 vs 6.9; P = 0.04) and a greater use of analgesics."
16981945,Premise,1611,1765,"However, this difference did not translate into a worse feeling of general well-being as measured by a simple visual analogue scale (5.8 vs 5.2; P = 0.3)."
16981945,Claim,1766,1885,"In conclusion, we were unable to identify a reduction in radiation-induced mucositis in patients receiving misoprostol."
16981945,MajorClaim,1886,2115,"There is a paucity of high-level evidence on potentially useful interventions and a continued need for new and innovative research, incorporating quality-of-life measurements, in patients experiencing radiation-induced mucositis."
17029276,Claim,1,140,"In vivo data have shown a more potent antiangiogenic effect and a higher antitumor activity of low-dose interferon (IFN) given twice daily."
17029276,Premise,720,932,"There were no significant differences in either PFS or OS between IFN1 and IFN5 (median of 3.7 months and median of 3.4 months PFS, respectively; median of 25.5 months and median of 17.5 months OS, respectively)."
17029276,Premise,933,1022,"The RRs were identical in the 2 arms (6.7%; 95% confidence interval [95% CI], 1.8-16.5%)."
17029276,Premise,1023,1151,"Two patients, 1 in each arm, remained in complete remission at the time of last follow-up, at 45+ and 38+ months from treatment."
17029276,Premise,1152,1358,"Thirty-two patients receiving IFN5 and 19 patients receiving IFN1 experienced Grade 3 or higher adverse events (graded using the National Cancer Institute Common Toxicity Criteria [version 2.0]) (P = .025)."
17029276,Premise,1359,1453,"Eighteen patients receiving IFN5 and 4 patients receiving IFN1 had dose reductions (P = .002)."
17029276,Premise,1454,1584,"There was a significant deterioration in QOL and an increase in depression associated with IFN5 but no change was noted with IFN1."
17029276,Claim,1585,1691,"Compared with IFN5, IFN1 is neither more nor less effective but is less toxic, with a better reported QOL."
17029276,Claim,1692,1806,"These results may have implications for the design of combination regimens incorporating IFN with targeted agents."
17039380,Premise,1183,1295,"A significant improvement in symptoms after treatment was found on day 5 (p < 0.001) and on day 10 (p = 0.0002)."
17039380,Claim,1296,1404,"""Laying on of hands"" resulted in a significant improvement of cancer- or cancer-therapy-associated symptoms."
17039380,Claim,1405,1523,"The magnitude of improvement obtained was similar whether on a self-declared-healer- or an actor-provided ""treatment""."
17039380,Premise,755,925,"There was no significant difference in average score values between the ""healer"" and the actor with regard to the primary (p = 0.34) or the secondary endpoint (p = 0.94),"
17039380,Premise,926,1070,"but the comparison was limited due to major protocol violations by the ""healer"" who unblinded his status after the first run and quit the study."
17047644,Premise,1136,1226,"There were no significant group differences in global QoL, pain or fatigue up to 26 weeks."
17047644,Premise,1227,1308,"The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),"
17047644,Premise,1309,1380,"but this finding was inconsistent across different methods of analysis."
17047644,Premise,1381,1484,"Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31)."
17047644,Premise,1485,1579,"One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively."
17047644,Premise,1580,1707,"Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08)."
17047644,Claim,1708,1866,"In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC."
17075117,Premise,761,847,"Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02)."
17075117,Premise,848,903,"Two-year survival rate was 18% with DCF and 9% with CF."
17075117,Premise,904,961,"Overall response rate was higher with DCF (chi2 P = .01)."
17075117,Premise,962,1053,"Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients."
17075117,Premise,1054,1197,"Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%)."
17075117,Premise,1198,1269,"Complicated neutropenia was more frequent with DCF than CF (29% v 12%)."
17075117,Claim,1270,1419,"Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity."
17075117,Claim,1420,1564,"Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer."
17090981,MajorClaim,144,212,"Quality of life is an important issue in pancreatic cancer patients."
17090981,Premise,1210,1424,"The analysis of quality of live assessment showed a statistically significant decrease in quality of life after treatment in patients with resectable pancreatic cancer and treated with radiotherapy and gemcitabine."
17090981,Premise,1425,1583,"Decreased quality of life later after treatment was also observed in patients diagnosed with unresectable pancreatic cancer and treated with the same regimen."
17090981,Claim,1584,1733,"Treatment with radiotherapy and 5-fluorouracil changed only some aspects of quality of life and did not have a significant impact on quality of life."
17143593,Premise,1238,1292,"There was no difference in any outcome between groups."
17143593,Premise,1293,1402,"Breast symptoms increased for both groups during radiotherapy, without loss of strength or range of movement."
17143593,Premise,1403,1506,"The incidence of lymphedema during the study was low for both groups and did not differ between groups."
17143593,Premise,1507,1659,"The pectoral stretching program did not influence the outcomes measured because the symptoms reported by patients were not a consequence of contracture."
17143593,Claim,263,331,"Stretching is an effective technique for increasing range of motion,"
17145528,Premise,650,730,"Forty-six patients (88%) were in disease remission 12 months after radiotherapy."
17145528,Premise,731,969,"At 12 months postradiotherapy, 12 (50.0%) and 20 patients (83.3%) in the IMRT group had recovered at least 25% of preradiotherapy SWS and SPS flow respectively, compared with 1 (4.8%) and 2 patients (9.5%), respectively, in the CRT group."
17145528,Premise,970,1062,"Global health scores showed continuous improvement in QoL after both treatments (p < 0.001)."
17145528,Premise,1063,1244,"However, after 12 months subscale scores for role-physical, bodily pain, and physical function were significantly higher in the IMRT group, indicating a better condition (p < 0.05)."
17145528,Premise,1245,1327,"Dry mouth and sticky saliva were problems in both groups 2 months after treatment."
17145528,Premise,1328,1501,"In the IMRT group, there was consistent improvement over time with xerostomia-related symptoms significantly less common than in the CRT group at 12 months postradiotherapy."
17145528,Claim,1502,1610,"IMRT was significantly better than CRT in terms of parotid sparing and improved QoL for early-stage disease."
17145528,Claim,1611,1744,"The findings support the case for assessment of health-related QoL in relation to head-and-neck cancer using a site-specific approach"
17159194,Premise,731,902,"Overall, patients receiving goserelin alone showed a marked improvement or less deterioration in QOL measures over the first 6 months than those patients treated with CMF."
17159194,Premise,903,1010,"There were no differences at 3 years after random assignment according to treatment except for hot flashes."
17159194,Premise,1011,1121,"As reflected in the hot flashes scores, patients in all three treatment groups experienced induced amenorrhea,"
17159194,Premise,1122,1225,"but the onset of ovarian function suppression was slightly delayed for patients receiving chemotherapy."
17159194,Premise,1226,1460,"Younger patients (< 40 years) who received goserelin alone returned to their premenopausal status at 6 months after the cessation of therapy, while those who received CMF showed marginal changes from their baseline hot flashes scores."
17159194,Claim,1461,1812,"Age-adjusted risk profiles that consider patient-reported outcomes enable patients to adapt to their disease and treatment, such as considering the trade-offs between delayed endocrine symptoms, but higher risk of permanent menopause with chemotherapy, and immediate but reversible endocrine symptoms with goserelin, in younger premenopausal patients."
17187405,Claim,133,250,"Somatostatin has been shown to have antimitotic activity in endocrine as well as in a variety of nonendocrine tumors."
17187405,Premise,251,305,"Expression of somatostatin receptors is found in HCCs,"
17187405,Claim,310,385,"the efficacy of the somatostatin analogue octreotide remains controversial."
17187405,Premise,829,880,"There was no difference in the cumulative survival."
17187405,Premise,881,991,"The median survival time was 4.7 months in the octreotide group compared with 5.3 months in the control group."
17187405,Premise,992,1093,"Six-month survival rates were 41% for octreotide patients and 42% for control patients, respectively."
17187405,Premise,1094,1243,"The unadjusted relative risk for mortality in the octreotide group compared with patients in the control group was 1.11 (95% CI 0.76-1.63; P = 0.59)."
17187405,Premise,1244,1428,"When adjusted for Okuda, CTP, and Cancer of the Liver Italian Program (CLIP) scores, the relative risk for octreotide did not change markedly and was 1.05 (95% CI 0.71-1.55; P = 0.83)."
17187405,Claim,1429,1507,"The CLIP score seems to predict survival better than both Okuda and CTP score."
17187405,Claim,1508,1662,"The randomized controlled double-blind HECTOR trial showed no survival benefit for HCC patients treated with long-acting octreotide compared with placebo."
17195085,Premise,478,554,"Operative time was 53 minutes longer in the laparoscopic group (P < 0.0001)."
17195085,Premise,555,665,"Postoperative morbidity rate was 28.9 percent in the laparoscopic vs. 40 percent in the open group (P = 0.18)."
17195085,Premise,666,792,"The mean length of hospital stay was 10 (4.9) days in the laparoscopic group and 13.6 (10) days in the open group (P = 0.004)."
17195085,Premise,793,866,"Local recurrence rate and five-year survival were similar in both groups;"
17195085,Claim,867,939,"however, the limited number of patients does not allow firm conclusions."
17195085,Premise,940,1043,"Quality of life was better in the laparoscopic group only in the first year after surgery (P < 0.0001)."
17195085,Premise,1044,1215,"The additional charge in the laparoscopic group was $1,748 per patient randomized ($1,194 the result of surgical instruments and $554 the result of longer operative time)."
17195085,Premise,1216,1409,"The saving in the laparoscopic group was $1,396 per patient randomized ($647 the result of shorter length of hospital stay and $749 the result of the lower cost of postoperative complications)."
17195085,Premise,1410,1511,"The net balance resulted in $351 extra cost per patient randomly allocated to the laparoscopic group."
17195085,Claim,1512,1577,"Short-term postoperative morbidity was similar in the two groups."
17195085,Claim,1578,1709,"Laparoscopic resection reduced length of hospital stay, improved first-year quality of life, and slightly increased hospital costs."
17251532,MajorClaim,1,168,"The efficacy and safety of uterine-artery embolization, as compared with standard surgical methods, for the treatment of symptomatic uterine fibroids remain uncertain."
17251532,Premise,664,778,"There were no significant differences between groups in any of the eight components of the SF-36 scores at 1 year."
17251532,Premise,779,957,"The embolization group had a shorter median duration of hospitalization than the surgical group (1 day vs. 5 days, P<0.001) and a shorter time before returning to work (P<0.001)."
17251532,Premise,958,1027,"At 1 year, symptom scores were better in the surgical group (P=0.03)."
17251532,Premise,1028,1211,"During the first year of follow-up, there were 13 major adverse events in the embolization group (12%) and 10 in the surgical group (20%) (P=0.22), mostly related to the intervention."
17251532,Premise,1212,1334,"Ten patients in the embolization group (9%) required repeated embolization or hysterectomy for inadequate symptom control."
17251532,Premise,1335,1520,"After the first year of follow-up, 14 women in the embolization group (13%) required hospitalization, 3 of them for major adverse events and 11 for reintervention for treatment failure."
17251532,Claim,1521,1677,"In women with symptomatic fibroids, the faster recovery after embolization must be weighed against the need for further treatment in a minority of patients."
17307761,Premise,1214,1313,"No significant effect was seen for general quality of life (FACT-G), which was the primary outcome."
17307761,Premise,1314,1458,"At the six month follow-up, most of these effects were maintained and an intervention effect for breast cancer specific quality of life emerged."
17307761,Premise,1459,1489,"No adverse effects were noted."
17307761,Claim,1490,1612,"Supervised group exercise provided functional and psychological benefit after a 12 week intervention and six months later."
17307761,Claim,1613,1669,"Clinicians should encourage activity for their patients."
17307761,Claim,1670,1774,"Policy makers should consider the inclusion of exercise opportunities in cancer rehabilitation services."
17307761,Premise,729,1213,"Mixed effects models with adjustment for baseline values, study site, treatment at baseline, and age gave intervention effect estimates (intervention minus control) at 12 weeks of 129 (95% confidence interval 83 to 176) for metres walked in 12 minutes, 182 (75 to 289) for minutes of moderate intensity activity reported in a week, 2.6 (1.6 to 3.7) for shoulder mobility, 2.5 (1.0 to 3.9) for breast cancer specific subscale of quality of life, and 4.0 (1.8 to 6.3) for positive mood."
17312332,Claim,1,164,"Previous trials have suggested a quality-of-life (QOL) improvement for anemic cancer patients treated with erythropoietin, but few used QOL as the primary outcome."
17312332,Premise,1046,1210,"This revealed a significant difference in the median survival in favor of the patients on the placebo arm of the trial (63 v 129 days; hazard ratio, 1.84; P = .04)."
17312332,Premise,1252,1319,"Patient numbers compromised the interpretation of the QOL analysis,"
17312332,Premise,1324,1386,"a positive Hgb response was noted with epoetin alfa treatment."
17312332,Claim,1387,1511,"An unplanned safety analysis suggested decreased overall survival in patients with advanced NSCLC treated with epoetin alfa."
17324657,Premise,1105,1250,"The nutrition intervention group had a higher mean total energy (P=0.029) and protein intake (P<0.001) compared with the standard practice group."
17324657,Premise,1251,1438,"Mean intake per kilogram of body weight for the nutrition intervention group ranged from 28 to 31 kcal/kg/day compared with 25 to 29 kcal/kg/day for the standard practice group (P=0.022)."
17324657,Premise,1439,1601,"The nutrition intervention group had a higher mean protein intake (1.1 to 1.3 g/kg/day) compared with the standard practice group (1.0 to 1.1 g/kg/day) (P=0.001)."
17324657,Premise,1602,1677,"Although the change in fiber intake between the groups was not significant,"
17324657,Premise,1678,1735,"there was a trend in the anticipated direction (P=0.083)."
17324657,Claim,1736,1994,"Intensive nutrition intervention following the ADA MNT protocol results in improved dietary intake compared with standard practice and seems to beneficially impact nutrition-related outcomes previously observed in oncology outpatients receiving radiotherapy."
17324657,MajorClaim,1995,2100,"The ADA MNT protocol for radiation oncology is a useful guide to the level of nutrition support required."
17369574,Claim,75,165,"It is not known whether imatinib may be stopped in patients in whom disease is controlled."
17369574,Premise,996,1145,"As of October 15, 2005, eight of 26 patients in the CONT group and 26 of 32 patients in the INT group had documented disease progression (P < .0001)."
17369574,Premise,1146,1253,"Twenty-four of 26 patients with documented progression in the INT arm responded to imatinib reintroduction."
17369574,Premise,1254,1347,"No differences in overall survival or imatinib resistance were observed between the two arms."
17369574,Premise,1348,1540,"Quality of life evaluated 6 months after random assignment using the 30-item Quality of Life Questionnaire was not significantly different between the two groups of randomly assigned patients."
17369574,Claim,1541,1722,"Imatinib interruption results in rapid progression in most patients with advanced GIST, and cannot be recommended in routine practice unless patient experience significant toxicity."
17467230,Claim,1,96,"Psychological interventions are efficacious in reducing emotional distress for cancer patients."
17467230,Claim,97,198,"However, it is not clear whether psychological improvements are, in turn, related to improved health."
17467230,Premise,918,1018,"A path model revealed that intervention participation directly improved health (p<.05) at 12 months."
17467230,Premise,1019,1196,"These effects remained when statistically controlling for baseline levels of distress, immunity, and health as well as sociodemographic, disease, and cancer treatment variables."
17467230,Premise,1197,1314,"Regarding the mechanisms for achieving better health, support was found for an indirect effect of distress reduction."
17467230,Premise,1315,1441,"That is, by specifically lowering intervention patients' distress at 4 months, their health was improved at 12 months (p<.05)."
17467230,Premise,1442,1563,"Although the intervention simultaneously improved patients' T-cell blastogenesis in response to phytohemagglutinin (PHA),"
17467230,Premise,1564,1619,"the latter increases were unrelated to improved health."
17467230,Premise,1620,1697,"A convergence of biobehavioral effects and health improvements were observed."
17467230,Claim,1698,1835,"Behavioral change, rather than immunity change, was influential in achieving lower levels of symptomatology and higher functional status."
17467230,Claim,1836,1928,"Distress reduction is highlighted as an important mechanism by which health can be improved."
17522936,Premise,966,1053,"There were no differences in functional outcome, morbidity, or QOL between LRP and ORP."
17522936,Premise,1181,1365,"The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively)."
17522936,Premise,1366,1483,"The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3)."
17522936,Claim,1484,1595,"This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP."
17522936,Claim,1596,1670,"Functional outcome, QOL, and morbidity are similar for the two approaches."
17522936,Claim,1671,1869,"The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women."
17548243,Claim,1,116,"Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer."
17548243,Premise,1418,1788,"Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes."
17548243,Premise,1789,1897,"Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03)."
17548243,Premise,1928,2211,"the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02)."
17548243,Premise,2212,2492,"However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20)."
17548243,Claim,2576,2761,"Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication."
17550132,Claim,180,271,"The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing."
17550132,Claim,1,179,"Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities."
17550132,Premise,938,1080,"The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037)."
17550132,Premise,1081,1238,"There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively)."
17550132,Premise,1239,1296,"Grades 3/4 toxicities occurred infrequently in both arms."
17550132,Premise,1297,1353,"The quality of life was almost the same between the arms"
17550132,Claim,1355,1457,"Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits."
17550132,Claim,1458,1697,"However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks."
17602075,Premise,986,1094,"Kaplan-Meier survival curves demonstrated better survival for the experimental group than the control group."
17602075,Premise,1095,1190,"The unadjusted significance level for group differences was P = .0006 for survival to 10 years."
17602075,Premise,1191,1347,"Cox regression models that took TNM staging or the residual tumor classification and tumor site into account also found significant differences at 10 years."
17602075,Premise,1348,1508,"Secondary analyses found that differences in favor of the experimental group occurred in patients with stomach, pancreatic, primary liver, or colorectal cancer."
17602075,Claim,1509,1795,"The results of this study indicate that patients with gastrointestinal cancer, who undergo surgery for stomach, pancreatic, primary liver, or colorectal cancer, benefit from a formal program of psychotherapeutic support during the inpatient hospital stay in terms of long-term survival."
17626056,Premise,1215,1464,"When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60))."
17626056,Premise,1465,1745,"There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89))."
17626056,Premise,1746,1871,"Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences."
17626056,Claim,1872,1993,"Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause."
17626056,Claim,1994,2111,"The results are consistent with the findings of the women's health initiative study and secondary prevention studies."
17626056,Claim,2112,2267,"Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different."
17661342,Claim,1,144,"It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors."
17661342,Premise,1342,1400,"The intervention demonstrated a trend toward improved CRF,"
17661342,Premise,1401,1485,"although this effect was reduced once confounders had been controlled statistically."
17661342,Premise,1486,1739,"There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically."
17661342,Premise,1740,1793,"No decrease in fatigue-related distress was detected."
17661342,Claim,1794,1988,"The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress."
17664468,MajorClaim,1,193,"Therapy of patients with advanced gastric or gastroesophageal junction cancer should provide symptom relief and improve quality of life (QOL) because most patients are symptomatic at baseline."
17664468,Premise,1197,1325,"Time to 5% deterioration of global health status (primary end point) significantly favored DCF over CF (log-rank test, P = .01)."
17664468,Premise,1326,1494,"QOL was preserved longer for patients on DCF than those on CF for all time to deterioration analyses, demonstrating the statistical superiority of DCF compared with CF."
17664468,Claim,1704,1954,"In V325, advanced gastric or gastroesophageal junction cancer patients receiving DCF not only had statistically improved overall survival and time to tumor-progression, but they also had better preservation of QOL compared with patients receiving CF."
17664469,Premise,902,1029,"ORR was 25.0% (95% CI, 13% to 41%) for ECF, 18.5% (95% CI, 9% to 34%) for TC, and 36.6% (95% CI, 23% to 53%) for TCF (n = 119)."
17664469,Premise,1030,1127,"Median overall survival times were 8.3, 11.0, and 10.4 months for ECF, TC, and TCF, respectively."
17664469,Premise,1128,1183,"Toxicity was acceptable, with one toxic death (TC arm)."
17664469,Premise,1184,1288,"Grade 3 or 4 neutropenia occurred in more treatment cycles with docetaxel (TC, 49%; TCF, 57%; ECF, 34%)."
17664469,Claim,1289,1408,"Global health status/QOL substantially improved with ECF and remained similar to baseline with both docetaxel regimens."
17664469,Premise,1517,1628,"A trend towards increased myelosuppression and infectious complications with TCF versus TC or ECF was observed."
17664469,Premise,1409,1516,"Time to response and ORR favor TCF over TC for further evaluation, particularly in the neoadjuvant setting."
17669280,Claim,1298,1564,"The hypothesised improvement in overall quality of life with the omission of radiotherapy was not seen in the EuroQol assessment or in the functionality and symptoms summary domains of the European Organisation for Research in the Treatment of Cancer (EORTC) scales."
17669280,Premise,1761,1845,"Differences were most apparent shortly after the time of completion of radiotherapy."
17669280,Claim,1846,1985,"Radiotherapy was then associated with increased breast symptoms and with greater fatigue but with less insomnia and endocrine side-effects."
17669280,Premise,1986,2154,"Patients had significant concerns about the delivery of radiotherapy services, such as transport, accommodation and travel costs associated with receiving radiotherapy."
17669280,Premise,2155,2303,"By the end of follow-up, patients receiving radiotherapy were expressing less anxiety about recurrence than those who had not received radiotherapy."
17669280,Premise,2304,2356,"Functionality was not greatly affected by treatment."
17669280,Premise,2357,2543,"Within the randomised controlled trial, the Barthel Index demonstrated a small but significant fall in functionality with radiotherapy compared with the no radiotherapy arm of the trial."
17669280,Premise,2544,2622,"Results from the non-randomised patients did not confirm this effect, however."
17669280,Premise,2623,2687,"Cosmetic results were better in those not receiving radiotherapy"
17669280,Premise,2688,2753,"but this did not appear to be an important issue to the patients."
17669280,Claim,2754,2869,"The use of home-based assessments by a research nurse proved to be an effective way of obtaining high-quality data."
17669280,Premise,2993,3121,"In the follow-up in this study, there were no recurrences, and the quality of life utilities from EuroQol were almost identical."
17669280,Premise,3122,3345,"Although there are no differences in overall quality of life scores between the patients treated with and without radiotherapy, there are several dimensions that exhibit significant advantage to the omission of irradiation."
17669280,Premise,3346,3439,"Over the first 15 months, radiotherapy for this population is not a cost-effective treatment."
17669280,Claim,3517,3598,"the eventual cost-effectiveness will only become clear after long-term follow-up."
17669280,Claim,3599,3817,"Extrapolations from these data suggest that radiotherapy may not be a cost-effective treatment unless it results in a recurrence rate that is at least 5% lower in absolute terms than those treated without radiotherapy."
17669280,Claim,3818,3987,"Further research is needed into a number of areas including the long-term aspects of quality of life, clinical outcomes, costs and consequences of omitting radiotherapy."
17669280,Claim,3453,3512,"early postoperative outcome does not give a complete answer"
17878480,Premise,864,978,"Vandetanib patients had more toxicity and required more dose modifications for gastrointestinal toxicity and rash."
17878480,Premise,979,1075,"Asymptomatic Corrected QT interval (QTC) prolongation was observed in eight vandetanib patients."
17878480,Premise,1076,1240,"Median progression-free survival for vandetanib and placebo was 2.7 and 2.8 months, respectively (hazard ratio [HR], 1.01; 80% CI, 0.75 to 1.36; one-sided P = .51)."
17878480,Premise,1241,1365,"Overall survival for vandetanib was 10.6 versus 11.9 months for placebo (HR, 1.43; 80% CI, 1.00 to 2.05; one-sided P = 0.9)."
17878480,Premise,1366,1645,"In planned subgroup analyses, a significant interaction was noted (P = .01): limited-stage vandetanib patients had longer overall survival (HR, 0.45; one-sided P = .07) and extensive-stage vandetanib patients shorter survival compared with placebo (HR, 2.27; one-sided P = .996)."
17878480,Claim,1646,1738,"Vandetanib failed to demonstrate efficacy as maintenance therapy for small-cell lung cancer."
17889449,Premise,996,1243,"Beyond tumor and nodal stage, Karnofsky performance status, primary site, cigarette use, use of concurrent chemotherapy, and altered fractionation schedules, the FACT-H&amp;N score was independently predictive of LRC (but not OS), with p = 0.0038."
17889449,Premise,1244,1350,"The functional well-being component of the FACT-H&amp;N predicted most significantly for LRC (p = 0.0004)."
17889449,Claim,1351,1495,"This study represents, to our knowledge, the largest analysis of HRQOL as a prognostic factor in locally advanced head and neck cancer patients."
17889449,Claim,1496,1678,"The results of this study have demonstrated the importance of baseline HRQOL as a significant and independent predictor of LRC in patients with locally advanced head and neck cancer."
17912635,MajorClaim,1,124,"Relapse after completing adjuvant tamoxifen therapy is a persistent threat for women with hormone-responsive breast cancer."
17912635,Premise,522,795,"At a median follow-up of 30 months, letrozole significantly improved disease-free survival (DFS; P<0.001), the primary end point, compared with placebo (hazard ratio [HR] for recurrence or contralateral breast cancer 0.58; 95% confidence interval [CI] 0.45, 0.76] P<0.001)."
17912635,Premise,796,987,"Furthermore, letrozole significantly improved distant DFS (HR=0.60; 95% CI 0.43, 0.84; P=0.002) and, in women with node-positive tumors, overall survival (HR=0.61; 95% CI 0.38, 0.98; P=0.04)."
17912635,Premise,988,1254,"Clinical benefits, including an overall survival advantage, were also seen in women who crossed over from placebo to letrozole after unblinding, indicating that tumors remain sensitive to hormone therapy despite a prolonged period since discontinuation of tamoxifen."
17912635,Claim,1474,1550,"MA.17 showed that letrozole is extremely well-tolerated relative to placebo."
17912635,Claim,1551,1617,"Letrozole should be considered for all women completing tamoxifen;"
17912635,Claim,1618,1819,"new results from the post-unblinding analysis suggest that letrozole treatment should also be considered for all disease-free women for periods up to 5 years following completion of adjuvant tamoxifen."
17921185,Premise,742,887,"The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods."
17921185,Premise,888,1006,"Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period."
17921185,Premise,1007,1225,"At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%."
17921185,Premise,1226,1575,"At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6)."
17921185,Premise,1576,1721,"Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment."
17921185,Premise,1722,1793,"No unique safety observations were reported during open-label exposure."
17921185,Premise,1794,2026,"Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease."
17932908,Premise,1117,1443,"There were no significant survival differences between the 244 interferon-alfa-treated patients and 248 noninterferon-alfa patients (hazard ratio, 1.00; 95% CI, 0.81-1.24) or between the 247 interleukin-2 and 245 noninterleukin-2-treated patients (hazard ratio, 1.07; 95% CI, 0.87-1.33; log rank, 0.99 and 0.52, respectively)."
17932908,Premise,1444,1572,"Grade 3-4 toxicities were significantly more frequent in cytokine-treated patients than in medroxyprogesterone-treated patients."
17932908,Claim,1573,1753,"Subcutaneous interleukin-2 and/or interferon-alfa provide no survival benefit in metastatic renal cancers of intermediate prognosis, and they induce a significant risk of toxicity."
17932908,Claim,1754,1833,"Newly available angiogenesis inhibitors should be preferred for these patients."
17947724,Claim,1,73,"Hormonal breast cancer treatment increases menopausal symptoms in women."
17947724,Premise,934,1024,"There were no significant differences in vaginal bleeding, mood alteration, or low energy."
17947724,Premise,1025,1107,"Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001)."
17947724,Premise,1108,1236,"Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03)."
17947724,Premise,1237,1317,"In both groups, the hot flash score peaked at 3 months and decreased thereafter."
17947724,Premise,1318,1533,"At 12 months, patients receiving tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared with a 7% increase from baseline with exemestane."
17947724,Premise,1534,1714,"At 12 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleeping."
17947724,Claim,1715,1751,"Symptoms were common in both groups."
17999405,Premise,1050,1180,"At 4-month follow-up, intervention patients reported less uncertainty and better communication with spouses than control patients,"
17999405,Premise,1181,1216,"but they reported no other effects."
17999405,Premise,1217,1498,"Intervention spouses reported higher quality of life, more self-efficacy, better communication, and less negative appraisal of caregiving, uncertainty, hopelessness, and symptom distress at 4 months compared with controls, and some effects were sustained to 8 months and 12 months."
17999405,Premise,1499,1638,"Men with prostate cancer and their spouses reported positive outcomes from a family intervention that offered them information and support."
17999405,Claim,1639,1750,"Programs of care need to be extended to spouses who likely will experience multiple benefits from intervention."
18025439,Premise,1005,1126,"After a median follow-up of 48 months, 79 deaths were observed in the HDCT arm and 77 deaths were observed in the ST arm;"
18025439,Premise,1127,1192,"seven patients (6%) in the HDCT arm died as a result of toxicity."
18025439,Premise,1193,1364,"The median OS was 24 months for the HDCT arm (95% CI, 21 to 35 months) and 28 months for ST (95% CI, 22 to 33 months; hazard ratio [HR], 0.9; 95% CI, 0.6 to 1.2; P = .43)."
18025439,Premise,1365,1469,"PFS was 11 months for HDCT and 9 months for ST (HR, 0.6 in favor of HDCT; 95% CI, 0.5 to 0.9; P = .006)."
18025439,Claim,1470,1580,"HDCT did not improve OS in women with MBC when used as consolidation after response to induction chemotherapy."
18064563,MajorClaim,86,216,"Women with breast cancer may have an even higher risk of depression particularly in a postmenopausal or estrogen deficiency state."
18064563,Premise,1280,1555,"The use of fluoxetine for 6 months resulted in an improvement in quality of life, a higher completion of adjuvant treatment (chemotherapy, hormonal therapy, chemotherapy plus hormonal therapy), and a reduction in depressive symptoms compared to patients who received placebo."
18064563,Claim,1556,1696,"An antidepressant should be considered for early stage breast cancer patients with depressive symptoms who are receiving adjuvant treatment."
18065731,Premise,777,864,"True acupuncture was associated with 0.8 fewer hot flashes per day than sham at 6 weeks"
18065731,Premise,866,954,"but the difference did not reach statistical significance (95% CI, -0.7 to 2.4; P = .3)."
18065731,Premise,955,1103,"When participants in the sham acupuncture group were crossed over to true acupuncture, a further reduction in the frequency of hot flashes was seen."
18065731,Claim,1206,1286,"Hot flash frequency in breast cancer patients was reduced following acupuncture."
18065731,Claim,1447,1588,"We cannot exclude the possibility that a longer and more intense acupuncture intervention could produce a larger reduction of these symptoms."
18065731,Premise,1296,1446,"when compared with sham acupuncture, the reduction by the acupuncture regimen as provided in the current study did not reach statistical significance."
18086760,Premise,1309,1425,"Improvements in self-esteem observed with RET during breast cancer chemotherapy were maintained at 6-month follow-up"
18086760,Premise,1434,1541,"reductions in anxiety not observed with AET during breast cancer chemotherapy emerged at 6-month follow-up."
18086760,Premise,1552,1712,"adopting a combined aerobic and resistance exercise program after breast cancer chemotherapy was associated with further improvements in patient-rated outcomes."
18086760,Claim,1713,1849,"Exercise training during breast cancer chemotherapy may result in some longer-term and late effects for selected patient-rated outcomes."
18086760,Premise,681,1023,"Adjusted linear mixed-model analyses showed that, at 6-month follow-up, the RET group reported higher self-esteem [adjusted mean difference, 1.6; 95% confidence interval (95% CI), 0.1-3.2; P = 0.032] and the AET group reported lower anxiety (adjusted mean difference, -4.7; 95% CI, -0.0 to -9.3; P = 0.049) compared with the usual care group."
18086760,Premise,1034,1308,"compared with participants reporting no regular exercise during the follow-up period, those reporting regular aerobic and resistance exercise also reported better patient-rated outcomes, including quality of life (adjusted mean difference, 9.5; 95% CI, 1.2-17.8; P = 0.025)."
18093738,MajorClaim,193,302,"Methods are needed to reduce professional time required while achieving sustained intervention effectiveness."
18093738,Premise,1146,1287,"Trained versus control patients reported reduced barriers to pain relief (P<.001), lower usual pain (P=.03), and greater opioid use (P<.001)."
18093738,Premise,1288,1384,"No pain training patients reported severe pain (>6 on a 0-10 scale) at 1-month outcomes (P=.03)."
18093738,Claim,1586,1767,"Using video and print materials, with brief individualized training, effectively improved pain management over time for cancer patients of varying diagnostic and demographic groups."
18165645,Premise,1086,1276,"GHRQL was initially worse for the RP+RT arm but improved over time and was better at the end of the period than the GHRQL reported for RP alone (treatment arm x time interaction, P = .0004)."
18165645,Premise,1277,1366,"Symptom distress was significantly worse for the RP+RT arm compared with the RP alone arm"
18165645,Premise,1368,1453,"but the treatment arms did not differ with respect to other general measures of HRQL."
18165645,Claim,1644,1692,"The addition of RT did not negatively impact ED."
18165645,Premise,1454,1570,"The addition of RT to surgery resulted in more frequent urination, as well as early report of more bowel dysfunction"
18165645,Premise,1572,1643,"although bowel function differences disappeared over the 5-year period."
18182665,Premise,696,790,"The survival benefit of D3P compared with MP has persisted with extended follow-up (P = .004)."
18182665,Premise,993,1117,"More patients survived >/= 3 years in the D3P and D1P arms (18.6% and 16.6%, respectively) compared with the MP arm (13.5%)."
18182665,Premise,1118,1364,"Similar trends in survival between treatment arms were seen for men greater than and less than 65 years of age, for those with and without pain at baseline, and for those with baseline PSA greater than and less than the median value of 115 ng/mL."
18182665,Claim,1365,1499,"The present analysis confirms that survival of men with metastatic HRPC is significantly longer after treatment with D3P than with MP."
18187401,Premise,1188,1348,"The SF-36 MCS and PCS, Health Utilities Index Mark 3, EuroQol 5D, and UDI scores were improved significantly in both groups at 6 months and afterward (P < .05)."
18187401,Claim,1920,1961,"Both UAE and hysterectomy improved HRQOL."
18187401,Claim,1962,2044,"No differences were observed between groups regarding HRQOL at 24-month follow-up."
18187401,Claim,2045,2146,"On the basis of HRQOL results, the authors determined that UAE is a good alternative to hysterectomy."
18187401,Premise,1789,1919,"At 24-month follow-up, patients in the hysterectomy group were significantly more satisfied than those in the UAE group (P = .02)."
18194401,Premise,697,911,"This negative impact tended to last longer in the HDC group, as for most of the QLQ-C30 scales, the QOL scores of HDC patients tend to improve at a slower rate than that of patients receiving standard chemotherapy."
18194401,Premise,927,1089,"physical functioning remains deteriorated 1 year after inclusion for HDC patients comparatively to conventional chemotherapy patients (85.99 vs. 76.65, P = 0.021)"
18194401,Premise,1091,1186,"and the pain score was still higher in the HDC group at that time (28.32 vs. 15.97, P = 0.004)."
18194401,Claim,1187,1247,"HDC has a negative impact on QOL even after treatment phase."
18194401,Premise,607,696,"Toxicity of HDC has a strong negative impact on patients' QOL during the treatment phase."
18216523,Premise,918,1066,"Postoperative side effects were significantly less in the SLN group and there was no negative impact of the SLN procedure on psychologic well being."
18216523,Claim,1409,1465,"SLN biopsy is an effective and well-tolerated procedure."
18216523,Claim,1466,1567,"However, its safety should be confirmed by the results of larger randomized trials and meta-analyses."
18216523,Premise,1317,1408,"However, the number of enrolled patients was not sufficient to draw definitive conclusions."
18257399,Claim,1438,1704,"Results of this randomized study incorporating prospective QOL measurements suggested that in patients with locally advanced NSCLC, analyzing QOL data by either gender or performance status alone may not accurately reflect how these factors depend upon each another."
18257399,Premise,963,1113,"There was a significant interaction between gender and KPS using FLIC (P = 0.009), which also showed a trend toward significance with FACT (P = 0.09)."
18257399,Premise,1114,1282,"Significant KPS-by-gender interactions were noted for FACT-L in the physical well-being and additional concerns-lung subscales (P = 0.012 and P = 0.0003, respectively)."
18257399,Premise,1283,1437,"The results of both the FLIC and FACT-L demonstrated significantly lower scores corresponding to lower KPS values (P = 0.009 and P = 0.016, respectively)."
18281662,Premise,979,1072,"The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056)."
18281662,Premise,1073,1209,"No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411)."
18281662,Premise,1210,1319,"However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,"
18281662,Premise,1320,1395,"although the P value was of borderline statistical significance (P = .048)."
18281662,Premise,1396,1537,"Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments."
18281662,Claim,1538,1793,"GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting."
18285602,Premise,785,875,"Breast IMRT significantly improved the dose distribution compared with standard radiation."
18285602,Premise,876,1088,"This translated into a lower proportion of patients experiencing moist desquamation during or up to 6 weeks after their radiation treatment; 31.2% with IMRT compared with 47.8% with standard treatment (P = .002)."
18285602,Premise,1089,1262,"A multivariate analysis found the use of breast IMRT (P = .003) and smaller breast size (P < .001) were significantly associated with a decreased risk of moist desquamation."
18285602,Premise,1263,1326,"The use of IMRT did not correlate with pain and quality of life"
18285602,Claim,1458,1571,"Breast IMRT significantly reduced the occurrence of moist desquamation compared with a standard wedged technique."
18285602,Claim,1572,1663,"Moist desquamation was correlated with increased pain and reduction in the quality of life."
18285602,Premise,1332,1457,"the presence of moist desquamation did significantly correlate with pain (P = .002) and a reduced quality of life (P = .003)."
18285602,MajorClaim,74,184,"It is more likely in full-breasted women and when the radiation is distributed nonhomogeneously in the breast."
18285602,MajorClaim,1,73,"Dermatitis is a frequent adverse effect of adjuvant breast radiotherapy."
18293016,Premise,1258,1487,"Based on the results of the area under the curve (AUC) analysis, patients receiving HMB/Arg/Gln had a strong trend higher LBM throughout the study as measured by both bioimpedance (p = 0.08) and skin-fold measurements (p = 0.08)."
18293016,Premise,1488,1613,"Among the subset of patients receiving concurrent chemotherapy, there were again no significant differences in the endpoints."
18293016,Claim,1694,1875,"This trial was unable to adequately test the ability of beta-hydroxy beta-methylbutyrate, glutamine, and arginine to reverse or prevent lean body mass wasting among cancer patients."
18293016,Premise,1614,1693,"The secondary endpoints were also not significantly different between the arms."
18306372,Premise,850,1080,"Patients who preferred RET improved QoL when they were assigned to receive RET compared with UC (mean difference, 16.5; 95% confidence interval [95% CI], 4.3-28.7; P= .008) or AET (mean difference, 11; 95% CI, -1.1-23.4; P= .076)."
18306372,Premise,1081,1233,"Patients who had no preference had improved QoL when they were assigned to receive AET compared with RET (mean difference, 23; 95% CI, 4.9-41; P= .014)."
18306372,Claim,1680,1846,"Patient preference, demographic variables, and medical variables moderated the effects of exercise training in breast cancer patients who were receiving chemotherapy."
18306372,Premise,1481,1618,"Unmarried, younger patients who were receiving nontaxane-based therapies and had more advanced disease stage experienced better outcomes."
18306372,Premise,1234,1480,"Marital status also moderated QoL response (P= .026), age moderated aerobic fitness response (P= .029), chemotherapy regimen moderated strength gain (P= .009), and disease stage moderated both lean body mass gain (P< .001) and fat loss (P= .059)."
18308419,Claim,2167,2388,"The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies."
18308419,Premise,1060,1135,"This difference was not statistically significant (log-rank test, p=0.818)."
18308419,Premise,959,1059,"Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one."
18308419,Premise,1136,1307,"Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259)."
18308419,Premise,1308,1386,"The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively."
18308419,Premise,1387,1643,"The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one."
18308419,Premise,1644,1903,"The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule."
18308419,Claim,1904,2049,"The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks."
18308419,Claim,2050,2166,"The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival."
18353696,Premise,1005,1064,"No differences in pain and symptom intensity were observed."
18353696,Premise,1206,1378,"At the doses used, methadone was significantly less expensive (p<0.0001), while the use and costs of supportive drugs and other analgesics were similar in the three groups."
18353696,Premise,1379,1509,"No relevant differences in adverse effects were observed among the groups during either the titration phase and chronic treatment."
18353696,Claim,1510,1658,"All the three opioids used as first-line therapy were effective, well tolerated, and required similar amounts of symptomatic drugs or co-analgesics."
18353696,Premise,1065,1205,"Opioid escalation index was significantly lower in patients receiving methadone (p<0.0001), although requiring up and down changes in doses."
18353696,Claim,1659,1835,"Methadone was significantly less expensive, but required more changes, up and down, of the doses, suggesting that dose titration of this drug requires major clinical expertise."
18386580,Claim,1236,1532,"For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy."
18386580,Premise,1057,1235,"The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group."
18386580,Premise,946,1056,"The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05)."
18386580,Premise,663,945,"The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05)."
18386581,Premise,595,912,"The KPS score in the treated group after treatment was improved in 13 patients (23.6%), stabilized in 27 (49.6%) and declined in 15 (27.3%), while in the control group, it was improved in 7 (13.2%), stabilized in 21 (39.6%) and declined in 25 (47.2%), the difference between the two groups was significant (P < 0.05)."
18386581,Premise,913,1077,"The results from evaluation with QLQ-C30 questionnaire and LC30 scale in the treated group was also superior to those in the control group (P < 0.05), respectively."
18386581,Premise,1078,1263,"The scores of TCM efficacy (24.52 +/- 8.98 vs 29.76 +/- 7.09, P < 0.05) and the 6-min walking distance (233.4 +/- 29.2 m vs 205.8 +/- 31.9 m, P < 0.05) were better in the treated group."
18386581,Premise,1264,1587,"After treatment in the treated group, the body weight was increased in 11 patients (20.0%), stabilized in 28 (50.9%) and decreased in 16 (29.1%), while in the control group it was increased in 5 (9.4%), stabilized in 26 (49.1%) and decreased in 22 (41.5%), difference between the two groups was significant, too (P < 0.05)."
18386581,Claim,1588,1733,"TCM therapy for removing toxic substance and unblocking meridians can improve the post-radiation QOL of patients with lung cancer to some extent."
18707619,Premise,894,1083,"Mean (+/- SD) increase in Hb from baseline to week 12 was 1.75 +/- 2.15 g/dL in the 30,000 IU group (P = 0.008 vs. baseline) and 1.04 +/- 1.75 g/dL in the 20,000 IU group (non-significant)."
18707619,Premise,1423,1519,"Both epoetin beta regiments were well tolerated and there were no dose-dependent adverse events."
18707619,Claim,1520,1642,"Epoetin beta 30,000 IU once weekly is an effective and well-tolerated treatment of anaemia in patients with solid tumours."
18707619,Premise,1084,1257,"Haemoglobin response (increase in Hb >or=2 g/dL from baseline) was observed in 78.3% of patients receiving epoetin beta 30,000 IU and 66.7% receiving epoetin beta 20,000 IU."
18786981,Premise,574,649,"There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32)."
18786981,Premise,650,718,"Median survival with GC and PE was 8.0 and 8.1 months, respectively."
18786981,Premise,719,798,"Median progression-free survival was 5.9 months with GC and 6.3 months with PE."
18786981,Premise,799,949,"Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),"
18786981,Premise,950,1041,"but these were not associated with increased hospital admissions, infections or fatalities."
18786981,Premise,1042,1137,"Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE."
18786981,Premise,1238,1380,"In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04)."
18786981,Claim,1381,1520,"GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients."
18802161,Claim,1728,2024,"ADAPt-C collaborative care is feasible and results in significant reduction in depressive symptoms, improvement in quality of life, and lower pain levels compared with EUC for patients with depressive disorders in a low-income, predominantly Hispanic population in public sector oncology clinics."
18802161,Premise,1214,1727,"Intervention patients also experienced greater rates of depression treatment (72.3% v 10.4% of EUC patients; P < .0001) and significantly better quality-of-life outcomes, including social/family (adjusted mean difference between groups, 2.7; 95% CI, 1.22 to 4.17; P < .001), emotional (adjusted mean difference, 1.29; 95% CI, 0.26 to 2.22; P = .01), functional (adjusted mean difference, 1.34; 95% CI, 0.08 to 2.59; P = .04), and physical well-being (adjusted mean difference, 2.79; 95% CI, 0.49 to 5.1; P = .02)."
18802161,Premise,1034,1213,"Improvement was also found for 5-point decrease in PHQ-9 score among 72.2% of intervention patients compared with 59.7% of EUC patients (OR = 1.99; 95% CI, 1.14 to 3.50; P = .02)."
18802161,Premise,757,1033,"At 12 months, 63% of intervention patients had a 50% or greater reduction in depressive symptoms from baseline as assessed by the Patient Health Questionnaire-9 (PHQ-9) depression scale compared with 50% of EUC patients (odds ratio [OR] = 1.98; 95% CI, 1.16 to 3.38; P = .01)."
18803678,Premise,1061,1289,"There was a significant decrease in QoL from baseline (t0) to t1 (RRA period) in the hypothyroid group with significant differences in FACIT-F TOI (P < 10(-3)), FACT-G total score (P = 0.005) and FACIT-F total score (P = 0.003)."
18803678,Premise,1290,1340,"By contrast, QoL was preserved in the rhTSH group."
18803678,Premise,1462,1584,"From 3 to 9 months, changes of QoL scales and subscales were no longer statistically different in both groups of patients."
18803678,Claim,1935,2047,"rhTSH preserves QoL of patients undergoing RRA with similar rates of ablation success compared to hypothyrodism."
18803678,Premise,1785,1860,"A higher rate of persistent thyroid remnants was observed in the rhTSH arm,"
18803678,Premise,1861,1934,"although in most cases uptake was < 0.1% and of no clinical significance."
18803678,Premise,1585,1784,"Based on serum rhTSH-stimulated Tg alone (Tg < 0.8 microg/l, BRAHMS Tg Kryptor), no difference in ablation success was observed between rhTSH and hypothyroidism groups, 91.7% and 97.1%, respectively."
18809612,MajorClaim,1,72,"Hot flashes are a significant problem for many breast cancer survivors."
18809612,MajorClaim,73,163,"Hot flashes can cause discomfort, disrupted sleep, anxiety, and decreased quality of life."
18809612,Premise,1024,1180,"By the end of the treatment period, hot flash scores (frequency x average severity) decreased 68% from baseline to end point in the hypnosis arm (P < .001)."
18809612,Premise,1181,1428,"Significant improvements in self-reported anxiety, depression, interference of hot flashes on daily activities, and sleep were observed for patients who received the hypnosis intervention (P < .005) in comparison to the no treatment control group."
18809612,Claim,1429,1597,"Hypnosis appears to reduce perceived hot flashes in breast cancer survivors and may have additional benefits such as reduced anxiety and depression, and improved sleep."
18809617,Premise,1175,1214,"fatigue, nausea, and vomiting worsened,"
18809617,Premise,1215,1277,"but there was a reduction in pain and no change in global QOL."
18809617,Premise,1278,1362,"Patients in the observation arm showed considerable improvements in QOL by 3 months."
18809617,Premise,977,1115,"The two groups were comparable, with low global QOL scores and significant symptom burden, especially pain and fatigue, after thoracotomy."
18809617,Premise,1363,1496,"QOL, except for symptoms of sensory neuropathy and hearing loss, in those treated with chemotherapy returned to baseline by 9 months."
18809617,Claim,1497,1702,"The findings of this trial indicate that the negative effects of adjuvant chemotherapy on QOL appear to be temporary, and that improvements (with a return to baseline function) are likely in most patients."
18959455,Claim,2021,2307,"This research study indicates that live music therapy using patient-preferred music can be beneficial in improving quality of life indicators such as anxiety, perception of the hospitalization or procedure, relaxation, and stress in patients undergoing surgical procedures of the brain."
18959455,Premise,1401,1603,"Results indicated statistically significant differences for 4 of the 6 quality of life measures: anxiety (p = .03), perception of hospitalization (p = .03), relaxation (p = .001), and stress (p = .001)."
18959455,Premise,1604,1700,"No statistically significant differences were found for mood (p > .05) or pain (p > .05) levels."
19039808,Premise,808,1108,"We observed a significant reduction in anxiety (STAI, POMS) among group participants, a reduction in anger, depression and fatigue (POMS), a significant improvement in vigor and interpersonal relationships (POMS), in emotional and role functioning, in health status and fatigue level (EORTC QLQ-C30)."
19039808,Premise,1122,1194,"coping strategies (MAC) were not significantly different between groups."
19039808,Premise,1195,1293,"No group-related negative effects were observed and the global satisfaction levels were very high."
19039808,Claim,1294,1493,"This study demonstrates the feasibility and effectiveness of a psycho-educational intervention, which can accelerate the reduction of those negative affects which are present at the end of treatment."
19039808,Claim,1494,1601,"It represents an excellent complement or an alternative to individual psycho-oncologic therapeutic support,"
19050973,Premise,1099,1199,"The average increase in arm volume was 2.8% in the SNBM group and 4.2% in the RAC group (P = 0.002)."
19050973,Premise,1200,1358,"Patients in the SNBM group gave lower ratings for arm swelling (P < 0.001), symptoms (P < 0.001), and dysfunctions (P = 0.02), but not disabilities (P = 0.5)."
19050973,Premise,1359,1465,"Sentinel nodes were found in 95% of the SNBM group (29% positive) and 93% of the RAC group (25% positive)."
19050973,Claim,1554,1672,"SNBM was successfully undertaken in a wide range of surgical centers and caused significantly less morbidity than RAC."
19064973,Claim,1503,1563,"Preliminary results suggested a positive impact on survival."
19064973,Premise,726,843,"There was a high rate of grade 3/4 neutropenia (97%) but not neutropenic fever (12%) during neoadjuvant chemotherapy."
19064973,Premise,844,946,"No significant differences in rates of acute toxicities were observed between the two arms during CRT."
19064973,Premise,947,1064,"Dose intensities of concurrent cisplatin, late RT toxicities and quality of life scores were comparable in both arms."
19064973,Premise,1065,1210,"The 3-year progression-free survival for neoadjuvant versus control arm was 88.2% and 59.5% (hazard ratio = 0.49; 95% CI, 0.20 to 1.19; P = .12)."
19064973,Premise,1211,1349,"The 3-year overall survival for neoadjuvant versus control arm was 94.1% and 67.7% (hazard ratio = 0.24; 95% CI, 0.078 to 0.73; P = .012)."
19064973,Claim,1350,1502,"Neoadjuvant docetaxel-cisplatin followed by CRT was well tolerated with a manageable toxicity profile that allowed subsequent delivery of full-dose CRT."
19074911,Claim,1556,1720,"Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy."
19074911,Claim,1721,1869,"Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice."
19074911,Premise,1028,1555,"At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4)."
19074911,Premise,777,987,"At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients."
19074911,Premise,988,1027,"There were no opportunistic infections."
19194996,Claim,1299,1399,"EW was associated with a higher level of satisfaction with emotional support compared with controls."
19194996,MajorClaim,1504,1644,"it seems feasible to suggest that EW may be a cost effective accessible treatment that could be incorporated into the ongoing care of women."
19194996,Premise,1207,1298,"Most participants found writing valuable and did not report any long-term negative effects."
19194996,Premise,1113,1206,"There were no significant effects of the intervention on mood, QOL or healthcare utilisation."
19194996,Premise,699,888,"There was a significant effect of group on women's perceptions of social support with those in the intervention group being more satisfied with the emotional support they received (p<0.05)."
19194996,Premise,889,1112,"Satisfaction with emotional support was negatively correlated with depression/dejection (p<0.05) and anger/hostility (p<0.05) and positively correlated with social and family well-being (p<0.001) 6 months post intervention."
19199105,Claim,1467,1696,"The study results suggest that K-tape could replace the bandage in DLT, and it could be an alternative choice for the breast-cancer-related lymphedema patient with poor short-stretch bandage compliance after 1-month intervention."
19199105,Premise,1294,1466,"The acceptance of K-tape was better than the bandage, and benefits included longer wearing time, less difficulty in usage, and increased comfort and convenience (P < 0.05)."
19199105,Premise,945,1063,"There was no significant difference between groups in all outcome variables (P > 0.05) through the whole study period."
19199105,Premise,1064,1197,"Excess limb size (circumference and water displacement) and excess water composition were reduced significantly in the bandage group;"
19199105,Premise,1198,1293,"excess circumference and excess water composition were reduced significantly in the tape group."
19199105,MajorClaim,1860,1926,"More efficient treatment protocol is needed for clinical practice."
19199105,Claim,1784,1859,"these two treatment protocols are inefficient and cost time in application."
19273701,Claim,1746,1858,"Cetuximab offers important HRQL and survival benefits for pretreated patients with advanced, wild-type KRAS CRC."
19273701,Premise,922,1086,"PF change scores were -3.9 for cetuximab and -8.6 for BSC (P = .046) at 8 weeks and were -5.9 and -12.5 for cetuximab and BSC, respectively, (P = .027) at 16 weeks."
19273701,Premise,1087,1229,"GHS change scores were -0.5 and -7.1 (P = .008) at 8 weeks and were -3.6 and -15.2 (P = .008) at 16 weeks for cetuximab and BSC, respectively."
19273701,Premise,1230,1419,"In patients who had tumors with wild-type KRAS status, cetuximab resulted in less PF deterioration at 8 weeks (-0.7 v -7.2; P = .11) and 16 weeks (-3.4 v -13.8; P = .008) compared with BSC."
19273701,Premise,1420,1587,"Patients with wild-type status who received cetuximab experienced improved GHS at 8 weeks, whereas patients who received BSC alone deteriorated (3.2 v -7.7; P = .002)."
19273701,Premise,1650,1745,"No significant differences were noted between study arms for patients with mutated KRAS tumors."
19273701,Premise,1588,1649,"Cetuximab preserved GHS at 16 weeks (-0.2 v -18.1; P < .001)."
19286422,Premise,1175,1452,"At 4 years, 64 (18%) of 353 patients on combined therapy and 39 (12%) of 337 on endocrine-alone therapy had moderate to severe urinary bother (p=0.005), and 16 (4%) of 355 on combined therapy and five (2%) of 338 on endocrine treatment alone had pain while urinating (p=0.024)."
19286422,Premise,1453,1590,"37 (11%) of 350 in the combined group and 23 (7%) of 35 in the endocrine-only group had overall bother from all bowel symptoms (p=0.022)."
19286422,Premise,1591,1725,"281 (85%) of 332 in the combined-treatment group and 227 (72%) of 313 in the endocrine-only group had erectile dysfunction (p=0.0002)."
19286422,Premise,1726,1874,"Quality of life at 4 years was similar, with the exception of decreased social function in patients receiving endocrine treatment plus radiotherapy."
19286422,Claim,1875,2007,"Although addition of radiotherapy to endocrine treatment significantly increased some treatment-related symptoms, none were serious."
19286422,Claim,2070,2213,"the increase of symptoms seems acceptable and has little extra effect on quality of life after 4 years compared with endocrine treatment alone."
19289630,Premise,646,852,"Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively)."
19289630,Premise,853,1156,"In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate."
19289630,Premise,1157,1200,"No unexpected adverse events were observed,"
19289630,Premise,1335,1524,"QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively."
19289630,Claim,1525,1705,"In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate."
19289630,Claim,1706,1857,"With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed."
19289630,Premise,1201,1334,"except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate)."
19330830,Premise,915,1136,"For the chemotherapy group, the mean Quality Adjusted Life Months over 24 months (QALM-24) was 9.6 (95% CI: 8.7, 11.2) months compared with the mean QALM-24 of 8.6 (95% CI: 7.6, 10.5) months for the no chemotherapy group."
19330830,Premise,1137,1315,"For the chemoradiation group, the mean QALM-24 was 7.1 (95% CI: 6.0, 9.0) months compared with the mean QALM-24 of 8.1 (95% CI: 7.0, 10.0) months for the no chemoradiation group."
19330830,Claim,1476,1622,"Chemotherapy provided on average an additional 1.0 quality-adjusted life months within a restricted 2-year time period from the time of resection."
19330830,Claim,1316,1475,"The previously reported survival advantage supporting the use of adjuvant chemotherapy is maintained when adjusted using quality adjusted survival methodology."
19333052,Premise,846,1090,"Compared with RELP, patients receiving UM had significantly shorter duration of operation and hospital stay, shorter time periods to walk, return to daily activities, or sit without pain and to return to work or school, and fewer complications."
19333052,Premise,1091,1244,"Time to final healing was significantly shorter and quality of life scores on the CWIS were higher in patients receiving RELP than in those receiving UM."
19333052,Premise,1245,1310,"Patients with UM had lower levels of pain one week after surgery."
19333052,Claim,1311,1515,"The unroofing and marsupialization procedure provides more clinical benefits in the treatment of pilonidal disease than rhomboid excision and Limberg flap and should be considered the procedure of choice."
19333052,Claim,1516,1649,"However, it may be associated with more inconvenience in wound care and longer healing time than rhomboid excision and Lindberg flap."
19347979,Premise,933,1035,"Patients carrying a GCLC 77 genotype had a worse overall survival (hazard ratio (HR) = 1.5, p = 0.05)."
19347979,Premise,1036,1360,"Patients carrying the GPX1-CC genotype had a clinically significant decline in the UNISCALE (odds ratio (OR): 7.5; p = 0.04), total Functional Assessment of Cancer Therapy-Lung score (OR: 11.0; p = 0.04), physical (OR: 7.1; p = 0.03), functional (OR: 5.2; p = 0.04), and emotional well-being constructs (OR: 23.8; p = 0.01)."
19347979,Claim,1361,1515,"Genotypes of glutathione-related enzymes, especially GCLC, may be used as host factors in predicting patients' survival after platinum-based chemotherapy."
19347979,Claim,1516,1576,"GPX1 may be an inherited factor in predicting patients' QOL."
19347979,Claim,1577,1737,"Further investigation to define and measure the effects of these genes in chemotherapeutic regimens, drug toxicities, disease progression, and QOL are critical."
19349389,Premise,1165,1362,"During follow-up, 71% of the patients showed unaltered or improved lung expansion and 9 patients (15%) needed new pleural procedures (VATS group, 5 recurrences; TS group, 4 recurrences; p = 0.999)."
19349389,Premise,1363,1489,"No differences were found between groups regarding quality of life, complications, drainage time, hospital stay, and survival."
19349389,Premise,1490,1640,"Immediate lung expansion did not correlate with radiologic recurrence, clinical recurrence, or complications (p = 0.60, 0.15, and 0.20, respectively)."
19349389,Premise,1641,1728,"Immediate partial lung expansion was a frequent finding and was more frequent after TS."
19349389,Claim,1742,1835,"no correlation between immediate lung expansion and clinical outcome was found in this study."
19436289,Premise,845,1123,"There was a significant difference in mean dysphagia grade between treatment arms 6 weeks following treatment (P=0.046), with worse swallowing reported by rigid stent-treated patients (mean dysphagia score difference=-0.49; 95% confidence interval (CI) -0.10 to -0.89, P=0.014)."
19436289,Premise,1124,1367,"Global QL scores were lower at both 1 and 6 weeks following treatment for patients treated by SEMSs (mean difference QL index week 1=-0.66; 95% CI: -0.02 to -1.30, P=0.04; mean difference QL index week 6=-1.01; 95% CI -0.30 to -1.72, P=0.006)."
19436289,Premise,1368,1619,"These findings were associated with higher post-procedure pain scores in the SEMS patient group (mean difference of the European Organisation for Research and Treatment of Cancer QLQ C-30 pain symptom score at week 1=11.13; 95% CI: 2.89-19.4; P=0.01)."
19436289,Premise,1620,1778,"Although mean EQ-5D QL values differed between the treatments (P<0.001), this difference dissipated following generation of quality-adjusted life year values."
19436289,Premise,1980,2063,"There were no differences in the in-hospital mortality or early complication rates,"
19436289,Premise,2064,2163,"but late complications were more frequent after rigid stenting (risk ratio=2.47; 95% CI 1.88-3.04)."
19436289,Premise,2164,2260,"There was a survival advantage for non-stent-treated patients (log-rank statistic=4.21, P=0.04)."
19436289,Claim,2261,2494,"The treatment choice for patients with inoperable esophageal cancer should be between a SEMS or a non-stent treatment after consideration has been given to both patient and tumor characteristics and clinician and patient preferences."
19495810,Premise,1365,1397,"QOL improved in the study group."
19495810,Claim,1398,1516,"ALT was found to be a safe method, with high adherence, in treating women who suffer from mild to moderate lymphedema."
19495810,Claim,1517,1601,"A significant immediate and insignificant long-term effect on limb volume was noted."
19495810,Premise,1139,1231,"ALT had a positive, statistically and clinically significant immediate effect on limb volume"
19495810,Premise,1232,1266,"but no long-term effect was noted."
19495810,Premise,1046,1138,"There was no episode of arm infection or aggravation in limb volume during the study period."
19495810,Premise,1267,1364,"The adherence rate to ALT was significantly higher than the adherence to self-management therapy."
19516032,Premise,1614,1706,"Adverse events in both groups included fatigue, diminished sexual function, and hot flushes."
19516032,Claim,1707,1924,"The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapy plus 3 years of androgen suppression in the treatment of locally advanced prostate cancer."
19516032,Premise,1186,1301,"After a median follow-up of 6.4 years, 132 patients in the short-term group and 98 in the long-term group had died;"
19516032,Premise,1302,1407,"the number of deaths due to prostate cancer was 47 in the short-term group and 29 in the long-term group."
19516032,Premise,1408,1512,"The 5-year overall mortality for short-term and long-term suppression was 19.0% and 15.2%, respectively;"
19546404,Premise,1034,1270,"Patients in the VBT group reported better social functioning (P < .002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P < .001)."
19546404,Premise,1469,1564,"Patients who received EBRT reported significantly higher levels of diarrhea and bowel symptoms."
19546404,Claim,1743,1849,"Vaginal brachytherapy provides a better QOL, and should be the preferred treatment from a QOL perspective."
19546404,Premise,1392,1468,"Sexual functioning and symptoms did not differ between the treatment groups."
19608997,Premise,764,924,"The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 1.09, 95% confidence interval [CI] = 0.93 to 1.27; P = .28)."
19608997,Premise,925,1060,"Among patients with limited-stage disease, there was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15),"
19608997,Premise,1061,1193,"but among patients with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 to 1.68)."
19608997,Premise,1194,1297,"Progression-free survival rates were also similar in the two groups (HR = 1.07, 95% CI = 0.92 to 1.24)."
19608997,Premise,1298,1505,"Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; P < .001)."
19608997,Premise,1506,1629,"There were no statistically significant differences between treatments in hematological and nonhematological toxic effects,"
19608997,Premise,1630,1714,"except more patients in the thalidomide group had rash, constipation, or neuropathy."
19608997,Claim,1724,1776,"QoL scores were similar in the two treatment groups,"
19608997,Claim,1777,1888,"but thalidomide was associated with less insomnia and diarrhea and more constipation and peripheral neuropathy."
19608997,Claim,1921,2076,"thalidomide in combination with chemotherapy did not improve survival of patients with SCLC but was associated with an increased risk of thrombotic events."
19621686,Premise,1137,1299,"The operation time was significantly longer, and the leakage rate was higher in the transthoracic group (Student's t-test and Fischer's exact test, respectively)."
19621686,Premise,1309,1417,"intraoperative blood loss and postoperative hospital stay were not significantly different (Student t-test)."
19621686,Premise,1424,1537,"the Kaplan-Meier survival curves of these two groups were not significantly different by log-rank test (p=0.286)."
19621686,Premise,1538,1694,"The score on the quality of life of transhiatal patients was significantly higher than that of transthoracic patients in the third, sixth and twelfth month."
19621686,Claim,1695,1750,"Transhiatal esophagectomy is a safe and fast procedure."
19621686,Claim,1751,1810,"The survival was similar to that of transthoracic approach."
19621686,Claim,1811,1869,"Its leakage rate was lower and quality of life was better."
19646443,Premise,880,937,"Baseline characteristics were comparable for both groups,"
19646443,Premise,938,1020,"except that more patients with ADPKD were assigned to the placebo group (P = .03)."
19646443,Premise,1021,1176,"The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide."
19646443,Premise,1177,1315,"In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01)."
19646443,Premise,1316,1514,"Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases)."
19646443,Claim,1515,1609,"In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume."
19652072,Premise,1082,1236,"The most common grade 3 treatment-related AEs were asthenia/fatigue (16%), diarrhea (11%), hypertension (11%), hand-foot syndrome (9%), and anorexia (8%)."
19652072,Premise,1386,1490,"Efficacy, tolerability, and quality-of-life results were similar between patients dosed in the AM or PM."
19652072,Claim,1491,1699,"Sunitinib 37.5 mg, administered on a continuous once-daily dosing regimen, has a manageable safety profile as second-line mRCC therapy, providing flexible dosing, which can be explored in combination studies."
19652072,Premise,1292,1385,"Median PFS and OS were 8.2 and 19.8 months, respectively, at median follow-up of 26.4 months."
19687337,Premise,856,1182,"At postintervention, AET was superior to UC for patient-rated physical functioning (mean group difference, +9.0; 95% CI, 2.0 to 16.0; P = .012), overall QoL (P = .021), fatigue (P = .013), happiness (P = .004), depression (P = .005), general health (P < .001), cardiovascular fitness (P < .001), and lean body mass (P = .008)."
19687337,Premise,1280,1358,"AET did not interfere with chemotherapy completion rate or treatment response."
19687337,Premise,1359,1574,"At 6-month follow-up, AET was still borderline or significantly superior to UC for overall QoL (P = .054), happiness (P = .034), and depression (P = .009) without an increased risk of disease recurrence/progression."
19687337,MajorClaim,1748,1860,"Exercise training to improve cardiovascular fitness should be considered in the management of lymphoma patients."
19687337,Claim,1575,1747,"AET significantly improved important patient-rated outcomes and objective physical functioning in lymphoma patients without interfering with medical treatments or response."
19690306,Premise,1720,1953,"The estimated treatment effects (intervention minus usual care) for all participants were a mean (SE) of 4.6 (2) for quality of life (P = .02), -27.8 (15) for symptom intensity (P = .06), and -1.8 (0.81) for depressed mood (P = .02)."
19690306,Premise,1954,2179,"The estimated treatment effects in participants who died during the study were a mean (SE) of 8.6 (3.6) for quality of life (P = .02), -24.2 (20.5) for symptom intensity (P = .24), and -2.7 (1.2) for depressed mood (P = .03)."
19690306,Claim,2238,2507,"Compared with participants receiving usual oncology care, those receiving a nurse-led, palliative care-focused intervention addressing physical, psychosocial, and care coordination provided concurrently with oncology care had higher scores for quality of life and mood,"
19690306,Claim,2508,2636,"but did not have improvements in symptom intensity scores or reduced days in the hospital or ICU or emergency department visits."
19691092,Premise,928,969,"No late arising QOL issues were observed."
19691092,Premise,676,766,"Regardless of treatment arm, participants reported high levels of QOL with few exceptions."
19691092,Premise,767,927,"cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time."
19691092,Premise,970,1168,"Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001)."
19691092,Premise,1169,1341,"Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem."
19691092,Claim,1342,1428,"In this randomized trial, no long-term QOL advantage for either treatment was apparent"
19691092,Claim,1429,1518,"with the exception of poorer sexual function reported by those treated with cryoablation."
19714296,Premise,1144,1187,"No QOL differences were noted between arms."
19714296,Premise,1188,1308,"GE/G Grade 3-4 toxicities included: neutropenia (18.3%/28.2%); thrombocytopenia (14.6%/25.6%); and fatigue (11.0%/7.7%)."
19714296,Premise,1309,1408,"No statistically significant relationships between biomarker expression and outcomes were observed."
19714296,Premise,1418,1514,"patients with low expression of cytoplasmic pGSK-3 trended toward greater OS with GE treatment."
19714296,Premise,1515,1565,"OS, PFS, QOL, and RR were comparable between arms."
19714296,Claim,1566,1620,"Adding E to G did not increase hematologic toxicities."
19714296,Claim,197,264,"Data suggest that the GE combination may improve clinical outcomes."
19720909,MajorClaim,1446,1564,"Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy."
19720909,Claim,1324,1396,"VC, GC, and TC are not superior to PC in terms of overall survival (OS)."
19720909,Claim,1397,1445,"However, the trend in RR, PFS, and OS favors PC."
19720909,Premise,1213,1323,"The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia."
19720909,Premise,1118,1212,"Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively."
19720909,Premise,947,1117,"The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC."
19720909,Premise,784,946,"The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC."
19760046,Premise,1012,1119,"Hospital stay for patients who received EOF (n=71) was 4.7 vs. 5.8 days for the TOF group (n=72) (P=0.006)."
19760046,Premise,1120,1237,"The mean level of postoperative satisfaction was significantly higher in the EOF group (82.8 vs. 71.7 mm, P B 0.001)."
19760046,Claim,1604,1718,"On the basis of these findings, the policy of EOF should be used after a complex gynecologic oncologic laparotomy."
19760046,Premise,1448,1603,"Variables such as nausea and vomiting, analgesic and antiemetic requirement as well as level of pain and quality of life were not different between groups."
19760046,Premise,1238,1447,"Patients who received the TOF scheme had significantly higher overall postoperative complications (39 vs. 17% in EOF group, P=0.003) and infective complications (14% in TOF group vs. 3% in EOF group, P=0.017)."
19826172,Premise,1733,1804,"No significant effect was seen on global health status/quality of life."
19826172,Claim,1805,2041,"A supervised multimodal exercise intervention including high and low intensity components was feasible and could safely be used in patients with various cancers who were receiving adjuvant chemotherapy or treatment for advanced disease."
19826172,Claim,2042,2197,"The intervention reduced fatigue and improved vitality, aerobic capacity, muscular strength, and physical and functional activity, and emotional wellbeing,"
19826172,Claim,2198,2222,"but not quality of life."
19826172,Premise,1496,1732,"Improvement was noted in physical capacity: estimated mean difference between groups for maximum oxygen consumption was 0.16 l/min (95% CI 0.1 to 0.2, P<0.0001) and for muscular strength (leg press) was 29.7 kg (23.4 to 34.9, P<0.0001)."
19826172,Premise,1250,1495,"Significant effects were seen on vitality (effect size 0.55, 95% CI 0.27 to 0.82), physical functioning (0.37, 0.09 to 0.65), role physical (0.37, 0.10 to 0.64), role emotional (0.32, 0.05 to 0.59), and mental health (0.28, 0.02 to 0.56) scores."
19826172,Premise,986,1249,"Adjusted for baseline score, disease, and demographic covariates, the intervention group showed an estimated improvement at six weeks for the primary outcome, fatigue, of -6.6 points (95% confidence interval -12.3 to -0.9, P=0.02; effect size=0.33, 0.04 to 0.61)."
19838842,Premise,1095,1306,"At 6 and 12 months, 55% and 39% of intervention patients had a 50% or greater reduction in depressive symptoms (SCL-20) from baseline compared to 34% and 20% of usual care participants (P = 0.003 and P = 0.029)."
19838842,Premise,1307,1544,"Intervention patients also experienced greater remission rates (P = 0.031), more depression-free days (P < 0.001), less functional impairment (P = 0.011), and greater quality of life (P = 0.039) at 12 months than usual care participants."
19838842,Claim,1545,1696,"The IMPACT collaborative care program appears to be feasible and effective for depression among older cancer patients in diverse primary care settings."
19858379,Premise,696,982,"GEM-CAP significantly improved objective response rate (19.1% v 12.4%; P = .034) and progression-free survival (hazard ratio [HR], 0.78; 95% CI, 0.66 to 0.93; P = .004) and was associated with a trend toward improved OS (HR, 0.86; 95% CI, 0.72 to 1.02; P = .08) compared with GEM alone."
19858379,Premise,983,1223,"This trend for OS benefit for GEM-CAP was consistent across different prognostic subgroups according to baseline stratification factors (stage and performance status) and remained after adjusting for these stratification factors (P = .077)."
19858379,Premise,1234,1434,"the meta-analysis of two additional studies involving 935 patients showed a significant survival benefit in favor of GEM-CAP (HR, 0.86; 95% CI, 0.75 to 0.98; P = .02) with no intertrial heterogeneity."
19858379,MajorClaim,1435,1608,"On the basis of our trial and the meta-analysis, GEM-CAP should be considered as one of the standard first-line options in locally advanced and metastatic pancreatic cancer."
19884558,Premise,928,1085,"Sleep quality differed over 1 years time (F [4,162] = 7.7, P < .001; by group, F [1,173] = 4.8, P = .029; and over time by group, F [4,162] = 3.3, P = .013)."
19884558,Premise,1086,1176,"Pairwise comparisons revealed significant differences between groups at 90 days (P = .002)"
19884558,Premise,1177,1206,"but not at 1 year (P = .052)."
19884558,Premise,1300,1459,"The night awakenings (Actigraph) pattern was significantly different by group over time (P = .046), with no differences between groups at 90 days or at 1 year."
19884558,Premise,1460,1504,"Fatigue was lower at 1 year than before CTX;"
19884558,Premise,1505,1533,"no group effects were found."
19884558,Claim,1534,1648,"The BT group, on average, experienced significant improvement on global sleep quality compared with the HEC group,"
19884558,Claim,1649,1696,"but not on objective sleep or fatigue outcomes."
20003966,Premise,475,624,"Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)"
20003966,Premise,625,815,"but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05)."
20003966,Premise,816,1108,"More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ."
20003966,Premise,1109,1226,"When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4)."
20003966,Premise,1227,1330,"There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life."
20003966,Premise,1331,1462,"Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians])."
20003966,Premise,1677,1718,"Despite slow initial symptom improvement,"
20003966,Claim,1719,1866,"GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer."
20003966,Claim,1867,1938,"Because stent placement was associated with better short-term outcomes,"
20003966,Claim,1939,2017,"this treatment is preferable for patients expected to live less than 2 months."
20033227,Premise,713,784,"Food intake improved more rapidly after stent placement than after GJJ,"
20033227,Premise,785,851,"but long-term relief of obstructive symptoms was better after GJJ."
20033227,Premise,852,985,"More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ."
20033227,Premise,986,1083,"Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001)."
20033227,Premise,1084,1126,"We found no difference in follow-up costs."
20033227,Premise,1127,1235,"Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049)."
20033227,Premise,1236,1423,"The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival."
20033227,Claim,1424,1461,"Medical effects were better after GJJ"
20033227,Claim,1463,1499,"although GJJ had higher total costs."
20033227,Claim,1569,1688,"cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO."
20033227,Claim,1500,1568,"Since the cost difference between the two treatments was only small,"
20038728,Premise,715,912,"Both groups exhibited significant decreases in hot flashes, depressive symptoms, and other quality-of-life symptoms, including significant improvements in mental health from pre- to post-treatment."
20038728,Premise,913,1016,"These changes were similar in both groups, indicating that acupuncture was as effective as venlafaxine."
20038728,Premise,1017,1184,"By 2 weeks post-treatment, the venlafaxine group experienced significant increases in hot flashes, whereas hot flashes in the acupuncture group remained at low levels."
20038728,Premise,1185,1367,"The venlafaxine group experienced 18 incidences of adverse effects (eg, nausea, dry mouth, dizziness, anxiety), whereas the acupuncture group experienced no negative adverse effects."
20038728,Premise,1368,1539,"Acupuncture had the additional benefit of increased sex drive in some women, and most reported an improvement in their energy, clarity of thought, and sense of well-being."
20038728,Claim,1540,1611,"Acupuncture appears to be equivalent to drug therapy in these patients."
20038728,Claim,1612,1760,"It is a safe, effective and durable treatment for vasomotor symptoms secondary to long-term antiestrogen hormone use in patients with breast cancer."
20151824,Premise,1224,1380,"In all study groups, serum TSH levels showed very good stimulation (mean, 82.24 +/- 18.21 mU/L), without significant between-group differences (p = 0.5213)."
20151824,Premise,1598,1766,"The successful ablation rate was 91.0% in T4-WD Group, 91.7% in T3-WD Group, and 91.3% in rhTSH Group, without significant between-preparation differences (p = 0.2061)."
20151824,Premise,1767,1851,"QoL was better preserved in rhTSH Group than in T4-WD and T3-WD Groups (p < 0.0001)."
20151824,Premise,1852,1944,"However, there was no QoL difference at the time of ablation between T4-WD and T3-WD Groups."
20151824,Claim,1945,2126,"Our study indicates that use of rhTSH preserves QoL in patients undergoing RI ablation and affords an ablation success rate comparable to that seen after thyroid hormone withdrawal."
20178647,Premise,732,881,"Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively."
20178647,Premise,547,731,"The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively."
20178647,Premise,882,1053,"Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01)."
20178647,Premise,1054,1140,"As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03)."
20178647,Claim,1141,1236,"Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC."
20178647,Claim,1237,1364,"Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted."
20189927,Premise,1241,1337,"Nausea and vomiting frequency, duration, and distress were lower for experimental group members,"
20189927,Premise,1338,1464,"although a high attrition rate (50%) resulted in insufficient power to detect statistically significant differences over time."
20189927,Claim,1857,1941,"Flavonoid-rich fruits and vegetables may provide additional protection against CINV."
20189927,Claim,1628,1781,"The effect of grape juice flavonoids on CINV should be investigated further with a larger sample to determine whether preliminary findings are supported."
20479425,Premise,973,1104,"In an intent-to-treat analysis, the 2-year OS rates were 65.7% for CIS and 66.2% for TPZ/CIS (TPZ/CIS--CIS: 95% CI, -5.9% to 6.9%)."
20479425,Premise,1105,1287,"There were no significant differences in failure-free survival, time to locoregional failure, or quality of life as measured by Functional Assessment of Cancer Therapy-Head and Neck."
20479425,Claim,1288,1457,"We found no evidence that the addition of TPZ to chemoradiotherapy, in patients with advanced head and neck cancer not selected for the presence of hypoxia, improves OS."
20530648,Premise,1032,1263,"The scapula-oriented exercise group showed improvements in pain, physical function, social function, and global quality of life compared with baseline, whereas the general exercise group showed improved fatigue and range of motion."
20530648,Premise,1264,1510,"The change in global quality of life (P = 0.067; effect size, 0.33) and strength of external rotation (P = 0.001; effect size, 0.55) were significantly greater in the scapula-oriented exercise group than in the general exercise and control group."
20530648,Claim,1511,1609,"Scapula-oriented exercise had beneficial effects on pain, quality of life and aspects of strength."
20538475,Premise,701,1000,"There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year."
20538475,Premise,1001,1164,"Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05)."
20538475,Premise,1165,1266,"Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery."
20538475,Premise,1275,1337,"recovery was found at both 6 months and 1 year in both groups."
20538475,Premise,1338,1445,"Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year."
20538475,Claim,1446,1628,"Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period."
20564162,Premise,921,1015,"Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001)."
20564162,Premise,1016,1137,"Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved."
20564162,Premise,1138,1210,"Of the 41 patients who reported swelling at baseline, 38 (93%) improved."
20564162,Premise,1211,1421,"Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),"
20564162,Premise,1422,1498,"but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077)."
20564162,Claim,1499,1687,"Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era."
20832982,Premise,997,1221,"Patients in both treatment conditions showed improvements in pain, depression, QOL, and self-efficacy, and caregivers in both conditions showed improvements in anxiety and self-efficacy from baseline to four-month follow-up."
20832982,Premise,1222,1363,"Results of exploratory analyses suggested that the CST intervention was more beneficial to patients/caregivers with Stage II and III cancers,"
20832982,Premise,1372,1470,"the education/support intervention was more beneficial to patients/caregivers with Stage I cancer."
20832982,Claim,1528,1660,"results from this study suggest that psychosocial interventions can lead to improvements in a range of outcomes for cancer patients."
20832982,Premise,1471,1527,"Taken together with the broader literature in this area,"
20842129,Premise,939,1015,"There was a trend towards improved global HRQOL during the treatment period."
20842129,Premise,1016,1107,"At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,"
20842129,Premise,1108,1177,"but the low compliance does not allow to draw definitive conclusions."
20842129,Premise,1178,1282,"Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,"
20842129,Premise,1283,1307,"but to a limited extent."
20842129,Claim,1308,1483,"Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner."
20855825,Premise,793,993,"PFS was significantly longer for fulvestrant 500 mg (n = 362) than 250 mg (n = 374) (hazard ratio [HR] = 0.80; 95% CI, 0.68 to 0.94; P = .006), corresponding to a 20% reduction in risk of progression."
20855825,Premise,994,1093,"Objective response rate was similar for fulvestrant 500 mg and 250 mg (9.1% v 10.2%, respectively)."
20855825,Premise,1094,1164,"CBR was 45.6% for fulvestrant 500 mg and 39.6% for fulvestrant 250 mg."
20855825,Premise,1165,1321,"DoCB and OS were 16.6 and 25.1 months, respectively, for the 500-mg group, whereas DoCB and OS were 13.9 and 22.8 months, respectively, in the 250-mg group."
20855825,Claim,1322,1398,"Fulvestrant 500 mg was well tolerated with no dose-dependent adverse events."
20855825,Claim,1399,1429,"QOL was similar for both arms."
20855825,Claim,1430,1556,"Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity,"
20855843,Premise,861,912,"Major toxicity was similar across all three groups."
20855843,Premise,913,1093,"With a median follow-up time of 12 months and 382 deaths, there was no clear survival benefit when comparing PCV with TMZ (hazard ratio [HR], 0.91; 95% CI, 0.74 to 1.11; P = .350)."
20855843,Premise,1094,1192,"For TMZ-5 versus TMZ-21, 12-week PFS rates were similar (63.6% and 65.7%, respectively; P = .745),"
20855843,Premise,1193,1417,"but TMZ-5 improved overall PFS (HR, 1.38; 95% CI, 1.05 to 1.82; P = .023), survival (HR, 1.32; 95% CI, 0.99 to 1.75; P = .056), and global quality of life (49% v 19% improved > 10 points at 6 months, respectively; P = .005)."
20855843,Claim,1418,1621,"Although TMZ (both arms combined) did not show a clear benefit compared with PCV, comparison of the TMZ schedules demonstrated that the 21-day schedule was inferior to the 5-day schedule in this setting."
20855843,Claim,1622,1721,"This challenges the current understanding of increasing TMZ dose-intensity by prolonged scheduling."
20863761,Premise,1397,1573,"Mean physical function at 12 months was 66 points (95% CI 629-700) in the 90 mg group and 68 points (646-714) in the 30 mg group (95% CI of difference -66 to 33; p=052)."
20863761,Premise,1574,1752,"Median time to first skeletal-related event in patients who had such an event was 92 months (81-107) in the 90 mg group and 102 months (73-140) in the 30 mg group (p=063)."
20863761,Premise,1782,1909,"eight patients in the pamidronate 90 mg group developed osteonecrosis of the jaw compared with two patients in the 30 mg group."
20863761,Claim,1910,2044,"Monthly infusion of pamidronate 30 mg should be the recommended dose for prevention of bone disease in patients with multiple myeloma."
20881891,Premise,1025,1234,"Relative to women continuing tamoxifen, women switching to anastrozole experienced a decrease of 53% (95% CI, 41%-63%) in double endometrial thickness and a decrease of 51% (95% CI, 39%-60%) in uterine volume."
20881891,Premise,1235,1412,"Vaginal dryness (b = 0.064; 95% CI, 0.016-0.112) and sexual problems (b = 0.054; 95% CI, 0.007-0.102) increased in women taking anastrozole compared with women taking tamoxifen."
20881891,Premise,1413,1516,"Treatment arms did not differ regarding withdrawal rate and the experience of (serious) adverse events."
20881891,Claim,1587,1710,"Switching to anastrozole strongly decreased the endometrial thickness and uterine volume but increased sexual disturbances."
20881891,MajorClaim,1711,1787,"Safe and effective interventions are needed to alleviate sexual dysfunction."
20885302,MajorClaim,1,50,"Systematic assessment is vital to palliative care"
20885302,Premise,938,1095,"Results showed improved patient depression (P < .001) as a result of the intervention and improvement in both groups in patients' quality of life (P < .001)."
20885302,Premise,1096,1248,"No other patient outcomes (symptom distress, spiritual needs) or caregiver outcomes (depression, support, spiritual needs) were significantly different."
20885302,Premise,1370,1535,"Hospice care was so good during the study that overall quality of life improved as a result of standard care and left little room for improvement in other variables."
20885302,Claim,1536,1602,"Systematic assessment of depression is needed in hospice patients."
20888993,Premise,1502,1747,"With a median follow-up of 569 months (IQR 374-818) from randomisation and 370 deaths (186 early, 184 delayed), there was no evidence of a difference in overall survival between early and delayed treatment (HR 098, 95% CI 080-120, p=085)."
20888993,Premise,1748,1909,"Median survival from randomisation was 257 months (95% CI 230-279) for patients on early treatment and 271 months (228-309) for those on delayed treatment."
20888993,Claim,1910,2047,"Our findings showed no evidence of a survival benefit with early treatment of relapse on the basis of a raised CA125 concentration alone,"
20888993,Claim,2048,2225,"and therefore the value of routine measurement of CA125 in the follow-up of patients with ovarian cancer who attain a complete response after first-line treatment is not proven."
20973982,Premise,1672,1724,"Reported adverse events were similar between groups."
20973982,Premise,1725,1788,"A slight increase in transfusions was reported in the QW group."
20973982,Claim,1789,1972,"Darbepoetin alfa, when administered synchronously with chemotherapy, on an EDS appears to be similarly efficacious to darbepoetin alfa weekly dosing with no unexpected adverse events."
20973982,Premise,1203,1321,"Seventy-one percent of patients in the EDS group and 76% in the QW group achieved the target hemoglobin of 11.0 g/dL."
21147514,Premise,1360,1530,"According to the Radiation Therapy Oncology Group scale, the Grade 2 or greater rectal toxicity rate was 14% and 19.5% for the 70- and 80-Gy arms (p = .22), respectively."
21147514,Premise,1531,1618,"The Grade 2 or greater urinary toxicity was 10% at 70 Gy and 17.5% at 80 Gy (p = .046)."
21147514,Premise,1676,1745,"Bladder toxicity was more frequent at 80 Gy than at 70 Gy (p = .039)."
21147514,Premise,1619,1675,"Similar results were observed using the LENT-SOMA scale."
21147514,Premise,1746,1912,"The quality-of-life questionnaire results before and 5 years after treatment were available for 103 patients with no differences found between the 70- and 80-Gy arms."
21147514,Claim,1913,2012,"High-dose radiotherapy provided a better 5-year biochemical outcome with slightly greater toxicity."
21149651,Claim,1349,1482,"Decreasing depression symptoms over the first year were associated with longer subsequent survival for women with MBC in this sample."
21149651,Premise,1081,1189,"There was a significant effect of change in CES-D over the first year on survival out to 14 years (P = .007)"
21149651,Premise,1190,1278,"but no significant interaction between treatment condition and CES-D change on survival."
21149651,Premise,937,1080,"Median survival time was 53.6 months for women with decreasing CES-D scores over 1 year and 25.1 months for women with increasing CES-D scores."
21149651,Claim,1483,1613,"Further research is necessary to confirm this hypothesis in other samples, and causation cannot be assumed based on this analysis."
21149658,Premise,1227,1298,"For BT versus RP, there was no difference in bowel or hormonal domains,"
21149658,Premise,1303,1467,"men treated with BT scored better in urinary (91.8 v 88.1; P = .02) and sexual (52.5 v 39.2; P = .001) domains, and in patient satisfaction (93.6 v 76.9; P < .001)."
21149658,Claim,1644,1778,"HRQOL evaluated 3.2 to 6.5 years after treatment showed an advantage for BT in urinary and sexual domains and in patient satisfaction."
21208247,Premise,1363,1445,"In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent."
21208247,Claim,1446,1594,"Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing."
21208247,Premise,970,1126,"PIDs were 09 and 03 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0001), and 15 and 03 respectively on day 3 (P < 0001)."
21208247,Premise,1127,1250,"Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0001)."
21208247,Premise,1251,1362,"The SF-6D score decreased to 212  25 in the oxycodone/paracetamol group at the end of the phase (P = 0001)."
21224783,Claim,1773,1847,"Pilates exercises are effective and safe in female breast cancer patients."
21224783,Premise,1650,1772,"When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05)."
21224783,Premise,1316,1486,"After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05)."
21224783,Premise,1500,1649,"no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05)."
21224783,Claim,1848,1920,"There is a need for further studies so that its effect can be confirmed."
21233603,Premise,832,950,"No significant longitudinal changes were detected in the global health status in both groups upon available follow-up."
21233603,Premise,951,1138,"Surgery was associated with worsened physical functioning and fatigue symptoms up to 6 months after treatment (P < 0.001 and P = 0.021, respectively) and these scales improved at 2 years."
21233603,Premise,1139,1364,"In terms of pulmonary function, dyspnoic and coughing symptoms were significantly worsened 3 months after surgery (P = 0.024 and P = 0.036, respectively) whereas symptoms in the CRT group progressively deteriorated over time."
21233603,Premise,1365,1496,"Concerning the eating function, both groups had improvements in dysphagia but there were frequent need for endoscopic intervention."
21233603,Premise,1497,1592,"Neither surgery nor definitive CRT significantly impaired the global health status of patients."
21233603,Claim,1593,1711,"Surgery was associated with a short-term negative impact in some aspects of health related quality of life assessments"
21233603,Claim,1712,1775,"but these changes became insignificant 2 years after treatment."
21233603,Claim,1785,1877,"CRT was associated with progressive deteriorations in pulmonary function in the longer term."
21236344,Premise,1531,1600,"Difference between groups (p=0.007) for BMD at femur was significant."
21236344,Premise,1601,1757,"The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620)."
21236344,Premise,1758,1889,"The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months."
21236344,Premise,1890,2040,"No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT."
21236344,Premise,2041,2161,"The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021)."
21236344,Premise,2162,2266,"After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,"
21236344,Premise,2267,2319,"but there were positive changes in group A patients."
21236344,Premise,2320,2430,"Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point."
21236344,MajorClaim,1,94,"Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women"
21236344,Claim,169,287,"Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies."
21237636,Premise,888,1177,"There was no significant difference in HRQoL between nurse-led telephone and hospital follow-up at 12 months after treatment (p = 0.42; 95% confidence interval (CI) for difference: -1.93-4.64) and neither between follow-up with or without EGP (p = 0.86; 95% CI for difference: -3.59-3.00)."
21237636,Premise,1191,1381,"no differences between the intervention groups and their corresponding control groups were found in role and emotional functioning, and feelings of control and anxiety (all p-values > 0.05)."
21237636,Claim,1382,1542,"Replacement of most hospital follow-up visits in the first year after breast cancer treatment by nurse-led telephone follow-up does not impede patient outcomes."
21237636,MajorClaim,1550,1677,"nurse-led telephone follow-up seems an appropriate way to reduce clinic visits and represents an accepted alternative strategy."
21300923,Premise,1320,1517,"Capecitabine treatment was associated with less nausea, vomiting, and constipation and with better appetite than standard treatment (P  .004), but worse hand-foot syndrome and diarrhea (P < .005)."
21300923,Premise,1010,1319,"Compared with patients who were treated with standard chemotherapy, patients who were treated with capecitabine had significantly better QoL, role function, and social function, fewer systemic adverse effects, less psychological distress, and less fatigue during and at the completion of treatment (P  .005)."
21300923,Claim,1563,1708,"Standard chemotherapy was superior to capecitabine in improving relapse-free and overall survival for older women with early-stage breast cancer."
21300923,Claim,1718,1778,"capecitabine was associated with better QoL during treatment"
21300923,Premise,1780,1822,"QoL was similar for both groups at 1 year."
21300930,Premise,837,995,"Amenorrhea 12 months after random assignment was significantly different between treatment groups: 69.8% for ACT, 57.7% for TAC, and 37.9% for AT (P < .001)."
21300930,Premise,996,1061,"The AT group without tamoxifen had the lowest rate of amenorrhea."
21300930,Premise,1062,1152,"QOL was poorer for patients receiving ACT at 6 months but similar to others by 12 months."
21300930,Premise,1153,1226,"Post-treatment symptoms were increased above baseline for all treatments."
21300930,Premise,1227,1410,"Multivariable repeated measures modeling demonstrated that treatment arm, time point, age, and tamoxifen use were significantly associated with symptom severity (all P values < .002)."
21300930,Claim,1411,1508,"Amenorrhea rates differed significantly by treatment arm, with the AT arm having the lowest rate."
21300930,Claim,1509,1684,"Patients treated with longer duration therapy (ACT) had greater symptom severity and poorer QOL at 6 months, but did not differ from shorter duration treatments at 12 months."
21396307,Premise,1014,1177,"Compared with standard TPN, a higher serum prealbumin level and better nitrogen balance were observed in glutamine-enriched TPN (P = 0.039 and 0.048 respectively)."
21396307,Premise,1178,1297,"A significantly lower serum interleukin-6 level was found in comparing glutamine-enriched with standard TPN (P = 0.01),"
21396307,Premise,1298,1383,"but not in interleukin-10 (P = 0.374) and tumor necrosis factor- levels (P = 0.653)."
21396307,Premise,1394,1523,"a significant lower serum C-reactive protein level was detected in glutamine-enriched TPN compared with standard TPN (P = 0.013)."
21396307,Premise,1532,1718,"four cases of postoperative infectious complications were noted in the control group, but no postoperative infectious complications were observed in the interventional group (P = 0.037)."
21396307,Claim,1719,1902,"Our present study shows that glutamine-enriched TPN may be beneficial in improving the inflammatory status and decreasing the infectious morbidity in postoperative GI cancer patients."
21439726,Premise,872,988,"Compared to EUC, TEC was associated with increased pain communication self-efficacy after the intervention (P<.001);"
21439726,Premise,989,1074,"both groups showed significant (P<.0001), similar, reductions in pain misconceptions."
21439726,Premise,1075,1244,"At 2 weeks, assignment to TEC was associated with improvement in pain-related impairment (-0.25 points on a 5-point scale, 95% confidence interval -0.43 to -0.06, P=.01)"
21439726,Premise,1245,1328,"but not in pain severity (-0.21 points on an 11-point scale, -0.60 to 0.17, P=.27)."
21439726,Premise,1329,1408,"The improvement in pain-related impairment was not sustained at 6 and 12 weeks."
21439726,Premise,1409,1481,"There were no significant intervention by subgroup interactions (P>.10)."
21439726,Claim,1482,1667,"We conclude that TEC, compared with EUC, resulted in improved pain communication self-efficacy and temporary improvement in pain-related impairment, but no improvement in pain severity."
21444867,Premise,784,946,"The 15-year actuarial locoregional recurrence rates were 5.8% for EBRT versus 15.5% for NAT (P < .001), and 15-year overall survival was 52% versus 60% (P = .14)."
21444867,Premise,1049,1245,"Patients treated with EBRT reported significant (P < .01) and clinically relevant higher rates of urinary incontinence, diarrhea, and fecal leakage leading to more limitations in daily activities."
21444867,Premise,1246,1390,"Increased symptoms were reflected by the frequent use of incontinence materials after EBRT (day and night use, 42.9% v 15.2% for NAT; P < .001)."
21444867,Premise,1391,1525,"Patients treated with EBRT reported lower scores on the SF-36 scales ""physical functioning"" (P = .004) and ""role-physical"" (P = .003)."
21444867,Claim,1526,1690,"EBRT for endometrial cancer is associated with long-term urinary and bowel symptoms and lower physical and role-physical functioning, even 15 years after treatment."
21444867,MajorClaim,1691,1819,"Despite its efficacy in reducing locoregional recurrence, EBRT should be avoided in patients with low- and intermediate-risk EC."
21452066,Premise,804,979,"Subdomain analysis revealed a clinically moderate improvement from baseline for LAC in total QOL index at 18months (P=0.02) as well as other small symptomatic improvements."
21452066,Premise,1212,1343,"Eighteen months after surgery, any differences in quality of life between patients randomized to LAC or open colectomy favored LAC."
21452066,Premise,1344,1393,"However, the magnitude of the benefits was small."
21452066,Claim,1394,1583,"Patients with poor preoperative QOL appear to be at higher risk for difficult postoperative courses, and may be candidates for enhanced ancillary services to address their particular needs."
21452066,Claim,1,211,"Postoperative outcomes of patients undergoing laparoscopic-assisted colectomy (LAC) have shown modest improvements in recovery but only minimal differences in quality of life (QOL) compared with open colectomy."
21471765,Premise,1211,1486,"At 6 months, there was a clinically relevant, but nonsignificant reduction in presentations to emergency departments (21% vs 33%; 1 = 1.41, P = .23) and readmission to the hospital (37% vs 47%; 1 = 0.82, P = .37) among intervention compared with control group participants."
21471765,Premise,1487,1629,"Nonsignificant differences between groups were found for all unmet supportive care need and quality-of-life scores, change scores, and trends."
21471765,Premise,1630,1755,"However, at 6 months, total quality-of-life scores were higher for intervention group patients than controls (106.0 vs 98.6)."
21471765,Claim,1803,2008,"Improvements in total quality-of-life change scores demonstrated that at 6 months, improvements were more than twice as large and clinically significant in the intervention compared with the control group."
21471765,Claim,2009,2173,"CONNECT has shown promising indications on health system and patient outcomes that warrant a larger study to further investigate the potential of this intervention."
21472373,Premise,745,885,"The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm."
21472373,Premise,886,1012,"During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001)."
21472373,Premise,1013,1187,"The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance."
21472373,Premise,1188,1357,"The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT."
21472373,Claim,1658,1832,"This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective."
21472373,Premise,1358,1657,"For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time  arm' interaction, indicating a persistent better patient perspective with MPT treatment."
21538678,Premise,848,1285,"Participants in the Internet group showed significant improvements at post-assessment compared with those in the control group in overall insomnia severity (F(1,26) = 22.8; p<0.001), sleep efficiency (F(1,24) = 11.45; P = 0.002), sleep onset latency (F(1,24) = 5.18; P = 0.03), soundness of sleep (F(1,24) = 9.34; P = 0.005), restored feeling upon awakening (F(1,24) = 11.95; P = 0.002), and general fatigue (F(1,26) = 13.88; P = 0.001)."
21538678,Premise,1286,1495,"Although other group  time interactions were not significant, overall adjusted effect sizes for all sleep variables as well as for fatigue, depression, anxiety, and quality of life ranged from small to large."
21538678,Claim,1496,1656,"CBT-I delivered through an interactive, individually tailored Internet intervention may be a viable treatment option for cancer survivors experiencing insomnia."
21538678,MajorClaim,1,55,"Insomnia is a common complaint among cancer survivors."
21538680,Premise,1066,1179,"No interactions were found between other domains of quality of life, functioning, psychological distress and CBT."
21538680,Premise,956,1065,"Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT."
21538680,Premise,1180,1261,"At T3, no significant difference on fatigue was found between CBT and usual care."
21538680,Premise,1262,1370,"Exploratory analyses showed that the difference nearly reached significance until 7months postintervention."
21538680,Premise,1371,1496,"Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators."
21538680,Premise,1497,1654,"After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7months postintervention."
21538680,Claim,1655,1772,"The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit."
21561791,Premise,1004,1132,"The 2-year risk of progression for PSA nadir  0.2 ng/ml, and > 0.2 to 4 ng/ml in CAD was 31% and 70% (P < 0.001), respectively."
21561791,Premise,1133,1176,"In the IAD group, a similar trend was seen."
21561791,Premise,1177,1327,"Patients with PSA nadir  0.2 ng/ml, though had significantly higher 2-year risk of progression compared to CAD (53% vs. 31% (P = 0.03), respectively."
21561791,Premise,1368,1458,"Patients without pain had a significantly lower 2-year risk of progression in both groups."
21561791,Premise,1620,1692,"No QOL difference was found, although more side effects occurred in CAD."
21561791,Claim,1693,1809,"Metastatic prostate cancer patients with high baseline PSA, pain, and high PSA nadir have a poor prognosis with ADT."
21561791,Claim,1810,1888,"Patients with low PSA nadir do significantly worse with IAD compared with CAD."
21561791,Claim,1989,2069,"IAD is not a good treatment option for many metastatic prostate cancer patients."
21561791,Premise,1459,1524,"Without ADT testosterone remained at castrate level for 4 months."
21592754,Premise,767,950,"The estimated median overall survival times for RS+WBRT and S+WBRT patients were 6.2 and 2.8 months, respectively (hazard ratio 0.53,95%confidence interval 0.20-1.43, P=0.20)."
21592754,Premise,951,1035,"Corresponding median failure-free survival times were 3.1 and 1.7 months (P=0.20)."
21592754,Premise,1036,1235,"For 19 'per protocol' patients, 2/10 in the RS+WBRT arm had distant intracranial failure (one also had local failure) and 3/9 S+WBRT patients had distant intracranial failure (no local failures)."
21592754,Premise,1236,1286,"There were no grade 3-4 late radiation toxicities."
21592754,Claim,1287,1397,"Two months after starting treatment there were no significant differences in quality of life between the arms."
21592754,Claim,1398,1586,"This randomised trial encountered the accrual difficulties and consequent low statistical power commonly associated with interdisciplinary studies drawing from a small eligible population,"
21690465,Premise,1199,1352,"Patients in the intervention arm discussed more symptoms over time compared with patients in the attention-control (P = .008) and control (P = .04) arms."
21690465,Premise,1353,1411,"No study arm effect was observed for function discussions."
21690465,Premise,1509,1637,"Clinic discussions were associated with severity of patient-reported symptoms but not with patient-reported functional concerns."
21690465,Premise,1638,1724,"A positive longitudinal impact of the intervention on symptom discussion was observed,"
21690465,Premise,1725,1826,"but not for function discussion, suggesting that potentially serious problems may remain unaddressed."
21690465,Claim,1827,1947,"Training oncologists in responding to patient-reported functional concerns may increase the impact of this intervention."
21709202,Premise,880,1074,"there was no difference in OS seen between ASA404 (n = 649) and placebo (n = 650) arms: median OS was 13.4 and 12.7 months respectively (hazard ratio [HR], 1.01; 95% CI, 0.85 to 1.19; P = .535)."
21709202,Premise,1086,1188,"no OS difference was seen in the histologic (squamous or nonsquamous) and sex (male or female) strata."
21709202,Premise,1189,1291,"Median PFS was 5.5 months in both arms (HR, 1.04; P = .727), while ORR was 25% in both arms (P = 1.0)."
21709202,Premise,1292,1380,"Overall rate of adverse events (AEs) was comparable between the ASA404 and placebo arms."
21709202,Premise,1381,1497,"Grade 4 neutropenia (27% v 19%) and infusion site pain (10% v 0.5%) were reported more frequently in the ASA404 arm."
21709202,Claim,1498,1642,"The addition of ASA404 to carboplatin and paclitaxel, although generally well tolerated, failed to improve frontline efficacy in advanced NSCLC."
21723792,Premise,814,951,"The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively."
21723792,Claim,1,132,"The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC)."
21723792,Premise,952,1258,"The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively."
21723792,Premise,1259,1354,"There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G."
21723792,Premise,1355,1618,"Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G."
21723792,Claim,1619,1724,"The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR."
21723792,Claim,1725,1803,"Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,"
21723792,Claim,1804,1854,"although the regimen generally was well tolerated."
21741309,Premise,1747,1869,"No significant differences were noted in the distress levels before and after completion of the study in the three groups."
21741309,Premise,1870,2274,"For the secondary outcomes, patients reported that dignity therapy was significantly more likely than the other two interventions to have been helpful ((2)=3550, df=2; p<00001), improve quality of life ((2)=1452; p=0001), increase sense of dignity ((2)=1266; p=0002), change how their family saw and appreciated them ((2)=3381; p<00001), and be helpful to their family ((2)=3386; p<00001)."
21741309,Premise,2275,2521,"Dignity therapy was significantly better than client-centred care in improving spiritual wellbeing ((2)=1035; p=0006), and was significantly better than standard palliative care in terms of lessening sadness or depression ((2)=938; p=0009);"
21741309,Premise,2522,2717,"significantly more patients who had received dignity therapy reported that the study group had been satisfactory, compared with those who received standard palliative care ((2)=2958; p<00001)."
21741309,Claim,2718,2863,"Although the ability of dignity therapy to mitigate outright distress, such as depression, desire for death or suicidality, has yet to be proven,"
21741309,Claim,2864,2987,"its benefits in terms of self-reported end-of-life experiences support its clinical application for patients nearing death."
21751205,Claim,1633,1667,"No difference in QOL was observed."
21751205,Premise,1152,1321,"A mean of 10.6 units of PRBCs over 5 months were administered to those who received epoetin alpha compared with 13 units for those who did not receive epoetin (P = .04)."
21751205,Premise,1322,1416,"There was no significant difference in QOL as assessed by the FACT-Anemia or ESAS instruments."
21751205,Premise,1417,1508,"The CR rate and the 3-year CR duration were not affected adversely by use of epoetin alpha."
21751205,Claim,1509,1632,"Epoetin alpha decreased the number of PRBC transfusions and did not appear to have a negative impact on remission duration."
21751205,Premise,1047,1151,"The trial was stopped early because of poor accrual before the target of 123 evaluable patients was met."
21751205,MajorClaim,1,115,"Anemia is an expected consequence of intensive chemotherapy regimens administered to patients with acute leukemia."
21751295,Premise,1087,1151,"The most common reason for dropout was patients feeling too ill."
21751295,Premise,1152,1214,"Attrition rates did not vary significantly between study arms."
21751295,Premise,1441,1574,"There were no other significant associations between attrition and any demographic, medical, psychiatric, or study-related variables."
21751295,Claim,1575,1838,"These findings highlight the challenge of maintaining advanced cancer patients in longitudinal research and suggest the need to consider alternative approaches (e.g., telemedicine) for patients who might benefit from group interventions but are too ill to travel."
21751295,MajorClaim,1,113,"The generalizability of palliative care intervention research is often limited by high rates of study attrition."
21751295,Premise,933,1086,"The rates of attrition at these time points were 28.1%, 17.7%, and 11.1%, respectively; 43.1% of the participants (66 of 153) completed the entire study."
21821474,Premise,1275,1474,"High self-assessed quality of life was reported by 62 (35%) of 179 men allocated radical prostatectomy, 55 (34%) of 160 men assigned to watchful waiting, and 93 (45%) of 208 men in the control group."
21821474,Premise,1475,1643,"Anxiety was higher in the SPCG-4 groups (77 [43%] of 178 and 69 [43%] of 161 men) than in the control group (68 [33%] of 208 men; relative risk 142, 95% CI 107-188)."
21821474,Premise,1644,1935,"Prevalence of erectile dysfunction was 84% (146 of 173 men) in the radical prostatectomy group, 80% (122 of 153) in the watchful-waiting group, and 46% (95 of 208) in the control group and prevalence of urinary leakage was 41% (71 of 173), 11% (18 of 164), and 3% (six of 209), respectively."
21821474,Premise,1936,2088,"Distress caused by these symptoms was reported significantly more often by men allocated radical prostatectomy than by men assigned to watchful waiting."
21821474,Premise,2089,2444,"In a longitudinal analysis of men in SPCG-4 who provided information at two follow-up points 9 years apart, 38 (45%) of 85 men allocated radical prostatectomy and 48 (60%) of 80 men allocated watchful waiting reported an increase in number of physical symptoms; 50 (61%) of 82 and 47 (64%) of 74 men, respectively, reported a reduction in quality of life."
21821474,Premise,2445,2564,"For men in SPCG-4, negative side-effects were common and added more stress than was reported in the control population."
21821474,Claim,2565,2677,"In the radical prostatectomy group, erectile dysfunction and urinary leakage were often consequences of surgery."
21821474,Claim,2678,2758,"In the watchful-waiting group, side-effects can be caused by tumour progression."
21821474,Claim,2759,2956,"The number and severity of side-effects changes over time at a higher rate than is caused by normal ageing and a loss of sexual ability is a persistent psychological problem for both interventions."
21821474,Claim,1,108,"For men with localised prostate cancer, surgery provides a survival benefit compared with watchful waiting."
21831722,Claim,1585,1763,"This study demonstrates that a brief, predominantly group-based resilience training intervention is feasible in patients with previous breast cancer; also, it may be efficacious."
21831722,Premise,1325,1501,"A statistically significant improvement in resilience, perceived stress, anxiety, and overall quality of life at 12 weeks, compared with baseline was observed in the study arm."
21831722,Premise,1502,1584,"No significant difference in any of these measures was noted in the control group."
21839414,Premise,977,1065,"Utility scores were significantly lower in the DTX group than in the ACP and ACD groups."
21839414,Premise,1066,1168,"Mean utility scores in the DTX group were lowest at 7 months and tended to remain low for a long time."
21839414,Premise,1169,1353,"The combined anthracycline followed by taxane group had significantly higher utility scores that the taxane-alone group, with no significant difference depending on the type of taxane."
21839414,Premise,1354,1464,"Only the FACT-G social/family well-being subscale had no relationship with EQ-5D responses and utility scores."
21839414,Claim,1465,1642,"Although the regimens in this study were similar in that they included taxane, the mean utility scores and longitudinal patterns of utility scores were different among regimens."
21871978,Premise,980,1083,"QOL scores were increased and complication scores were improved in the postoperative periods (P < .01)."
21871978,Premise,1084,1174,"Postoperative BMI significantly deteriorated compared with preoperative BMI in each group."
21871978,Premise,1175,1335,"The postoperative QOL and complication scores at 60 months after surgery were significantly better than those at 3 months after surgery in each group (P < .01)."
21871978,Premise,1345,1469,"there was no significant difference of QOL scores and postoperative complication scores between the 2 reconstruction groups."
21871978,Premise,1470,1557,"The nutritional condition in the INT group was nearly the same as that in the RY group."
21871978,Premise,1558,1664,"Although our patient sample was small and patients who did not complete the follow-up survey were present,"
21871978,Claim,1665,1778,"we could not identify any clinical difference between INT and RY after total gastrectomy 60 months after surgery."
21871978,MajorClaim,1779,1889,"The safer and simpler RY method may be a more suitable reconstruction method than INT after total gastrectomy."
21871978,MajorClaim,1,173,"The postoperative clinical superiority of the interposition of jejunum reconstruction (INT) to Roux-en-Y reconstruction (RY) after total gastrectomy has not been clarified."
22104618,Premise,1001,1087,"A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026)."
22104618,Premise,727,1000,"Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores."
22104618,Premise,1088,1166,"HRQOL changes within chemotherapy response strata revealed stable index scores"
22104618,Premise,1167,1301,"but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease."
22104618,Premise,1302,1502,"Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029)."
22104618,Claim,1611,1715,"Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL."
22104618,Claim,1805,1898,"Those who respond to gemcitabine may experience a slight slowing of functional deterioration."
22113257,Premise,1164,1511,"Participants randomized to the exercise group increased physical activity by more than 100 versus 22% in controls (54.5 vs. 14.6 min, P = 0.13), and experienced significant increases in fitness (increased 6-min walk test distance by 186.9 vs. 81.9 feet, P = 0.006) and physical functioning (7.1 vs. 2.6, P = 0.04) as compared to the control group."
22113257,Claim,1512,1730,"Breast and colorectal cancer survivors enrolled in a multicenter, telephone-based physical activity intervention increased physical activity and experienced significant improvements in fitness and physical functioning."
22113257,MajorClaim,1731,1806,"Lifestyle intervention research is feasible in a cooperative group setting."
22120301,Premise,899,1108,"The 1-, 2-, and 3-year survival rates were 88.9%, 44.4%, and 16.7% for the vaccine group, respectively, and 75.0%, 18.8%, and 0%, respectively, for the control group, (P = 0.299, 0.0035, 0.0014, respectively)."
22120301,Premise,1109,1215,"The median OS for the vaccine group was 31.9 months and for the control group was 15.0 months (P < 0.002)."
22120301,Premise,1216,1346,"The median progression-free survival (PFS) for the vaccine group was 8.5 months, and 8.0 months for the control group (P = 0.075)."
22120301,Premise,1347,1447,"The surviving fraction was significantly higher in the vaccine group based on Kaplan-Meier analysis."
22120301,Claim,1448,1549,"Adjuvant immunotherapy with whole-cell lysate dendritic cell vaccine may improve short-term survival."
22120301,Claim,1550,1638,"It seems to be safe, and its long-term effectiveness is worthy of further investigation."
22133572,Premise,908,1133,"Analysing response to FUFA and FOLFIRI in the per protocol set (n=119) after un-blinding TS in the data base revealed a trend to better overall response to FOLFIRI (9/19, 47%) in TS high compared to FUFA (5/23, 22%, p=0.077)."
22133572,Premise,1134,1294,"In patients with biopsies taken from liver lesions (n=91) overall response to FOLFIRI and FUFA in TS high was 53% (9/17) and 18% (3/17), respectively (p=0.035)."
22133572,Premise,1295,1398,"In patients with low TS, no remarkable difference in overall response to FOLFIRI and FUFA was observed."
22133572,Claim,1399,1470,"Taking a pre-treatment biopsy is a safe and feasible procedure in mCRC."
22133572,Claim,1471,1646,"After validation of our data in a larger group TS determination may have the potential to better help direct systemic treatment in patients with primarily non-resectable mCRC."
22157367,Premise,592,681,"Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388)."
22157367,Premise,682,836,"Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V."
22157367,Premise,837,913,"Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975)."
22157367,Premise,914,960,"Toxicities were generally mild in both groups."
22157367,Premise,961,1164,"Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034)."
22157367,Premise,1165,1265,"Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001)."
22157367,Claim,1266,1381,"Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC."
22157367,Claim,1382,1501,"EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received."
22172923,Premise,1116,1262,"Comparing the changes in low-frequency low-intensity electrotherapy with manual lymphatic drainage changes, there were no significant differences."
22172923,Premise,1263,1378,"Low-frequency low-intensity electrotherapy did not reduce lymphoedema volume (mean of change = 19.77 mL, P = 0.36),"
22172923,Premise,1383,1609,"significant reductions were observed in pain, heaviness and tightness (mean of change = 13.1, 16.2 and 6.4 mm, respectively), and FACT-B+4 summaries improved significantly (Trial Outcome Index mean of change = 5.4, P = 0.015)."
22172923,Premise,1610,1689,"Manual lymphatic drainage showed no significant changes in any of the outcomes."
22172923,Claim,1763,1890,"the observed trend towards a better health-related quality of life is remarkable in low-frequency low-intensity electrotherapy."
22172923,Claim,1690,1762,"Although there are no significant differences between treatment changes,"
22198049,Premise,1318,1418,"The combination arm was more effective than arm 2 with respect to LBM, REE, fatigue, and global QoL."
22198049,Premise,1419,1537,"As for the secondary efficacy endpoints, patient appetite increased, and ECOG PS decreased significantly in both arms."
22198049,Premise,1538,1697,"The inflammation and oxidative stress parameters IL-6, TNF-, CRP, and ROS decreased significantly in arm 1, while no significant change was observed in arm 2."
22198049,Claim,1698,1779,"The combined treatment improved both immunometabolic alterations and patient QoL."
22198049,MajorClaim,1780,1966,"Multimodality therapies for cachexia ideally should be introduced within a context of ""best supportive care"" that includes optimal symptom management and careful psychosocial counseling."
22228392,Premise,919,1001,"Upon the completion of PMP, pain scores were significantly reduced in both groups,"
22228392,Premise,1002,1266,"yet patients in the experimental group showed a significant increase in the use of PRN analgesics and nonpharmacological strategies to relieve pain (P < .05) and significantly reduce barriers to managing their cancer pain (P < .05) compared with the control group."
22228392,Claim,1267,1409,"Cancer patients should be empowered with pain management education to gain knowledge and correct misconceptions in managing their cancer pain."
22228392,Claim,1410,1521,"Integration of the PMP into routine clinical work may help to improve the standard of care for cancer patients."
22234519,Premise,882,1069,"FACT-B scores increased after treatment began and remained significantly higher in the tamoxifen group than in the exemestane group or anastrozole group during the first year (P=0.045)."
22234519,Premise,1070,1143,"FACT-B scores were similar in the exemestane group and anastrozole group."
22234519,Premise,1144,1208,"ES scores and CES-D scores were similar in all treatment groups."
22234519,Premise,1209,1365,"Arthralgia and fatigue were less frequent, but vaginal discharge was more frequent in the tamoxifen group than in the exemestane group or anastrozole group."
22234519,Claim,1366,1489,"HRQOL was better in Japanese postmenopausal women treated with tamoxifen than those treated with exemestane or anastrozole."
22234519,Claim,1490,1549,"HRQOL and AEs were similar with exemestane and anastrozole."
22234519,Claim,1550,1743,"Given the results of the TEAM trial, upfront use of tamoxifen followed by an aromatase inhibitor (AI) may be an important option for adjuvant endocrine therapy in Japanese postmenopausal women."
22282373,MajorClaim,1,89,"Cisplatin reduces plasma ghrelin levels through the 5-hydroxytryptamine (5-HT) receptor."
22282373,Premise,1297,1521,"Food intake and appetite VAS scores were significantly higher in the ghrelin group than in the placebo group (18.2  5.2 kcal/kg/day vs 12.7  3.4 kcal/kg/day [P = .001] and 6.2  0.9 vs 4.1  0.9 [P < .0001], respectively)."
22282373,Premise,1522,1663,"Patients in the ghrelin group had fewer adverse events during chemotherapy related to anorexia and nausea than patients in the control group."
22282373,Premise,1664,1811,"Significant deterioration was noted after chemotherapy in the placebo group in QoL scores, appetite, nausea and vomiting, and global health status."
22282373,Claim,1812,1956,"Short-term administration of exogenous ghrelin at the start of cisplatin-based chemotherapy stimulated food intake and minimized adverse events."
22290808,Premise,1103,1437,"A model measuring effectiveness of CCSP on QOL (total and subscale) at 1-year follow-up showed that the CCSP group (n = 38) had significant improvement in overall QOL (p < 0.01), health and functioning (p < 0.05), and socioeconomic (p < 0.05) and psychological/spiritual well-being (p < 0.01) compared with the control group (n = 35)."
22290808,Premise,1438,1536,"The CCSP patients frequently used the CCSP to manage psychological (51%) and sleep problems (60%)."
22290808,Premise,1537,1592,"The CCSP improved QOL for patients at 1-year follow-up."
22290808,Premise,1593,1651,"Patients overwhelmingly reported that CCSP was beneficial."
22290808,Claim,1652,1768,"The CCSP as an effective coping intervention has potential as a self-management program for breast cancer survivors."
22290823,Premise,1257,1458,"Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05)."
22290823,Premise,1538,1598,"Risk for distress accounted for very few moderation effects."
22290823,Premise,1599,1683,"Both brief and extensive programs had positive outcomes for patient-caregiver dyads,"
22290823,Premise,1684,1710,"but few sustained effects."
22290823,Claim,1711,1777,"Patient-caregiver dyads benefit when viewed as the 'unit of care'."
22321518,Premise,893,1103,"Patients in the IG had significantly improved scores on the FACIT-Fatigue Scale at study completion, improved fatigue and pain scores, as well as overall physical functioning and mental health composite scores."
22321518,Premise,1104,1288,"At study completion, participants in the IG were walking twice as far and were significantly more likely to have continued walking or another form of exercise as compared with the UCG."
22321518,Premise,1396,1483,"Kaplan-Meier survival analysis did not indicate an overall survival benefit for the IG."
22321518,Claim,1484,1741,"This is the first prospective, randomized controlled trial to report that participation in a home walking program confers a significant benefit in resected PPC patients with regard to fatigue levels, physical functioning, and health-related quality of life."
22336221,Premise,1410,1596,"Longer time to worsening was recorded for pain (hazard ratio [HR] 076, 95% CI 059-099; p=0041) and haemoptysis (HR 058, 95% CI 034-097; p=0038) with pemetrexed than with placebo;"
22336221,Premise,1597,1674,"no other significant differences in analyses of time to worsening were noted."
22336221,Premise,1675,1832,"Additional longitudinal analyses showed a greater increase in loss of appetite in the pemetrexed group than in the placebo group (43 mm vs 02 mm; p=0028)."
22336221,Premise,1833,2115,"Rates of resource use were statistically higher for pemetrexed than for placebo: admissions to hospital for drug-related adverse events (19 [4%] vs none; p=0001), transfusions (42 [10%] vs seven [3%]; p=0003), and erythropoiesis-stimulating agents (26 [6%] vs four [2%]; p=0017)."
22336221,Claim,2116,2197,"Quality of life during maintenance therapy with pemetrexed is similar to placebo,"
22336221,Claim,2198,2307,"except for a small increase in loss of appetite, and significantly delayed worsening of pain and haemoptysis."
22336221,MajorClaim,2420,2557,"such treatment is an option for patients with advanced non-squamous NSCLC who have not progressed after platinum-based induction therapy."
22340282,Premise,808,905,"The mean reduction in AK count was 59.2% for ALA-PDT and 41.4% for imiquimod 5% cream (p=.002)."
22340282,Premise,718,807,"The 75% AK clearance rate was 34.6% for ALA-PDT and 25% for imiquimod 5% cream (p=.30)."
22340282,Premise,906,1050,"Dermatology Life Quality Index (DLQI) scores were assessed for each treatment modality at week 4 and were 1.95 and 1.38, respectively (p=.20)."
22340282,Premise,1051,1176,"The sample size was small, and patients applied a small amount of imiquimod 5% cream (half a sachet) to a large surface area."
22340282,Claim,1177,1301,"There was no statistically significant difference in treatment response when the 100% or 75% clearance rate cutoff was used,"
22340282,Claim,1302,1425,"but our secondary outcome suggests that two sessions of ALA-PDT is superior to imiquimod 5% cream for the treatment of AKs."
22340282,Claim,1426,1532,"There was no statistically significant difference in effect on quality of life as assessed using the DLQI."
22340966,MajorClaim,167,242,"Hormone replacement therapy is often either undesirable or contraindicated."
22340966,MajorClaim,243,294,"Safe, effective non-hormonal treatments are needed."
22340966,Premise,1626,1886,"Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -167, 95% CI -243 to -091; p<00001) and improvements were maintained at 26 weeks (mean difference -176, -254 to -099; p<00001)."
22340966,Premise,1887,1929,"We recorded no CBT-related adverse events."
22340966,Claim,1930,2110,"Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life."
22357901,Premise,878,1063,"Numeric rating scale scores for pain intensity in group 1 and group 2 were significantly lower than those in group 3 at T(0-12) (P < .001); T(12-24) (P < .001); and T(24-48) (P < .001)."
22357901,Premise,1064,1224,"When group 1 with group 2 were compared, numeric rating scale scores were significantly lower in group 1 than in group 2 during the period of T(0-12) (P < .001)"
22357901,Premise,1225,1307,"but were not significantly different at T(12-24) (P = .68) and T(24-48) (P = .10)."
22357901,Premise,1308,1410,"Analgesic cost and hospital stay were significantly lower in treated groups than in the placebo group."
22357901,Premise,1411,1537,"No significant difference was observed in quality of life and adverse events between the treated groups and the placebo group."
22357901,Claim,1538,1698,"CRO is effective, safe, and cost-effective in the control of postoperative pain after transarterial chemoembolization for patients with inoperable liver cancer."
22370314,Premise,900,1056,"Gefitinib did not show better OS compared with GP (hazard ratio [HR], 0.932; 95% CI, 0.716 to 1.213; P = .604; median OS, 22.3 v 22.9 months, respectively)."
22370314,Premise,1057,1157,"The 1-year PFS rates were 16.7% with gefitinib and 2.8% with GP (HR, 1.198; 95% CI, 0.944 to 1.520)."
22370314,Premise,1158,1224,"Response rates were 55% with gefitinib and 46% with GP (P = .101)."
22370314,Premise,1225,1307,"Myelosuppression, renal insufficiency, and fatigue were more common in the GP arm,"
22370314,Premise,1312,1388,"skin toxicities and liver dysfunction were more common in the gefitinib arm."
22370314,Premise,1389,1475,"Two patients (1.3%) in the gefitinib arm developed interstitial lung disease and died."
22370314,Claim,1476,1569,"Gefitinib failed to demonstrate superior OS compared with GP as first-line therapy for NSLAs."
22370330,Premise,854,1209,"At the post-treatment assessment, IMCP participants demonstrated significantly greater improvement than the control condition for the primary outcomes of spiritual well-being (b = 0.39; P <.001, including both components of spiritual well-being (sense of meaning: b = 0.34; P = .003 and faith: b = 0.42; P = .03), and quality of life (b = 0.76; P = .013)."
22370330,Premise,1210,1449,"Significantly greater improvements for IMCP patients were also observed for the secondary outcomes of symptom burden (b = -6.56; P < .001) and symptom-related distress (b = -0.47; P < .001) but not for anxiety, depression, or hopelessness."
22370330,Premise,1450,1606,"At the 2-month follow-up assessment, the improvements observed for the IMCP group were no longer significantly greater than those observed for the TM group."
22370330,Claim,1607,1719,"IMCP has clear short-term benefits for spiritual suffering and quality of life in patients with advanced cancer."
22412149,Premise,999,1240,"Compared with the control group, the intervention group had an improvement in fatigue as shown by a significantly greater decrease in BFI global score (-0.66 points; 95% CI -1.04 to -0.27) and FSS total score (-0.49; 95% CI, -0.78 to -0.21)."
22412149,Premise,1241,1501,"In secondary outcomes, the intervention group experienced a significantly greater decrease in HADS anxiety score (-0.90; 95% CI, -1.51 to -0.29) as well as global quality of life (5.22; 95% CI, 0.93 to 9.50) and several functioning scores of the EORTC QLQ-C30."
22412149,Claim,1502,1600,"An Internet-based education program based on NCCN guidelines and TTM may help patients manage CRF."
22412149,Claim,25,148,"Internet-based tailored education program is effective for disease-free cancer survivors with cancer-related fatigue (CRF)."
22430268,MajorClaim,1794,1852,"MBSR is recommended to support survivors of breast cancer."
22430268,Claim,1608,1793,"To our knowledge, this study provided novel evidence that MBSR can help alleviate long-term emotional and physical adverse effects of medical treatments, including endocrine treatments."
22430268,Premise,923,1400,"There were statistically significant improvements in outcome in the experimental group compared with control group at both 8 and 12 weeks (except as indicated) for POMS total mood disturbance (and its subscales of anxiety, depression [8 weeks only], anger [12 weeks only], vigor, fatigue, and confusion [8 weeks only]), FACT-B, FACT-ES, (and Functional Assessment of Cancer Therapy subscales of physical, social [8 weeks only], emotional, and functional well-being), and WHO-5."
22430268,Premise,1401,1607,"MSBR improved mood, breast- and endocrine-related quality of life, and well-being more effectively than standard care in women with stage 0 to III breast cancer, and these results persisted at three months."
22438297,Premise,793,990,"Among the 17 participants with depressive symptoms at baseline, both the Onward and the III-only condition showed large reductions in the depression scale of HADS (d=1.27 and 0.89, respectively)."
22438297,Premise,991,1162,"Improvement over time and time x treatment effects only reached trend significance levels (ps=0.07 &amp; 0.12) as this pilot was not powered to detect these differences."
22438297,Claim,1163,1337,"Both the III+ISG and III-only demonstrated pre-post reductions in depressive symptoms and high rates of utilization compared with other web-based treatments for depression."
22438297,Claim,1338,1462,"Although it is premature to make any determination as to the efficacy of the interventions tested in this feasibility study,"
22438297,Claim,1463,1588,"these results indicate that pursuing the III+ISG model, as well as standard IIIs, may be fruitful areas of future research."
22469559,Premise,1131,1246,"By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP."
22469559,Premise,1247,1345,"From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP."
22469559,Premise,1346,1443,"Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms."
22469559,Premise,1444,1622,"Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR)."
22469559,Premise,1623,1766,"Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores."
22469559,Claim,1767,1871,"Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity."
22469559,Claim,1872,2075,"These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities."
22469559,Claim,2076,2193,"However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP."
22494567,Premise,1292,1472,"PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057)."
22494567,Premise,1473,1602,"There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233)."
22494567,Premise,1603,1717,"The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025)."
22494567,Claim,1718,1813,"Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation."
22494567,Premise,1814,1896,"The most common treatment-related adverse events were rash, diarrhea and pruritus."
22494567,Claim,1897,2042,"Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population."
22494567,MajorClaim,2043,2217,"Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy."
22500884,Premise,1711,1847,"At week 12, changes in TPV for degarelix and goserelin were similar (-37.2% vs -39.0%) and met the predefined non-inferiority criterion."
22500884,Premise,1848,2045,"Decreases in IPSS were greater in degarelix than in goserelin-treated patients, differences being statistically significant in patients with baseline IPSS > 13 (-6.7  1.8 vs -4.0  1.0; P = 0.02)."
22500884,Premise,2046,2201,"The number of patients with an IPSS change of  3 over baseline was also significantly higher in patients treated with degarelix (61.0 vs 44.3%, P = 0.02)."
22500884,Claim,2202,2247,"Both treatments were safe and well tolerated."
22500884,Claim,2248,2328,"Medical castration reduces TPV and could also improve LUTS in patients with PCa."
22500884,Claim,2335,2440,"the short-term efficacy of degarelix and goserelin + bicalutamide was the same in terms of TPV reduction,"
22500884,Claim,2441,2671,"degarelix showed superiority in LUTS relief in symptomatic patients, which could highlight the different actions of these drugs on extrapituitary gonadotrophin-releasing hormone (GnRH) receptors in the bladder and/or the prostate."
22508621,Premise,816,1070,"There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P=.88)."
22508621,Premise,1080,1358,"intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P=.03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P=.009])."
22508621,Premise,1359,1460,"There was no significant difference in scores at months 9 and 12 (P=.24 and P=.93, respectively)."
22508621,Premise,1461,1559,"The same pattern between intervention and control patients was observed for scores on the PSS-H&N."
22508621,Claim,1560,1740,"Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT."
22508621,Claim,1741,1916,"The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study."
22523181,Premise,476,702,"Intention-to-treat analyses indicated that AET resulted in a nonsignificant (P = 0.16) improvement in global sleep quality compared with usual care [mean group difference = -0.64; 95% confidence interval (CI), -1.56 to +0.27]."
22523181,Premise,703,1053,"In planned subgroup analyses, statistically significant or borderline significant interactions were identified for type of lymphoma (P(interaction) = 0.006), current treatment status (P(interaction) = 0.036), time since diagnosis (P(interaction) = 0.010), body mass index (P(interaction) = 0.075), and baseline sleep quality (P(interaction) = 0.041)."
22523181,Premise,1068,1333,"AET improved global sleep quality in patients with lymphoma who had indolent non-Hodgkin lymphoma (P = 0.001), were receiving chemotherapy (P = 0.013), were <2 years post-diagnosis (P = 0.005), were obese (P = 0.025), and were poor sleepers at baseline (P = 0.007)."
22523181,Claim,1334,1437,"AET did not significantly improve sleep quality in this heterogeneous sample of patients with lymphoma;"
22523181,Claim,1438,1501,"however, clinically identifiable subgroups appeared to benefit."
22526159,Premise,1209,1278,"Anemia was the most common hematological toxicity (88 % of patients)."
22526159,Premise,1279,1382,"Most frequent non-hematological toxicities were nausea (76 %), constipation (68 %), and fatigue (64 %)."
22526159,Claim,1383,1523,"Treatment was generally well tolerated despite the fact that most patients suffered from multiple comorbidities and were heavily pretreated."
22526159,Claim,1524,1595,"There were no unexpected hematological or non-hematological toxicities."
22544562,Claim,1611,1737,"Findings suggest that self-efficacy may influence long-term maintenance of healthy lifestyle practices among cancer survivors."
22544562,Claim,1072,1372,"Results suggest that change in self-efficacy for fat restriction partially explained the intervention's effect on fat intake (mean indirect effect=-0.28), and change in self-efficacy for F&V consumption partially explained the intervention's effect on daily F&V intake (mean indirect effect=.11)."
22544562,Premise,1373,1536,"Change in self-efficacy for fat restriction partially accounted for the intervention's impact on overall diet quality among men only (mean indirect effect=0.60)."
22551127,Premise,1197,1245,"There were no unexpected serious adverse events."
22551127,Premise,1246,1504,"In the 684 patients with data that could be evaluated, ultrasonography of the neck was normal in 652 (95%), and the stimulated thyroglobulin level was 1.0 ng per milliliter or less in 621 of the 652 patients (95%) without detectable thyroglobulin antibodies."
22551127,Premise,1505,1568,"Thyroid ablation was complete in 631 of the 684 patients (92%)."
22551127,Premise,1569,1675,"The ablation rate was equivalent between the (131)I doses and between the thyrotropin-stimulation methods."
22551127,Claim,1676,1839,"The use of recombinant human thyrotropin and low-dose (1.1 GBq) postoperative radioiodine ablation may be sufficient for the management of low-risk thyroid cancer."
22551128,Premise,924,1156,"Ablation success rates were 85.0% in the group receiving low-dose radioiodine versus 88.9% in the group receiving the high dose and 87.1% in the thyrotropin alfa group versus 86.7% in the group undergoing thyroid hormone withdrawal."
22551128,Premise,1157,1267,"All 95% confidence intervals for the differences were within 10 percentage points, indicating noninferiority."
22551128,Premise,1268,1474,"Similar results were found for low-dose radioiodine plus thyrotropin alfa (84.3%) versus high-dose radioiodine plus thyroid hormone withdrawal (87.6%) or high-dose radioiodine plus thyrotropin alfa (90.2%)."
22551128,Premise,1475,1604,"More patients in the high-dose group than in the low-dose group were hospitalized for at least 3 days (36.3% vs. 13.0%, P<0.001)."
22551128,Premise,1605,1837,"The proportions of patients with adverse events were 21% in the low-dose group versus 33% in the high-dose group (P=0.007) and 23% in the thyrotropin alfa group versus 30% in the group undergoing thyroid hormone withdrawal (P=0.11)."
22551128,Claim,1838,1960,"Low-dose radioiodine plus thyrotropin alfa was as effective as high-dose radioiodine, with a lower rate of adverse events."
22552194,Premise,1246,1451,"16 (29%) patients in the open oesophagectomy group had pulmonary infection in the first 2 weeks compared with five (9%) in the minimally invasive group (relative risk [RR] 030, 95% CI 012-076; p=0005)."
22552194,Premise,1452,1624,"19 (34%) patients in the open oesophagectomy group had pulmonary infection in-hospital compared with seven (12%) in the minimally invasive group (035, 016-078; p=0005)."
22552194,Premise,1625,1827,"For in-hospital mortality, one patient in the open oesophagectomy group died from anastomotic leakage and two in the minimally invasive group from aspiration and mediastinitis after anastomotic leakage."
22552194,Claim,1828,1973,"These findings provide evidence for the short-term benefits of minimally invasive oesophagectomy for patients with resectable oesophageal cancer."
22689807,Premise,1568,1642,"Incidence of adverse events was consistent with previously reported rates."
22689807,Premise,880,1193,"In this updated final analysis of all patients randomly assigned with strata (n = 291), lapatinib plus trastuzumab continued to show superiority to lapatinib monotherapy in PFS (hazard ratio [HR], 0.74; 95% CI, 0.58 to 0.94; P = .011) and offered significant OS benefit (HR, 0.74; 95% CI, 0.57 to 0.97; P = .026)."
22689807,Premise,1194,1327,"Improvements in absolute OS rates were 10% at 6 months and 15% at 12 months in the combination arm compared with the monotherapy arm."
22689807,Premise,1328,1567,"Multiple baseline factors, including Eastern Cooperative Oncology Group performance status of 0, nonvisceral disease, < three metastatic sites, and less time from initial diagnosis until random assignment, were associated with improved OS."
22689807,Claim,1643,1843,"These data demonstrated a significant 4.5-month median OS advantage with the lapatinib and trastuzumab combination and support dual HER2 blockade in patients with heavily pretreated HER2-positive MBC."
22698292,Premise,878,983,"Seventeen of 25 HBO-treated patients (68%) improved versus 8 of 21 controls (38.1%; P = .043, (2) test)."
22698292,Premise,984,1184,"Mean time to improvement was 39.7 weeks (95% confidence interval [CI], 22.4 to 57.0 weeks) for HBO-treated patients versus 67.9 weeks (95 CI, 48.4 to 87.5 weeks) for controls (P = .03, log-rank test)."
22698292,Premise,1185,1489,"However, complete gingival healing occurred in only 14 of 25 HBO-treated patients (52%) versus 7 of 21 controls (33.3%; P = .203, (2) test), and time to healing was 59 weeks (95% CI, 42.8% to 75.8%) for HBO-treated patients versus 70 weeks (95 CI, 52.2% to 88.36%) for controls (P = .32, log-rank test)."
22698292,Premise,1490,1566,"Pain decreased faster for HBO-treated subjects (P < .01, linear regression)."
22698292,Premise,1567,1719,"Quality-of-life scores for physical health (P = .002) and perceived health (P = .043) decreased at 6 months for control group but for not the HBO group."
22698292,Claim,1720,1799,"ONJ is multifactorial and no single treatment modality is likely to reverse it;"
22698292,Claim,1800,1903,"however, it is treatable and even advanced presentations can improve with intensive multimodal therapy."
22698292,Claim,1904,2070,"Clinically, HBO appears to be a useful adjunct to ONJ treatment, particularly for more severe cases, although this study was underpowered to fully support this claim."
22705939,Premise,1118,1242,"After intervention, EG participants showed improved QOL via decreased fear of recurrence and increased mindfulness attitude."
22705939,Premise,1243,1285,"At 6 weeks, initial effects were retained."
22705939,Premise,1286,1390,"The MMP appears to benefit older BCSs by reducing fear of recurrence and improving mindfulness attitude."
22705939,Claim,1391,1533,"Although these findings are promising, a larger study is needed to determine more specifically what short- and long-term effects are possible."
22705939,Claim,1534,1714,"The combination of self-directed movement and mindfulness, as tested here, may be a valuable tool for promoting health and well-being in older long-term survivors of breast cancer."
22715124,Premise,854,972,"Depression scores yielded a linear interaction comparing UCO and SMEX (p = 0.019), with decreases in SMEX but not UCO."
22715124,Premise,973,1100,"Anxiety scores yielded a quadratic interaction comparing UCO and SMEX (p = 0.049), with trends for changes in SMEX but not UCO."
22715124,Premise,770,853,"Interaction effects for mental and physical well-being scores were not significant."
22715124,Premise,1101,1400,"Additional analyses yielded quadratic interactions for exercise activity comparing UCO and SMEX (p = 0.022), with positive changes in SMEX but not UCO, and for stress management activity comparing UCO and SM (p < 0.001) and UCO and SMEX (p = 0.013), with positive changes in SM and SMEX but not UCO."
22715124,Claim,1401,1526,"Only the combined intervention yielded effects on quality of life outcomes, and these were limited to anxiety and depression."
22715124,Premise,1527,1673,"These findings are consistent with evidence that only the combined intervention yielded increases in both exercise and stress management activity."
22825506,MajorClaim,1,95,"The incidence and development of cancer are closely related to dysfunction of immune function."
22825506,Premise,1003,1133,"DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05)."
22825506,Premise,1134,1275,"In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment."
22825506,Premise,1276,1397,"Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment."
22825506,Premise,1398,1524,"In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia."
22825506,Claim,1525,1682,"DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects."
22825506,Claim,1683,1794,"DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer."
22825550,Claim,1681,1839,"Nocturnal administration of BCAA granules in patients with cirrhosis reduced the occurrence of muscle cramps in the leg but did not improve the patients' QOL."
22825550,Premise,1107,1333,"There was no significant difference in any of the subjects revealed by the questionnaire regarding subjective or objective symptoms, or by the SF-8 between the daytime group and the nocturnal group after 3 months of treatment."
22825550,Premise,1334,1487,"The daytime group showed a significant effect on general health, vitality, social functioning, mental health, and role emotional as revealed on the SF-8."
22825550,Premise,1488,1680,"Conversely, the nocturnal group exhibited a significant decrease in the occurrence of muscle cramps in the legs (P = 0.014) and significantly improved Fisher's ratio after 3 months (P = 0.04)."
22984910,Premise,831,983,"both treatment modalities resulted in significant decrease in the total arm volume (12.2% decrease in Group II and 14.9% decrease in Group I) (p<0.001),"
22984910,Premise,984,1055,"no significant difference (p=0.582) was found between those two groups."
22984910,Premise,1056,1194,"Similarly, ASES scores were significantly (p=0.001) improved in both Group I and II without any significant difference between the groups."
22984910,Premise,1195,1411,"While emotional functioning, fatigue, and pain scores were significantly improved in both groups, global health status, functional and cognitive functioning scores appeared to be improved only in patients of group I."
22984910,Claim,1412,1641,"Different treatment modalities consisting of MLD and compression bandage(complex decongestive therapy) or IPC and SLD appear to be effective in the treatment of LE with similar therapeutic efficacy in patients with breast cancer."
22984910,Claim,1642,1757,"However, combination modalities including IPC and SLD may be the preferred choices for their applicability at home."
23041585,Premise,803,924,"The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93]."
23041585,Premise,718,802,"Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001)."
23041585,Premise,635,717,"The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001)."
23041585,Premise,925,1051,"The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82)."
23041585,Premise,1052,1274,"In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value."
23041585,Claim,1275,1368,"Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe."
23041585,Claim,1369,1444,"However, it provided no improvement in PFS or OS compared with flat dosing."
23045575,Premise,769,1244,"Compared with the control group, the intervention groups had a significant decrease in levels of endocrine symptoms (Functional Assessment of Cancer Therapy-Endocrine Symptoms; P<.001; effect size, 0.31-0.52) and urinary symptoms (Bristol Female Lower Urinary Tract Symptoms Questionnaire; P=.002; effect size, 0.29-0.33), and they showed an improvement in physical functioning (36-Item Short Form Health Survey physical functioning subscale; P=.002; effect size, 0.37-0.46)."
23045575,Premise,1245,1559,"The groups that included CBT also showed a significant decrease in the perceived burden of hot flashes and night sweats (problem rating scale of the Hot Flush Rating Scale; P<.001; effect size, 0.39-0.56) and an increase in sexual activity (Sexual Activity Questionnaire habit subscale; P=.027; effect size, 0.65)."
23045575,Claim,1640,1834,"CBT and PE can have salutary effects on endocrine symptoms and, to a lesser degree, on sexuality and physical functioning of patients with breast cancer experiencing treatment-induced menopause."
23045575,Claim,1835,1948,"Future work is needed to improve the design and the planning of these interventions to improve program adherence."
23070101,Premise,670,821,"In the UAE group, mean  standard deviation uterine volume was 670  503, 422  353, and 292  287 mL at baseline, 6 months, and 5 years, respectively."
23070101,Premise,822,929,"Mean dominant fibroid diameter was 7.6  3.0, 5.8  2.9, and 5  2.9 cm at baseline, 6 months, and 5 years."
23070101,Premise,930,1037,"Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %."
23070101,Premise,1038,1125,"Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123)."
23070101,Premise,1126,1171,"No myomectomy cases had further intervention."
23070101,Premise,1172,1284,"At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008)."
23070101,Premise,1285,1418,"There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE."
23070101,Claim,1419,1518,"Complete fibroid infarction does not translate into total freedom from a subsequent reintervention."
23070101,Claim,1519,1582,"New fibroid formation is significantly higher after myomectomy."
23075680,Premise,889,986,"The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively."
23075680,Premise,987,1064,"The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%."
23075680,Premise,1065,1153,"The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively."
23075680,Premise,1154,1347,"The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively."
23075680,Premise,1348,1461,"The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group."
23075680,Premise,1462,1505,"The results were statistically significant."
23075680,Premise,1650,1839,"The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group."
23075680,Premise,1840,1883,"The results were statistically significant."
23075680,Claim,1884,2038,"The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,"
23075680,Claim,2039,2141,"but the adverse reactions decreased significantly in the PP group compared with those in the GP group."
23075680,MajorClaim,2142,2294,"Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC."
23084254,Premise,1033,1311,"CRF was significantly reduced in the intervention group, corresponding to a Fatigue score reduction of 3.04 (effect size of 0.44, 95% CI 0.17-0.72) (P = .002), the FACT-An score by 5.40 (P = .015), the FACT-An Toi score by 5.22 (P = .009) and the Anaemia-ANS by 3.76 (P = .002)."
23084254,Premise,1312,1533,"There was no statistically significant effect on the General Quality of Life score (FACT-G) or on any of the individual wellbeing scores; Physical (P = .13), Emotional (P = .87), Social (P = .83) and Functional (P = .26)."
23084254,Claim,1534,1702,"In summary, this six-week supervised multimodal exercise intervention can lead to significant reduction in self-reported CRF in cancer patients undergoing chemotherapy."
23109700,Premise,1121,1283,"The difference in the mean General Fatigue score, between those who received the intervention and those who did not, was -3.11 (95% CI, -3.97 to -2.25; P < .001)."
23109700,Premise,1284,1780,"The intervention also improved all other fatigue aspects measured by MFI, including Physical Fatigue and Mental Fatigue (acupuncture effect, -2.36 and -1.94, respectively; both at P < .001), anxiety and depression (acupuncture effect, -1.83 and -2.13, respectively; both at P < .001), and quality of life (Physical Well-Being effect, 3.30; Functional Well-Being effect, 3.57; both at P < .001; Emotional Well-Being effect, 1.93; P = .001; and Social Functioning Well-Being effect, 1.05; P < .05)."
23109700,Claim,1781,1894,"Acupuncture is an effective intervention for managing the symptom of CRF and improving patients' quality of life."
23139058,Premise,794,954,"There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group."
23139058,Premise,955,1009,"Trends observed for the treatment groups were similar."
23139058,Premise,1010,1169,"The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant."
23139058,Premise,1170,1275,"In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention."
23139058,Premise,1276,1349,"Although improvements in the UC group occurred by 12-months post-surgery,"
23139058,Premise,1350,1408,"the change did not meet the clinically relevant threshold."
23139058,Premise,1409,1490,"There were no differences in other treatment-related side effects between groups."
23139058,Claim,1491,1725,"This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment."
23182307,Premise,1036,1166,"The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P=0.006)."
23182307,Premise,1167,1403,"The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P=0.02 and -7.4, 95% CI -13.7 to -1.1; P=0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P=0.01) also differed significantly."
23182307,Premise,1404,1488,"The incremental cost-effectiveness ratio was 19,390 per quality-adjusted life year."
23182307,Claim,1489,1608,"This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective."
23182307,Claim,1609,1664,"Despite small numbers, the main effect size was robust."
23182307,Claim,1665,1765,"We recommend implementation alongside evaluation inwider clinical settings and patient populations."
23185753,Premise,805,999,"Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01)."
23185753,Premise,1000,1155,"Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01)."
23185753,Premise,1156,1334,"Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;"
23185753,Premise,1335,1425,"the 2-year somatic functions and psychological functions decreased in the treatment group;"
23185753,Premise,1426,1572,"the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05)."
23185753,Premise,1573,1772,"Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05)."
23185753,Claim,1773,1925,"FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans."
23211715,Premise,1264,1455,"Median survival was: OSC+WBRT 49 days (95% confidence interval 39-61), OSC 51 days (95% confidence interval 27-57) - hazard ratio 1.11 (95% confidence interval 0.80-1.53) in favour of WBRT."
23211715,Premise,1456,1528,"Quality of life assessed using EQ-5D showed no evidence of a difference."
23211715,Premise,1529,1659,"The estimated mean QALYs was: OSC+WBRT 31 days and OSC 30 days, difference -1 day (95% confidence interval -12.0 to +13.2 days)."
23211715,Claim,1660,1801,"These interim data indicate no early evidence of detriment to quality of life, overall survival or QALYs for patients allocated to OSC alone."
23224689,Claim,1945,2057,"LLLT was effective in improving the patient's subjective experience of OM and QOL in HNC patients receiving CRT."
23224689,Premise,1809,1944,"a significant reduction (p<0.001) in incidence of severe OM, need for opioid analgesics, and total parenteral nutrition was observed."
23224689,Premise,1635,1802,"Results analysis revealed that OMWQ-HN (F=12.199, df =6,1314, p<0.001) and FACT-HN (p<0.05) scores were significantly lower in LLLT than placebo group patients."
23245940,Premise,1170,1254,"We found no difference in severe ARSR between the groups at any point of assessment."
23245940,Premise,1019,1169,"The incidence of severe ARSR (RTOG/EORTC grade 2) at the follow-up visit was 23% (n = 45) in the Calendula group and 19% (n = 38) in the Essex group."
23245940,Premise,1255,1388,"The patients reported low levels of skin related symptoms and no statistically significant differences between the groups were found."
23245940,Claim,1389,1478,"No differences in ARSR between patients randomised to Calendula or Essex cream was found."
23245940,Claim,1479,1638,"ARSR seem to be a relatively limited problem, probably more influenced by treatment related factors than by choice of skin care products in this patient group."
23254324,MajorClaim,1662,1734,"Rigorous standard operating procedures for data collection are required."
23254324,Claim,1535,1661,"A blinded RCT investigating the role of epidural and WIC administration for postoperative analgesia following LCR is feasible."
23254324,Claim,1382,1534,"Qualitative interviews suggested that patients found participation in the trial acceptable and that they would consider participating in a future trial."
23254324,Premise,1027,1140,"Mean(s.d.) pain scores on the day of discharge were 19(31) in the epidural group and 07(07) in the WIC group."
23254324,Premise,1141,1212,"Median length of stay was 4 (range 2-35, interquartile range 3-5) days."
23254324,Premise,1213,1335,"Mean use of additional analgesia (intravenous morphine equivalents) was 12 mg in the WIC arm and 9 mg in the epidural arm."
23284036,Premise,1142,1371,"We found significant improvements over time in favor of PPT for the primary outcome general fatigue (P = .01), with significant group differences at month 1 (effect size, 0.26; P = .007) and month 2 (effect size, 0.35; P = .005)."
23284036,Premise,1372,1615,"Improvements in favor of PPT were also found for the following secondary outcomes: fatigue dimensions ""reduced activity"" and ""reduced motivation,"" fatigue NRS, symptom burden, interference of fatigue with daily life, and anxiety (all P  .03)."
23284036,Claim,1616,1764,"In fatigued patients with advanced cancer, nurse-led monitoring and protocolized treatment of physical symptoms is effective in alleviating fatigue."
23379385,Premise,869,982,"Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment."
23379385,Premise,983,1115,"Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;"
23379385,Premise,1116,1277,"women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time."
23379385,Premise,1278,1403,"Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;"
23379385,Premise,1404,1488,"women with higher intrusions at baseline started worse and remained worse over time."
23379385,Claim,1489,1685,"Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes."
23406994,Claim,1674,1775,"A combination regimen of MA and thalidomide is more effective than MA alone in the treatment of CACS."
23406994,Premise,1611,1673,"Toxicity was found to be relatively negligible in both groups."
23406994,Premise,639,1018,"Analysis of the trial group demonstrated a significant increase from baseline in body weight (<0.01), quality of life (p = 0.02), appetite (p = 0.01), and grip strength (p = 0.01), and a significant decrease in fatigue, Glasgow Prognostic Score (p = 0.05), Eastern Cooperative Oncology Group performance status (p = 0.03), IL-6 (p < 0.01), and tumor necrosis factor- (p = 0.02)."
23406994,Premise,1019,1165,"In contrast, in the control group, endpoints with a significant improvement from baseline included body weight (p < 0.02) and appetite (p = 0.02)."
23406994,Premise,1166,1610,"The mean changes in the endpoints from baseline in the trial group were significantly greater compared with the control group: in the primary endpoints, body weight (p = 0.05), fatigue (p < 0.01) and quality of life (p = 0.01), and in the secondary endpoints, grip strength (p = 0.05), Glasgow Prognostic Score (p = 0.02), Eastern Cooperative Oncology Group performance status (p = 0.02), IL-6 (p < 0.01) and tumor necrosis factor- (p = 0.01)."
23439759,Claim,1454,1603,"In cachectic patients with advanced cancer, oral melatonin 20 mg at night did not improve appetite, weight, or quality of life compared with placebo."
23439759,Premise,1271,1453,"There were no significant differences between groups for appetite (P = .78) or other symptoms, weight (P = .17), FAACT score (P = .95), toxicity, or survival from baseline to day 28."
23455717,Premise,1563,1715,"there was no significant difference regarding time to definitive deterioration of global health status/quality of life from baseline (primary endpoint)."
23455717,Premise,1105,1227,"Patients receiving FLOT exhibited higher response rates and had improved disease-free and progression-free survival (PFS)."
23455717,Premise,1725,1821,"patients receiving FLO or FLOT as palliative treatment (n = 98) achieved comparable QOL results."
23455717,Premise,1822,1878,"Although toxicity was higher in patients receiving FLOT,"
23455717,Premise,1879,1967,"no negative impact of the addition of docetaxel on QOL parameters could be demonstrated."
23455717,Claim,1974,2101,"elderly patients in need of intensified chemotherapy may receive FLOT without compromising patient-reported outcome parameters."
23466360,Premise,1004,1075,"Urinary function declined when the IUS V285 was 0.4% (=-0.32, p=0.04);"
23466360,Premise,1076,1177,"bother worsened when the IUS V35 was 99% (=-0.31, p=0.05) or the EUS V240 was 63% (=-0.31, p=0.05);"
23466360,Premise,1178,1285,"irritation increased when the IUS V35 was 95% (=-0.37, p=0.02) and the EUS V265 was 24% (=-0.32, p=0.04);"
23466360,Premise,1290,1352,"urgency worsened when the IUS V35 was 99.5% (=-0.38, p=0.02)."
23466360,Premise,1353,1405,"Incontinence did not correlate with EUS or IUS dose."
23466360,Claim,1406,1529,"Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency."
23466360,MajorClaim,1530,1676,"Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy."
23477998,Premise,1231,1486,"Maintenance therapy with erlotinib did not impact on deterioration in HRQoL: TSP (hazard ratio [HR]=0.91 [95% confidence interval (CI) 0.74-1.12]; n=785), TTD in TOI (HR=1.06 [95% CI 0.87-1.31]; n=781) and TTD in HRQoL (HR=0.96 [95% CI 0.79-1.16]; n=776)."
23477998,Premise,1487,1701,"Time to pain and time to analgesic use were significantly delayed in patients receiving erlotinib compared with placebo (HR=0.61 [95% CI 0.42-0.88]; p=0.0080 and HR=0.66 [95% CI 0.46-0.94]; p=0.0199, respectively)."
23477998,Premise,1702,1869,"A non-significant trend towards delayed time to cough and time to dyspnoea (HR=0.77 [95% CI 0.49-1.21] and HR=0.75 [95% CI 0.48-1.17], respectively) was also observed."
23477998,Claim,1870,2045,"Erlotinib maintenance therapy significantly extends progression-free survival without compromising patient HRQoL in comparison with placebo, with some improvement in symptoms."
23477998,Premise,1022,1152,"Compared with placebo, erlotinib maintenance therapy prolonged progression-free and overall survival by 41% and 23%, respectively."
23504821,Premise,1640,1759,"The median TDD in HRQOL was 8.3 months with EVE + EXE versus 5.8 months with PBO + EXE (hazard ratio, 0.74; P = .0084)."
23504821,Premise,1760,1917,"At the 10-point minimal important difference, the median TDD with EVE + EXE was 11.7 months versus 8.4 months with PBO + EXE (hazard ratio, 0.80; P = .1017)."
23504821,Claim,1918,2122,"In patients with advanced breast cancer who develop disease progression after treatment with nonsteroidal aromatase inhibitors, EVE + EXE was associated with a longer TDD in global HRQOL versus PBO + EXE."
23525453,Premise,1179,1292,"Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01)."
23525453,Premise,994,1178,"In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05)."
23525453,Premise,1293,1481,"In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01)."
23525453,Premise,1482,1600,"In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01)."
23525453,Premise,1601,1691,"There was no significant difference in grade III/IV adverse events between the two groups."
23525453,Premise,1692,1743,"All procedures were well tolerated by the patients."
23525453,Claim,1744,1859,"Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE."
23525453,MajorClaim,1860,1965,"We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy."
23525453,MajorClaim,1,106,"Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC)."
23525453,MajorClaim,107,283,"Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid."
23549581,Premise,1459,1687,"Individuals receiving duloxetine as their initial 5-week treatment reported a mean decrease in average pain of 1.06 (95% CI, 0.72-1.40) vs 0.34 (95% CI, 0.01-0.66) among those who received placebo (P = .003; effect size, 0.513)."
23549581,Premise,1688,1803,"The observed mean difference in the average pain score between duloxetine and placebo was 0.73 (95% CI, 0.26-1.20)."
23549581,Premise,1804,1945,"Fifty-nine percent of those initially receiving duloxetine vs 38% of those initially receiving placebo reported decreased pain of any amount."
23549581,Claim,1946,2114,"Among patients with painful chemotherapy-induced peripheral neuropathy, the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain."
23551928,Premise,1654,1839,"Body image, anxiety, and cancer-specific posttraumatic distress were notable in their association with subscales of sexual functioning, while a global QOL measure was largely unrelated."
23551928,Premise,1840,2105,"For sexually active female rectal and anal cancer survivors enrolled in a sexual health intervention, sexual dysfunction was significantly and consistently associated with specific measures of psychological well-being, most notably Sexual/Relationship Satisfaction."
23551928,Claim,2106,2226,"These results suggest that sexual functioning may require focused assessment by providers, beyond broad QOL assessments,"
23551928,Claim,2236,2381,"attention to Sexual/Relationship Satisfaction may be critical in the development and implementation of interventions for this cohort of patients."
23551928,Premise,1515,1653,"The Sexual/Relationship Satisfaction subscale was associated with all measures of psychological well-being (r=-0.45 to -0.70, all P<0.01)."
23562564,Premise,1249,1348,"There was substantial deterioration in QOL scores immediate post-treatment (3-months) in both arms."
23562564,Premise,1349,1430,"However, QOL scores gradually but definitely improved over time for most domains."
23562564,Premise,1431,1694,"Global QOL, emotional/role functioning, nausea/vomiting, pain, swallowing, speech, social contact/eating, insomnia showed rapid recovery (<6months) while physical/cognitive functioning, dry mouth, sticky saliva, fatigue, senses showed delayed recovery (>6months)."
23562564,Premise,1695,1783,"There were no significant differences in loco-regional or survival between the two arms."
23562564,Claim,1784,1904,"There is substantial deterioration in QOL after curative-intent head-neck irradiation that gradually improves over time."
23562564,Claim,1905,2143,"IMRT results in clinically meaningful and statistically better QOL scores for some domains compared to 3D-CRT at several time points with comparable disease outcomes that could support its widespread adoption in routine clinical practice."
23569311,Claim,1889,1998,"Combining bevacizumab with docetaxel and trastuzumab did not significantly improve investigator-assessed PFS."
23569311,Premise,1725,1888,"High baseline plasma vascular endothelial growth factor A (VEGF-A) concentrations were associated with greater bevacizumab benefit (not statistically significant)."
23569311,Claim,1624,1724,"Grade  3 febrile neutropenia and hypertension were more common with bevacizumab-containing therapy."
23569311,Premise,1571,1623,"The RR was 70% versus 74%, respectively (P = .3492)."
23569311,Premise,1203,1402,"The hazard ratio for investigator-assessed PFS was 0.82 (95% CI, 0.65 to 1.02; P = .0775; median PFS, 13.7 v 16.5 months in the non-bevacizumab and bevacizumab arms, respectively; PFS events in 72%)."
23569311,Premise,1403,1570,"The Independent Review Committee-assessed PFS hazard ratio was 0.72 (95% CI, 0.54 to 0.94; P = .0162; median PFS, 13.9 v 16.8 months, respectively; PFS events in 53%)."
23589316,Claim,1595,1661,"Intraperitoneal administration limits cardiotoxicity of verapamil."
23589316,Claim,1458,1594,"Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life."
23589316,Premise,762,869,"The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission."
23589316,Premise,592,761,"The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %."
23589316,Premise,876,992,"the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group)."
23589316,Premise,1084,1230,"The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group)."
23589316,Premise,1240,1327,"cumulative survival rate was also significantly higher in the combined treatment group."
23589316,Premise,1328,1457,"Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups."
23866850,Premise,935,1231,"Patients randomly assigned to the intervention arm showed significant improvements on symptoms of depression (p<0.05) and anxiety (p<0.05), health-related QOL (p<0.05) (i.e. better global health status, and physical and emotional functioning, and less insomnia) when compared with controls."
23866850,Claim,1232,1413,"In the subset analysis, female patients, those that received high dose irradiation, and those that underwent adjuvant chemotherapy could benefit more from psychosocial intervention."
23866850,Premise,1414,1683,"There was no difference between the two groups in disease-free survival (DFS) (2-year DFS 79.8% in the intervention arm and 76.4% in the control arm; p=0.527) and overall survival (OS) (2-year OS 83.1% in the intervention arm and 84.3% in the control arm; p=0.925)."
23866850,Claim,1807,1897,"However, the intervention was not found to reduce the risk of cancer recurrence and death."
23866850,Claim,1684,1806,"Psychosocial intervention is a cost-effective approach that can improve a patient's mood and QOL both during and after RT."
23873790,Premise,794,963,"Results showed overall significant improvements in psychosocial stress and quality of life in both the MBAT and educational support groups immediately post-intervention;"
23873790,Premise,964,1141,"however, participants with high stress levels at baseline had significantly improved overall outcomes only in the MBAT group, both immediately post-intervention and at 6 months."
23873790,Premise,1155,1311,"at 6 months follow-up, participants attending five or more sessions trended toward retaining treatment effects better in the MBAT than in the control group."
23873790,Premise,1321,1511,"black women and white women were similar in terms of how they benefited from the MBAT intervention, even though white participants tended to have higher educational level and marital status."
23873790,Claim,1512,1676,"In conclusion, MBAT is associated with significant, sustained benefits across a diverse range of breast cancer patients, particularly those with high stress levels."
23910712,Claim,1435,1501,"There was no differences in acute toxicities between the 2 groups."
23910712,Claim,1502,1646,"Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group."
23910712,Claim,1656,1826,"there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT."
23910712,Premise,1264,1324,"The rhDNase group showed no change in OPS-DNA concentration,"
23910712,Premise,1334,1434,"the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045)."
23910712,Premise,1082,1263,"Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046)."
23910712,Premise,896,1081,"Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery."
23910712,Premise,715,781,"Both groups showed an increase in symptom and interference scores,"
23910712,Premise,791,895,"patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment."
23910712,Premise,614,714,"There were no statistically significant differences in patients' QOL outcomes over the study period."
23917308,Premise,1398,1491,"No adverse events or skeletal complications occurred during the supervised exercise sessions."
23917308,Premise,1492,1748,"The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.81.5)."
23917308,Premise,1749,2064,"The change in physical function (muscle strength 11%; submaximal aerobic exercise capacity 5% and ambulation 12%), physical activity level (24%) and lean mass (3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group."
23917308,Premise,2065,2175,"No significant between-group differences were observed for fatigue, quality of life or psychological distress."
23917308,Claim,2176,2478,"This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass."
23917308,Claim,2479,2573,"Future trials involving larger sample sizes are required to expand these preliminary findings."
23945243,Premise,640,818,"For the Pemetrexed group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months."
23945243,Premise,819,911,"In the Gefitinib group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months."
23945243,Premise,912,1041,"Compared with the Pemetrexed group, the ORR, DCR, and mPFS in the Gefitinib group exhibited no statistical significance (P>0.05)."
23945243,Premise,1055,1260,"the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Gefitinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%)."
23945243,Premise,1261,1342,"Compared with baseline, the QoL improved in both groups but to different degrees."
23945243,Premise,1353,1521,"emotional, functional well-being, and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group (P<0.05)."
23945243,Claim,1522,1598,"The effects of Pemetrexed and Gefitinib as second line therapy were similar,"
23945243,Premise,1599,1627,"although with different AEs."
23945243,Claim,1628,1661,"Both drugs could improve the QoL,"
23945243,Claim,1666,1722,"Gefitinib showed better overall results than Pemetrexed."
23962028,Premise,1322,1615,"Linear mixed models (primary model) demonstrated no statistically significant overall difference between EVE+EXE and PBO+EXE for QL2 (LSM difference = -1.91; 95% CI = -4.61, 0.78), BRBS (LSM difference = -0.18; 95% CI = -1.98, 1.62), or BRAS (LSM difference = -0.42; 95% CI = -2.94, 2.10)."
23962028,Premise,1722,1862,"In the expanded pattern-mixture model, EVE+EXE-treated patients who did not drop out early had stable BRBS and BRAS relative to PBO+EXE."
23962028,Claim,1920,2115,"These analyses confirm that EVE+EXE provides clinical benefit without adversely impacting HRQOL in patients with HR(+) ABC who recurred/progressed on prior NSAIs versus endocrine therapy alone."
23989945,Premise,845,1043,"There was no statistically significant QOL difference between treatment in the combined community locations relative to hospital (difference of -7.2, 95% confidence interval: -195 to +52, P=0.25)."
23989945,Premise,1044,1163,"There was a significant difference between the two community locations in favour of home (+152, 13 to 291, P=0.033)."
23989945,Premise,1259,1332,"There was no evidence that community treatment compromised patient safety"
23989945,Premise,1337,1442,"no significant difference between treatment arms in terms of overall costs or Quality Adjusted Life Year."
23989945,Premise,1443,1662,"Seventy-eight percent of patients expressed satisfaction with their treatment whatever their location, whereas 57% of patients preferred future treatment to continue at the hospital, 81% at GP surgeries and 90% at home."
23989945,Claim,1864,1949,"Patient QOL favours delivering cancer treatment in the home rather than GP surgeries."
23989945,Claim,1950,2124,"Nevertheless, both community settings were acceptable to and preferred by patients compared with hospital, were safe, with no detrimental impact on overall health-care costs."
23993401,Premise,778,903,"55.6% patients treated over 4 days and 33.3% of patients treated over 11 days experienced acute grade  2 toxicity (p=0.085)."
23993401,Premise,904,985,"Dyspnea, fatigue and coughing domains were worse in the 11 day group at baseline."
23993401,Premise,986,1202,"At 1 and 4 months, more patients in the 4 day group experienced a clinically meaningful worsening in the dyspnea QOL domain compared to the 11 day group (44.5% vs 15.4%, p=0.02; 38.5% vs 12.0%, p=0.03, respectively)."
23993401,Premise,1203,1292,"However, raw QOL scores were not different at these time-points between treatment groups."
23993401,Claim,1293,1399,"Grade 2 or higher acute toxicity was more common in the 4 day group, approaching statistical significance."
23993401,Claim,1400,1497,"More patients treated on 4 consecutive days reported a clinically meaningful increase in dyspnea,"
23993401,Claim,1498,1605,"although interpretation of these results is challenging due to baseline imbalance between treatment groups."
23993401,Claim,1606,1660,"Larger studies are required to validate these results."
24001635,Premise,1406,1560,"Long-term benefits for older patients were seen in the anger-hostility scale at week 27 (92.2 vs. 84.2, p = 0.027) and week 52 (96.3 vs. 85.9, p = 0.005)."
24001635,Premise,1185,1405,"Older adult patients reported better overall QOL (LASA 74.4 vs. 62.9, p = 0.040), higher social well-being (FACT-G 91.1 vs. 83.3, p = 0.045), and fewer problems with anger (POMS anger-hostility 95.0 vs. 86.4, p = 0.028)."
24001635,Claim,1561,1765,"Older adult patients who received a multidisciplinary intervention to improve QOL while undergoing advanced cancer treatments benefited differently in some QOL domains, compared to younger adult patients."
24067488,Claim,1901,2005,"Our findings suggest that, for most patients, this algorithm-based care can be given by a trained nurse."
24067488,Claim,1714,1900,"Patients given targeted intervention following a detailed clinical algorithm had better improvements in radiotherapy-induced gastrointestinal symptoms than did patients given usual care."
24067488,Premise,1576,1713,"Outcomes in the nurse group were not inferior to outcomes in the gastroenterologist group (mean difference 136, one sided 95% CI -148)."
24067488,Premise,1368,1575,"We recorded the following pair-wise mean difference in change in IBDQ-B score between groups: nurse versus booklet 412 (95% CI 004-819; p=004), gastroenterologist versus booklet 547 (114-981; p=001)."
24075621,Claim,2906,2995,"These results provide further support for the efficacy of abiraterone in this population."
24075621,Claim,1,250,"Abiraterone acetate plus prednisone significantly improves radiographic progression-free survival in asymptomatic or mildly symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer compared with prednisone alone."
24075621,Claim,2728,2905,"Abiraterone plus prednisone delays patient-reported pain progression and HRQoL deterioration in chemotherapy-naive patients with metastatic castration-resistant prostate cancer."
24075621,Premise,2303,2727,"Median time to HRQoL deterioration was longer in patients assigned to abiraterone plus prednisone than in those assigned to placebo plus prednisone as assessed by the FACT-P total score (127 months [95% CI 111-140] vs 83 months [74-106]; HR 078, 95% CI 066-092; p=0003) and by the score on its prostate-cancer-specific subscale (111 months [86-138] vs 58 months [55-83]; HR 070, 95% CI 060-083; p<00001)."
24075621,Premise,2024,2302,"Median time to progression of worst pain was also longer with abiraterone plus prednisone (267 months [95% CI 194-not estimable]) than with placebo plus prednisone (194 months [166-not estimable]), but the difference was not significant (HR 085, 95% CI 069-104; p=0109)."
24075621,Premise,1561,2023,"Median time to progression of mean pain intensity was longer in patients assigned to abiraterone plus prednisone (267 months [95% CI 193-not estimable]) than in those assigned to placebo plus prednisone (184 months [149-not estimable]; hazard ratio [HR] 082, 95% CI 067-100; p=00490), as was median time to progression of pain interference with daily activities (103 months [95% CI 93-130] vs 74 months [64-86]; HR 079, 95% CI 067-093; p=0005)."
7502428,Premise,918,1183,"Treatment effects favored castration for both endpoints (P < or = 0.002), with hazard ratios (bicalutamide:castration) of 1.54 (95% confidence interval [CI], 1.18 to 2.00) for time to treatment failure and 1.6 (95% CI, 1.19 to 2.15) for time to disease progression."
7502428,Premise,1184,1293,"From the 1-year survival analysis, the hazard ratio for probability of death was 1.29 (95% CI, 0.96 to 1.72)."
7502428,Premise,1294,1394,"Thus far, with a median follow-up of 86 weeks, median survival has not been reached in either group."
7502428,Premise,1395,1586,"Changes from baseline in several quality of life variables were significantly different (P < or = 0.01) between treatment groups periodically from months 1 to 6, and all favored bicalutamide."
7502428,Premise,1587,1657,"Overall, the antiandrogen was well tolerated compared with castration;"
7502428,Premise,1658,1759,"with bicalutamide, hot flushes occurred less often and breast tenderness and gynecomastia more often."
7502428,Premise,1760,1849,"Although a dosage of 50 mg of bicalutamide once daily was not as effective as castration,"
7502428,Claim,1850,2030,"the favorable quality of life outcomes and the low incidence of nonhormonal adverse events provide reasons to evaluate bicalutamide, as a single therapeutic agent, at higher doses."
7680374,Premise,798,1040,"In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02)."
7680374,Premise,1041,1129,"The event-free period (EFP), radiologic course of disease, and survival did not improve."
7680374,Claim,1130,1192,"Subgroup analyses suggested a dose-dependent treatment effect."
7680374,Premise,1193,1349,"Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002)."
7680374,Premise,1350,1429,"In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04)."
7680374,Premise,1430,1498,"Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,"
7680374,Claim,1499,1573,"but other cancer-associated factors seemed to contribute to this toxicity."
7680374,Claim,1574,1663,"Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity."
7680374,Claim,1664,1705,"The effect appeared to be dose-dependent."
7680374,Claim,1706,1766,"Further research on dose and mode of treatment is mandatory."
7786823,Premise,761,825,"The overall remission rate was 87% with 31% complete remissions."
7786823,Premise,826,932,"The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years."
7786823,Premise,933,1107,"The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms."
7786823,Premise,1108,1248,"In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms."
7786823,Premise,1249,1437,"Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01)."
7786823,Premise,1438,1590,"In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm."
7786823,Premise,1591,1809,"Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment."
7786823,Claim,1810,1973,"Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity."
7786823,Claim,1982,2066,"patients with early alternating chemotherapy achieve a better subjective adjustment,"
7786823,Claim,2067,2252,"late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease."
7989941,Premise,1,164,"Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian cancer."
7989941,Premise,988,1075,"Severe HSRs were rare (1.5% patients) and were not affected by either dose or schedule."
7989941,Premise,1076,1157,"Response was slightly higher at the 175-mg/m2 dose (20%) than at 135 mg/m2 (15%),"
7989941,Premise,1158,1210,"but this was not statistically significant (P = .2)."
7989941,Premise,1211,1319,"However, progression-free survival was significantly longer in the high-dose group (19 v 14 weeks; P = .02)."
7989941,Premise,1320,1410,"Significantly more neutropenia was seen when Taxol was administered as a 24-hour infusion."
7989941,Premise,1411,1504,"Response rates were similar in the 24- and 3-hour groups (19% and 16%, respectively; P = .6)."
7989941,Premise,1505,1540,"No survival differences were noted."
7989941,Claim,1541,1648,"The 3-hour infusion of Taxol is safe when given with premedication and is associated with less neutropenia."
7989941,Claim,1725,1938,"The observation that longer infusion produces more myelosuppression but does not yield higher response rates should lead to further studies to determine the optimal dose and schedule of this interesting new agent."
8229122,Premise,802,1118,"At 3 months, women treated with 160 mg/d reported less severe side effects (P < .0005), better physical functioning (FLS, P < .0005), less psychologic distress (MHI, P = .008), and an improvement in overall quality of life (FLIC, P = .003) from the time of study entry as compared with those treated with 1,600 mg/d."
8229122,Premise,1119,1243,"Patients who received the 800-mg/d dose fell between the low- and high-dose arms in reported intensity of drug side effects,"
8229122,Premise,1244,1383,"but responded similarly to those in the 160-mg/d group in terms of physical functioning, psychologic distress, and overall quality of life."
8229122,Claim,1384,1588,"Unless additional follow-up data demonstrate a survival advantage at higher doses, the 160-mg/d dose is optimal, achieving maximal treatment effect with the fewest side effects and better quality of life."
8628043,Claim,1106,1136,"Both measures were responsive;"
8628043,Premise,1137,1338,"out of 24 changes over time, 19 were in the expected direction for the linear analogue self-assessment scale (p < or = 0.05 for 9 of 19) and 17 for the adjective checklist (p < or = 0.05 for 10 of 17)."
8628043,Premise,1339,1671,"The linear analogue self-assessment scale was less but significantly efficient for detection of treatment effects, with relative efficiency estimates ranging from 0.16 to 2.45 and a median of 0.66 among the comparisons with relatively stable estimates (/t/ > or = 1.0) and more efficient for recurrence than the adjective checklist."
8628043,Claim,1672,1886,"The mood linear analogue self-assessment scale is a valid indicator of emotional well-being in patients with breast cancer in large multicenter, multicultural trials in which comprehensive scales are less feasible."
8628043,Claim,1887,2053,"This investigation supports the clinical relevance of linear analogue self-assessment scales as indicators of components of quality of life in cancer clinical trials."
9166485,Premise,625,733,"The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group."
9166485,Premise,734,1159,"A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement."
9166485,Premise,1160,1294,"Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively)."
9166485,Premise,1295,1403,"However, the magnitude of this difference was not helpful in defining which patients were likely to respond."
9166485,Premise,1404,1536,"There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group."
9166485,Premise,1537,1603,"There were no significant adverse effects associated with r-HuEPO."
9166485,Claim,1604,1781,"r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy."
9166485,Claim,1782,1861,"After 1 month of r-HuEPO, there is also a reduction in transfusion requirement."
9402173,Premise,441,598,"Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024)."
9402173,Premise,599,794,"The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone."
9402173,Premise,795,897,"Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%."
9402173,Premise,898,1017,"PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia."
9402173,Premise,1018,1179,"Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2."
9402173,Premise,1180,1248,"The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,"
9402173,Premise,1249,1297,"but the remaining QL data showed no differences."
9402173,Claim,1298,1469,"PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage."
9402173,Premise,1470,1546,"There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2."
9414057,Claim,1324,1373,"The Pain Education Program proved to be feasible:"
9414057,Premise,1374,1531,"75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary."
9414057,Claim,1532,1685,"Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity."
9414057,Premise,1686,1784,"However, pain relief was mainly found in the intervention group patients without district nursing."
9414057,Claim,1785,1895,"It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain."
9414057,MajorClaim,1896,1993,"The use of the Pain Education Program by nurses should be seriously considered on oncology units."
9496390,Premise,567,676,"Symptomatic response during the first four weeks was seen after pamidronate, but not with placebo (P < 0.05)."
9496390,Premise,677,767,"Quality of life was maintained with pamidronate and deteriorated after placebo (P < 0.05)."
9496390,Premise,768,818,"Resorption markers did not decrease after placebo,"
9496390,Premise,819,893,"but NTx and Crosslaps both decreased by 70% after pamidronate (P = 0.001)."
9496390,Premise,894,963,"A second infusion of pamidronate did not decrease resorption further,"
9496390,Premise,964,1052,"but maintained the suppression of resorption at similar levels for a further four weeks."
9496390,Premise,1053,1141,"Symptomatic response to pamidronate correlated closely with the rate of bone resorption;"
9496390,Premise,1142,1557,"it was more frequent in those patients with an initial NTx value of < 2 times the upper limit of normal (17 of 27, 62%) and in those where the level of Ntx returned to normal (19 of 32, 59%), than in the patients with either high baseline values of NTx (> 2 times the upper limit of normal) or Ntx levels which failed to normalise for whom the response frequencies were 2 of 16 (13%) and 0 of 11 (0%), respectively."
9496390,Claim,1558,1653,"Subjective benefit after intravenous pamidronate is confirmed in this placebo-controlled study."
9496390,Claim,1654,1762,"The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate."
9531327,Premise,559,711,"CR after remission induction treatment was achieved in 55% of the patients in the control group and in 56% of the patients in the GM-CSF group (P = NS)."
9531327,Premise,712,892,"The duration of survival and disease-free survival at 2 years after randomization were estimated at 22% and 19% for the control group and 22% and 14% for the GM-CSF group (P = NS)."
9531327,Premise,893,1049,"Considering the short-term quality of life, the administration of GM-CSF resulted in more problems with regard to depressed mood, diarrhoea and rash/eczema."
9531327,Premise,1050,1156,"With regard to the long-term quality of life there were no significant differences between the two groups."
9531327,Premise,1157,1318,"The average costs of the primary treatment were higher in GM-CSF-treated patients than in the control group, i.e. US$40782 and US$34465, respectively (P < 0.01)."
9531327,Premise,1319,1395,"The costs during the follow-up period did not differ between the two groups."
9531327,Claim,1396,1600,"The results of this randomized clinical trial indicate that daunomycin-cytosine arabinoside plus GM-CSF is not a cost-effective treatment strategy when compared with daunomycin-cytosine arabinoside alone."
9554521,MajorClaim,62,136,"there is no standard therapy for patients with advanced gastric carcinoma."
9554521,Claim,137,237,"The superiority of combination therapy over monochemotherapy has not been demonstrated convincingly."
9554521,Premise,1312,1405,"The median duration of response was 8.8 and 8.3 months, respectively, in Study A and Study B."
9554521,Premise,1406,1478,"The median survival reached 8 months in Study A and 9 months in Study B."
9554521,Premise,1479,1589,"In the whole population of patients survival was significantly higher in patients with a PS of 0-1 (P < 0.05)."
9554521,Premise,1590,1756,"Patients with a PS of 0-1 and a resected tumor had the significantly longest survival both in EEP-L treated patients and in all evaluable patients in the two studies."
9554521,Premise,1757,1885,"The most frequent World Health Organization Grade 3-4 toxic effects were gastrointestinal in Study A and hematologic in Study B."
9554521,Premise,1886,1926,"No treatment-related death was observed."
9554521,Claim,1927,2069,"The efficacy of 5-FU, modulated with 6S-LV, is moderate in patients with advanced gastric carcinoma, similar to cisplatin-containing regimens."
9554521,Claim,2070,2236,"PS and other prognostic factors could influence the response rate, which does not appear to be a reliable parameter for evaluating the outcome of chemotherapy trials."
9667255,Premise,989,1175,"At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided)."
9667255,Premise,1176,1309,"The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided)."
9667255,Premise,1310,1444,"CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity,"
9667255,Premise,1453,1592,"the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity."
9667255,Premise,1593,1643,"There were three treatment-related deaths with CAF"
9667255,Premise,1644,1678,"but none with the 16-week regimen."
9667255,Premise,1679,1775,"During treatment, quality of life declined significantly more with the 16-week regimen than CAF,"
9667255,Premise,1776,1831,"but by 4 months posttreatment, there was no difference."
9667255,Premise,1832,1993,"The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life."
9667255,Claim,1994,2177,"The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule."
9667255,Claim,2178,2219,"It should probably not be tested further,"
9667255,Claim,2220,2361,"but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens."
9747868,Premise,872,1096,"Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and tamoxifen groups, respectively."
9747868,Premise,1214,1381,"risk was also reduced in women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and in those with any category of predicted 5-year risk."
9747868,Premise,1382,1464,"Tamoxifen reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002)."
9747868,Premise,1465,1625,"Tamoxifen reduced the occurrence of estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen receptor-negative tumors was seen."
9747868,Premise,1626,1796,"Tamoxifen administration did not alter the average annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and spine fractures was observed."
9747868,Premise,1797,1998,"The rate of endometrial cancer was increased in the tamoxifen group (risk ratio = 2.53; 95% confidence interval = 1.35-4.97); this increased risk occurred predominantly in women aged 50 years or older."
9747868,Premise,2080,2137,"no endometrial cancer deaths have occurred in this group."
9747868,Premise,2138,2246,"No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in the tamoxifen group."
9747868,Premise,2247,2421,"The rates of stroke, pulmonary embolism, and deep-vein thrombosis were elevated in the tamoxifen group; these events occurred more frequently in women aged 50 years or older."
9747868,Claim,2422,2498,"Tamoxifen decreases the incidence of invasive and noninvasive breast cancer."
9747868,Claim,2499,2671,"Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease."
9790546,Claim,1,152,"For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels."
9790546,Premise,1171,1510,"Cross-sectional analyses (corrected for multiple testing) identified statistically significant differences that favored orchiectomy plus placebo for two of the five primary QOL parameters as follows: patients receiving flutamide reported more diarrhea at 3 months (P = .001) and worse emotional functioning at 3 and 6 months (both P<.003)."
9790546,Premise,1511,1559,"Longitudinal analyses replicated these findings."
9790546,Premise,1560,1625,"Other analyzed QOL parameters favored the group receiving placebo"
9790546,Premise,1626,1703,"but were not statistically significant after adjustment for multiple testing."
9790546,Claim,1704,1923,"We found a consistent pattern of better QOL outcomes at each follow-up assessment during the first 6 months of treatment for orchiectomized patients with metastatic prostate cancer who received placebo versus flutamide."
9790546,Claim,1924,2026,"Improvement over time was evident in both treatment groups but more so for patients receiving placebo."
9807987,Premise,812,1025,"With a median follow-up of 13 months, the overall survival was significantly better in the irinotecan group (p=0.0001), with 36.2% 1-year survival in the irinotecan group versus 13.8% in the supportive-care group."
9807987,Premise,1026,1139,"The survival benefit, adjusted for prognostic factors in a multivariate analysis, remained significant (p=0.001)."
9807987,Premise,1140,1341,"Survival without performance-status deterioration (p=0.0001), without weight loss of more than 5% (p=0.018), and pain-free survival (p=0.003) were significantly better in the patients given irinotecan."
9807987,Premise,1342,1468,"In a quality-of-life analysis, all significant differences, except on diarrhoea score, were in favour of the irinotecan group."
9807987,Claim,1469,1760,"Our study shows that despite the side-effects of treatment, patients who have metastatic colorectal cancer, and for whom fluorouracil has failed, have a longer survival, fewer tumour-related symptoms, and a better quality of life when treated with irinotecan than with supportive care alone."
9849452,Premise,983,1123,"Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group."
9849452,Premise,1124,1186,"Group differences were smaller within the psychosocial domain,"
9849452,Premise,1187,1249,"although trends were seen in favour of the chemotherapy group."
9849452,Premise,1250,1326,"No significant differences were seen in favour of the supportive care group,"
9849452,Premise,1327,1348,"except for hair loss."
9849452,Premise,1349,1502,"Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%."
9849452,Premise,1503,1623,"Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy."
9849452,Premise,1624,1661,"No treatment-related deaths occurred."
9849452,Claim,1662,1804,"In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC."
9849454,Premise,1149,1214,"Complete remission was achieved in 91% (170/186) of all patients."
9849454,Premise,1215,1380,"With a median follow-up of 8 years, the 5-year overall survival was 68% (+/- 3% standard error of the mean (SEM) and the 5-year event-free survival 53% (+/- 4% SEM)."
9849454,Premise,1381,1506,"These results show an improvement over previous SIOP study (RMS75) in which survival was 52% and event-free survival was 47%."
9849454,Premise,1507,1699,"Among the 54 patients who exhibited isolated local relapse, 35% (19/54) survived in further remission longer than 2 years after retreatment, including local therapy (surgery +/- radiotherapy)."
9849454,Claim,2258,2522,"Compared with the results obtained in the previous SIOP study, treatment in MMT84 was based on response to initial chemotherapy and, despite an overall reduction of the use of local therapy, significantly improved survival for patients with non-metastatic disease."
9849454,Claim,2523,2655,"This trial, also for the first time, provides evidence that retreatment after local relapse can achieve long-term second remissions."
9850014,Premise,891,1040,"An objective response (complete [CR] or partial [PR]) was obtained in 55%, 48%, 16%, and 7% of patients treated with CEF, E, M, and MV, respectively."
9850014,Premise,1041,1138,"A response to CEF tended to last longer than a response to E (median, 12 v 10.5 months; P = .07)."
9850014,Premise,1139,1263,"Treatment-related toxicity was less in the single-agent arm and quality-of-life (QOL) analysis favored the single-agent arm."
9850014,Premise,1264,1356,"No significant difference in time to progression or survival was found between the two arms."
9850014,Premise,1357,1577,"Similarly, no difference in survival was found when the patients who received both the planned first-and second-line treatments were compared or when survival was calculated from the beginning of the second-line therapy."
9850014,Claim,1578,1770,"Patients treated with single-agent E followed by single-agent M had similar survival, but less treatment-related toxicity and better QOL as compared with those treated with CEF followed by MV."
9890172,Claim,1,154,"Vinorelbine, a semisynthetic vinca alkaloid, represents a well-tolerated treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC)."
9890172,Premise,1260,1450,"Vinorelbine-treated patients scored better than control patients on QoL functioning scales, and they reported fewer lung cancer-related symptoms but reported worse toxicity-related symptoms."
9890172,Premise,1451,1563,"There was a statistically significant (two-sided P = .03) survival advantage for patients receiving vinorelbine;"
9890172,Premise,1564,1643,"median survival increased from 21 to 28 weeks in the vinorelbine-treated group."
9890172,Premise,1644,1736,"The relative hazard of death for vinorelbine-treated patients was 0.65 (95% CI = 0.45-0.93)."
9890172,Claim,1737,1841,"Vinorelbine improves survival of elderly patients with advanced NSCLC and possibly improves overall QoL."
